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Abstract 
The radioisotope selenium-73 (half-life: 7.1 h, positron-branching: 65 %) is an interesting label for appli-
cation in positron emission tomography, serving as a possible substitute of sulfur in thio compounds of 
interest. Furtheron, the half-life of selenium-73 offers the possibility to study relatively slow pharmaco-
kinetics of selenated radiotracers. Previous methods for labelling with radioselenium suffered from the 
drawback of an indispensable addition of (nat)Se-carrier, resulting in tracers of low specific activity. In 
consideration of the possible toxicity of selenium compounds, two new radiosynthetic pathways were 
developed in this work for the preparation of Se-73-labelled compounds at the no-carrier-added (n.c.a.) 
level. Selenium-75 (half-life: 120.4 d) was used for the development and optimization of these radio-
syntheses. 
The first method developed started with a homogenous or polymer-supported reaction of elemental 
n.c.a. Se-75 with an isocyanide and subsequently an amine. Radioselenoureas formed were alkylated via 
alkyl triflates to yield the corresponding Se-75-labelled selenouronium salts, which were purified after-
wards. Hydrolysis under basic conditions and a subsequent second alkylation yielded various asymmetric 
n.c.a. Se-75-labelled dialkyl selenoethers with a radiochemical yield of 13 to 56 % (related to elemental 
Se-75) depending on the substituents. The use of the polymer-supported pathway provides the advan-
tages of a shorter reaction time (35 min in comparison to 130 min in homogenous phase) and a more 
convenient separation of Se-75-labelled intermediates, thus appearing very attractive for automation. 
Subsequently, Se-73-labelled model compounds such as benzylmethylselenide and 1-phenyl-1-(propyl-
seleno)ethane were synthesized using the optimized reaction conditions. 
The second labelling method was based on the initial reaction of elemental n.c.a. Se-75 with sodium 
cyanide, yielding sodium radioselenocyanate. Treatment of this intermediate in situ with alkyl bromides 
resulted in Se-75-labelled alkyl selenocyanates. After separation via reversed phase cartridges, the alkyl 
radioselenocyanates reacted with organic lithium or Grignard compounds to asymmetric Se-75-labelled 
selenoethers with a radiochemical yield of 9 to 55 % (related to elemental Se-75) depending on the sub-
stituents. This pathway offers the advantage to generate both aliphatic and aromatic radioseleno com-
pounds by using appropriate alkyl or aryl lithium or Grignard compounds. 
The new approaches to n.c.a. labelling with radioselenium developed in this work extensively enlarge 
the availability of Se-73,75-labelled compounds. In particular, a method is described for the first time to 
prepare n.c.a. aryl radioselenoethers. For proof of identity via radioanalysis appropriate radio high 
performance liquid chromatography and radio thin layer chromatography methods were developed. 
Several non-radioactive seleno compounds, which served as reference substances, were prepared for 
the first time. 
Besides various simple asymmetric selenoethers, two more complex, physiologically relevant 
molecules, i.e. the c.a. Se-75-labelled amino acid derivative L-homocysteine selenolactone and the n.c.a. 
Se-75-labelled adenosine A(1) receptor ligand 5’-(methylseleno)-N(6)-cyclopentyladenosine, were 
synthesized using preferentially the selenourea method with total radiochemical yields of 20 – 30 % 
(related to elemental Se-75). 
    
Kurzzusammenfassung 
Selen-73 (Halbwertzeit: 7.1 h, Positronenemission: 65 %) ist ein vielversprechendes Radionuklid für die 
Anwendung in der Positronen-Emissions-Tomographie, das als Substitut für Schwefel in physiologisch 
relevanten Thioverbindungen fungieren kann. Außerdem ermöglicht seine Halbwertzeit die Untersuchung 
relativ langsamer Pharmakokinetiken entsprechend selenierter Radiotracer. Etablierte Markierungs-
techniken mit Radioselen besitzen jedoch den Nachteil, dass aufgrund des unvermeidlichen (nat)Se-
Trägerzusatzes Tracer mit nur geringer spezifischer Aktivität hergestellt werden können. Im Hinblick auf 
die mögliche Toxizität von Selenverbindungen wurden im Rahmen dieser Arbeit zwei neue Radio-
synthesen im trägerarmen (n.c.a.) Bereich etabliert. Hierbei wurde das Isotop Selen-75 (Halbwert-
zeit: 120.4 d) für die Entwicklung und Optimierung eingesetzt. 
Das erste Radiosynthesekonzept basierte auf der Reaktion von elementarem n.c.a. Se-75 mit einem 
Isonitril und einem Amin in homogener oder an fester Phase. Die resultierenden Radioselenoharnstoffe 
wurden mittels Alkyltriflaten zu entsprechenden Se-75-markierten Selenoniumsalzen umgesetzt. Nach 
deren Aufreinigung, basischer Hydrolyse und anschließendem zweiten Alkylierungsschritt erhielt man 
verschiedene asymmetrische, Se-75-markierte n.c.a. Dialkylselenoether in radiochemischen Ausbeuten 
von 13 bis 56 % (bezogen auf elementares Se-75) abhängig von den Alkylsubstituenten. Die Reaktions-
führung an fester Phase bietet die Vorteile einer erheblich geringeren Gesamtsynthesedauer (35 min im 
Vergleich zu 130 min in homogener Phase) und einer einfacheren Aufreinigung der Se-75-markierten 
Zwischenprodukte und bietet sich daher für automatisierte Synthesen an. Mit Hilfe der optimierten 
Reaktionsbedingungen ließen sich Se-73-markierte Modellverbindungen wie Benzylmethylselenoether 
und 1-Phenyl-1-(propylseleno)ethan synthetisieren. 
Die zweite Markierungstechnik basierte auf der Reaktion von elementarem n.c.a. Se-75 mit Natrium-
cyanid zu Natriumradioselenocyanat, das in situ mit Alkylbromiden zu Se-75-markierten Alkylseleno-
cyanaten umgesetzt wurde. Nach Aufreinigung mittels Festphasenfixierung wurden die Alkylradioseleno-
cyanate mit organischen Lithium- oder Grignard-Verbindungen zu asymmetrischen, Se-75-markierten 
Selenoethern umgesetzt, die man abhängig von den Substituenten in radiochemischen Ausbeuten von 9 
bis 55 % (bezogen auf elementares Se-75) erhielt. Diese Radiosynthese bietet den Vorteil, dass sowohl 
aliphatische als auch aromatische Se-73,75-markierte Verbindungen mittels entsprechender Alkyl- oder 
Aryl-Lithium- bzw. Grignard-Verbindungen synthetisiert werden können. 
Durch diese neuen trägerarmen Radioselenierungstechniken wurde im Rahmen dieser Arbeit die 
Klasse der zugänglichen Se-73,75-markierten Verbindungen erheblich erweitert. Insbesondere wurde 
erstmals eine Methode zur Synthese von n.c.a. Arylradioselenoethern entwickelt. Zur Identifizierung der 
Reaktionsprodukte mittels Radioanalytik wurden im Rahmen dieser Arbeit entsprechende RadioHPLC- 
und RadioTLC-Methoden entwickelt. Mehrere nicht-radioaktive Selenverbindungen wurden erstmalig 
synthetisiert. 
Neben verschiedenen einfacheren asymmetrischen Selenoethern gelang zudem die Synthese des 
Se-75-markierten Aminosäurederivates L-Homocysteinselenolacton und des Se-75-markierten Adenosin 
A(1)-Rezeptorliganden 5’-(Methylseleno)-N(6)-cyclopentyladenosin. Diese zwei komplexeren, physio-
logisch relevanten Moleküle konnten mittels der Selenoharnstoff-Methode in radiochemischen Gesamt-
ausbeuten von 20 bis 30 % (bezogen auf elementares Se-75) synthetisiert werden. 
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Chapter 1 
 
Introduction 
 
1.1 Radionuclides in Life Sciences 
 
Building on the discovery of radioactivity by H. Becquerel in 1896, the science of nuclear 
chemistry was born in 1898 when the Curies carried out the very first radiochemical 
investigations, leading to the discovery of polonium and radium. Since those years the work of 
many chemists made possible the rapid development of this new branch of natural science [1]. 
Among those chemists the Hungarian G. de Hevesy and the Austrian F. Paneth distinguished 
themselves by the idea to use radionuclides as indicators. The simple purpose of this 
radiotracer chemistry is to follow the behaviour of an element in a chemical reaction using 
radiolabelled atoms, which can be easily detected [2]. The first application (1912) was in the 
determination of the solubilities of lead chromate and sulfide [3], and Hevesy subsequently 
made use of this technique in work on chemical reactions, for example, isotopic exchange and 
electrolytic deposition. In 1920 he carried out the first biological experiments showing the 
distribution of lead atoms in a plant [4], thus discovering the possible application of this 
technique for the study of metabolic turnover. Further biological studies followed, and much of 
tracer studies in general and modern nuclear medicine in particular takes advantage of 
Hevesy’s realization that the state of radioactivity of radionuclides affects in no way their 
biochemical behaviour because the chemical properties of all isotopes of the same element are 
identical. He saw that a radioactive isotope might be used as a “representative” tracer of stable 
atoms of the same element whenever and wherever it accompanies them. This concept was 
followed by several other scientists and has become an important tool in life sciences. Thus, 
Hevesy is often attributed as “Grandfather of Nuclear Medicine”, and he received a Nobel Prize 
in 1943 as acknowledgement of his life’s work [5]. 
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The number of elements, however, for which radioactive isotopes were available, was 
comparatively small in the 1920s and possible applications of the method were in consequence 
strictly limited. But with the invention of the cyclotron by E.O. Lawrence (1930) and the 
construction of the first nuclear reactor by E. Fermi (1942) a wealth of artificial radionuclides 
became available, and their applications in life sciences have rapidly increased during the last 
century [6]. Because of their decay properties, their achievable chemical and radiochemical 
purity as well as their biochemical usefulness, only a small part of the more than 2400 
radionuclides known today can be used in nuclear medicine. They can be classified as 
diagnostic or therapeutic radioisotopes. The former are mostly short-lived single photon and 
positron emitters for in vivo tracer studies [7] and the latter longer-lived corpuscular radiation 
emitting radionuclides for brachytherapy and endoradiotherapy [8]. Apart from these in vivo 
medical applications, many radioactive in vitro methods (e.g. radioimmunoassay and auto-
radiography) have been developed. The radiotracer technique now extends over large fields of 
life sciences and has played a key role e.g. in the discovery of metabolic principles, of the 
function of receptor systems and in the development of pharmaceuticals. 
 
 
 
1.2 Emission tomography of radiotracers 
 
During the last three decades new powerful non-invasive imaging procedures have been 
developed to improve the diagnosis of diseases. The methods differ in their underlying physical 
basics, the achievable image with respect to temporal and spatial resolution as well as in the 
kind of information they produce. Whereas the strengths of computed tomography (CT), 
magnetic resonance tomography (MRT) and ultrasound (US) lie in the display of structural 
information, the attractive characteristics of nuclear medicine methods are their ability to reflect 
a variety of metabolic and physiological processes all over the body using, dependent on the 
radionuclide involved, single photon emission computed tomography (SPECT) or positron 
emission tomography (PET). For these purposes, substrates, which take part in metabolic and 
physiological processes, are labelled with radioisotopes and used as in vivo indicators [9 – 11], 
according to the radiotracer principle introduced by Hevesy. The use of radioactive tracers in 
clinical diagnosis and pharmaceutical research is still increasing because of their advantage of 
detection from outside the body. Because the radiotracer concentrations are generally 
extremely low, often in the subnanomolar range, these agents exert no pharmacodynamic 
effects and do not disturb the biological system in any kind [12]. 
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SPECT is the more widely available and routinely used tomographic tool of nuclear medicine 
due to its lower cost, providing qualitative images. The success of SPECT is strongly coupled to 
the artificial single photon emitter 99mTc. It emits a monoenergetic radiation of 140 keV and has 
a convenient half-life of about 6 h. Furthermore, it is available with a generator system, thus 
making SPECT independent of a nearby radionuclide production. Over the years the radio-
pharmaceutical industry has developed many kits containing precursor compounds to be 
labelled with Tc-99m. In addition, other photon emitters such as 123I and 201Tl are also used 
routinely. 
 
On the other hand, PET is regarded as an advanced method with a better sensitivity of a 
factor up to 100 over SPECT and therefore able to record shorter time frames in dynamic 
studies. Moreover, accurate transmission measurement and exact attenuation correction lead to 
quantitative interpretation of the PET images. As a result, this technique offers the possibility to 
quantify tracer concentrations and kinetics in organs and allows the application of bio-
mathematical models in order to calculate physiological reactions [13]. 
 
 
Fig. 1.1: Principle of coincidence measurement; the zoomed part scheme indicates the 
positron emission of 18F and the subsequent annihilation process 
 
Figure 1.1 shows the physical principles underlying PET. A positron is the primary result of 
the radioactive decay of an appropriate radiolabel used in PET. Depending on its energy, which 
is specific for the individual radionuclide, the positron travels a short distance (between less 
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than 1 mm to up to several mm) until it is nearly at rest and now able to interact with an 
electron, its anti-particle, in the surrounding material. As a result, both particles annihilate and 
produce a pair of tissue-penetrating photons that are emitted in 180° apart both with a 
characteristic energy of 511 keV, corresponding to the rest energy of one electron [14]. 
This event can be detected externally by a PET device, consisting of a circular array of 
scintillation detectors. If the two photons of a photon pair hit two opposite detectors of the ring 
within a very short time window (   12 ns), it is assumed that these photons belong to the same 
annihilation process (coincidence measurement). In this case, the positron emitter is located 
inevitable on the connecting line between the two detectors, and the spatial resolution is widely 
determined by the size of the detector crystal pair. Due to the fact that the 511 keV  -rays will 
completely penetrate the body when measured, an attenuation factor can be determined by an 
independent transmission measurement performed with 68Ge prior to the tracer injection in 
order to correct for scattering and absorption. This allows an accurate measurement of the dis-
tribution of radioactivity in the body. 
Nevertheless, the intrinsic loss of spatial resolution due to the uncertainty in distance between 
the origin of positron emission and of positron-electron annihilation may be a disturbing factor in 
applications requiring high resolution. The larger the positron energy, the larger is the average 
distance that it travels before annihilating and, consequently, the larger the loss of spatial 
resolution. This intrinsic effect is characteristic for the radionuclide and is independent of the 
design and imaging properties of the PET cameras. Therefore, nuclides for PET should ideally 
emit positrons having low energy. 
In vivo functional imaging with PET has been regarded mostly as a research tool, too 
expensive to become of general importance for routine clinical use. Indeed, in the late 1970s 
first PET devices were introduced mainly in research environments where necessary cyclotrons 
for the production of the short-lived neutron-deficient positron emitters were available [15]. 
Since then the sensitivity and image resolution of PET systems have been drastically improved. 
In addition, the rapid development of radiochemistry, in particular with regard to labelling with 
short-lived radionuclides at the no-carrier-added level played a key role in this context. The 
establishment of reliable labelling techniques, reasonable costs and clinical significance have 
led to a rapid world-wide increase of PET scanners from several dozens in 1990 to more than 
300 in 2000, used for routine medical imaging and pharmaceutical research. Modern PET 
cameras consist of up to 30 rings of detectors with a spatial resolution down to 3 – 5 mm and 
are sometimes combined with CT or MRT systems. This fusion of PET and MRT/CT facilitates 
three-dimensional images with exact attribution of physiological to morphological information. In 
addition, high resolution PET for animals [16] opens the possibility to perform repeatable drug 
trials in one animal, i.e. without the need for vivisection. This reduces the expense for such 
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experiments, saving animal lives and cutting costs for the development of new radio-
pharmaceuticals. 
 
 
 
1.3 Radiotracers for PET application 
 
Due to the high sensitivity and the good spatial resolution together with the precise quantitation 
obtained by PET technique one can acquire more (patho)physiological information about the 
nature of tissue function at the biochemical level than by any other non-invasive imaging 
procedure. This metabolic imaging or rather the measurement of regional biochemical functions 
requires endogenous or exogenous labelled substrates that participate in a metabolic process. 
Thus, the design of such tracers (termed as radiopharmaceuticals) is based on physiological 
concepts such as: 
 
• metabolic turnover of biological substrates and drugs, 
• perfusion, 
• enzyme function, 
• neurotransmitter biochemistry and 
• immuno reactions. 
 
Biomolecules (e.g. glucose, amino acids, fatty acids) and drugs mainly consist of carbon, 
hydrogen, oxygen, nitrogen, sulfur and phosphorus; therefore short-lived positron emitting iso-
topes of these elements lend themselves as authentic labels for those substances because of 
the unchanged chemical and physiological properties of the labelled molecules. In addition, a 
short half-life is advantageous for imaging in humans since large amounts of radioactivity can 
be administered for good counting rates while keeping the total absorbed radiation dose below 
a tolerably low rate. 
The so-called organic radionuclides 11C, 15O, 13N and 30P meet these demands, but due to 
their very short half-lives ranging from two to twenty minutes their applications are quite limited. 
In case of N-13 (T1/2 = 10 min) and O-15 (T1/2 = 2 min), simple molecules such as [13N]NH3, 
[15O]H2O and [15O]C4H9OH act as perfusion tracers and allow the measurement of blood flow 
and volume; molecular oxygen metabolism can be studied using [15O]O2. The half-life of car-
bon-11 (20.4 min), on the other hand, is more suitable for complex radiosyntheses and more 
extended PET studies. Several primary precursors such as the most important [11C]CO2, 
[11C]CH4 and [11C]CO [17] and the very significant secondary precursor [11C]CH3I are readily 
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available and offer the possibility to label a wealth of organic molecules with carbon-11 with 
high specific activity [18]. These radiosyntheses have been automated to facilitate the produc-
tion of 11C-labelled compounds, thus enabling diagnostic nuclear medicine to use some radio-
tracers (e.g. [methyl-11C]methionine [19], [11C]flumazenil [20] and [11C]raclopride [21]) routinely 
as PET radiopharmaceuticals. 
 
The short half-lives of the organic positron emitting radioisotopes, however, do not allow 
studies of slow biochemical processes. These require labels with longer half-lives than the 
available organic PET isotopes. The idea is to introduce a radioisotope of an element not 
present in the original biomolecule. This is referred to as foreign labelling resulting in a so-called 
analogue tracer. Radiohalogens (18F, 75,76Br and 124I) play a key role in this approach to 
radiopharmaceutical development [22, 23]. Structural analogues are obtained when a halogen 
atom replaces a hydrogen atom [e.g. 24], a hydroxyl or a methyl group. While structural 
changes are negligible with a fluorine atom substituting a hydrogen atom or a bromine or iodine 
atom formally replacing a methyl group, electronic changes can be significant, particularly in the 
case of fluorine. Substitution with a halogen also leads to an increase in lipophilicity (besides in 
case of aliphatic fluorination), which often results in an increased non-specific binding or even 
leads to a blood flow tracer, particularly in the case of iodine. So the biochemical properties of 
the halogenated analogue can be quite different from those of the original molecule. Since the 
suitability of a radiopharmaceutical is based on its ability to trace a physiological or biochemical 
response in specific tissue, this characteristic has to be tested in each individual case [12, 25, 
26]. 
Apart from those standard positron emitters, the increasing significance and spreading of PET 
stimulate the evaluation of alternative PET radionuclides (e.g. 73Se, see subchapter 1.6) to 
supplement the commonly used labels for two reasons mainly. First, studies of slow 
biochemical processes may require access to radionuclides that are more long-lived than the 
conventional PET nuclides. Secondly, due to a possible shipment of longer-lived positron 
emitters, satellite PET imaging units would benefit and would be more cost-effective. 
Furthermore, the newest generation of PET scanners makes increased use of long-lived 
radionuclides more acceptable, since much lower amounts of injected radioactivity are required 
for comparable images. 
 
Metallic positron emitters represent the third group of available PET isotopes. Unlike the 
organic and analogue counterparts, a number of cationic radionuclides can be produced by 
generators (e.g. 82Rb, 62Cu and 68Ga), thus being readily accessible even in facilities lacking a 
cyclotron [27]. For in vivo investigations they are applied as free cationic tracers or in 
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complexed form. In addition, the cyclotron-produced positron emitters Y-86 and Tc-94m are of 
some interest; the former primarily for the possibility of using PET to quantitatively assess the 
pharmacokinetics of 90Y-labelled agents used in therapeutic treatment and the latter to use PET 
for quantitative estimation of uptake of gamma emitting 99mTc-labelled SPECT radiopharma-
ceuticals [28]. 
 
 
Tab. 1.1: Nuclear properties of important PET radionuclides [from 7, 12] 
 
Nuclide     Half-life  Decay mode (%)          E(  +max) [MeV] 
 
 
organic 
 
11C      20.4 min   + (99.8); EC (0.2)        0.96 
 
13N      10 min  

+
 (100)         1.19 
 
15O        2 min  

+
 (99.9); EC (0.1)        1.72 
 
30P        2.5 min   + (99.8)         3.25 
 
 
analogue 
 
18F    109.6 min  

+
 (97); EC (3)        0.64 
 
73Se       7.1 h   + (65); EC (35)        1.30 
 
75Br      98 min  

+
 (75.5); EC (24.5)        1.74 
 
76Br      16 h  

+
 (57); EC (43)        3.90 
 
120I       1.35 h   + (64); EC (36)        4.10 
 
124I       4.2 d  

+
 (25); EC (75)        2.14 
 
 
metallic 
 
38K       7.6 min   + (100)         2.68 
 
62Cu       9.7 min  

+
 (98); EC (2)        2.93 
 
68Ga      68 min  

+
 (90); EC (10)        1.90 
 
82Rb       1.3 min   + (96); EC (4)        3.35 
 
86Y     14.7 h  

+
 (34); EC (66)        1.30 
 
94mTc     52 min   + (72); EC (28)        2.47 
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For several years, the most important and most used PET radionuclide for routine as well as 
research application has been fluorine-18. This is due to its very suitable nuclear and chemical 
properties, i.e.: 
 
• production in good yields, even with low-energy cyclotrons, 
• convenient half-life, allowing extended radiosyntheses and PET studies and even shipment  
 within a range of at least 100 km, 
• low positron energy, being advantageous with respect to high resolution PET and minor  
 radiation dose to the patient, 
• high specific activity, due to low natural occurrence of 19F, 
• several facile labelling reactions, developed to replace a C-H bond with a C-18F bond and 
• stability of the C-18F bond. 
 
As mentioned before, the introduction of fluorine into a biomolecule can alter its primary 
physiological properties. This is very useful in the case of 2-[18F]fluoro-2-deoxy-D-glucose 
(FDG), which is the most widely used fluorine-18 labelled radiotracer for PET. In vivo, FDG 
undergoes carrier-mediated uptake as a glucose analogue and serves as a substrate for 
hexokinase. But structural differences of FDG from the parent molecule (glucose) lead to no 
further metabolic acceptance. Since the labelled molecules remain in the cell, this is referred to 
as metabolic trapping, which allows quantitation of the regional glucose metabolism with the 
help of a three-compartment model [29]. FDG is used predominantly in the study of cerebral 
and myocardial metabolism and in the diagnosis of tumours due to the increased glucose 
metabolism characteristic of tumour cells [30, 31]. 
The importance of 18F-labelled PET tracers is still spreading thanks to the facile introduction of 
the label by fully automated black boxes or robots. Routine in vivo applications of such radio-
pharmaceuticals become more and more significant in medical imaging providing a new window 
to brain, heart and tumour in particular [32 – 34]. 
 
 
 
1.4 Basic aspects of no-carrier-added radio-labelling 
 
Radiopharmaceuticals are administered in the no-carrier-added state if possible, i.e. at doses in 
the subnanomolar range. Due to these chemically and physiologically insignificant quantities of 
radioactive material, pharmacodynamic as well as toxic and immunological reactions do not 
arise. Therefore, a decisive criterion for the quality of a radiotracer is its specific activity, which 
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depends on the amount of a carrier, i.e. an element or a compound with identical (isotopic 
carrier) or very similar (non-isotopic carrier) chemical properties to the radionuclide or the 
radiolabelled molecule, respectively. In radiochemical practice, radiosyntheses can be classified 
as 
 
• carrier-free (c.f.), 
• no-carrier-added (n.c.a.) or 
• carrier-added (c.a.). 
 
The absolute lack of a carrier is ideally only achieved when artificial radioelements (e.g. 
astatine) are used and the presence of longer-lived radioisotopes of the element can be 
excluded. This is the only case one can correctly term a carrier-free radiosynthesis. In contrast, 
when performing labelling reactions with cyclotron-produced radioisotopes of natural-occuring 
elements, traces of stable isotopes of these elements are omnipresent and act as isotopic 
carriers, provided that they are in the same chemical state. Possible sources of such 
contaminations are the air, target and reaction vessels, chemicals and solvents. The stable 
isotopes present in the reaction mixture are far in excess of the radioactive species but still 
below the limits of purification by normal chemical methods. In this case one speaks of a no-
carrier-added radiosynthesis. Under several circumstances, weighable quantities of the natural-
occuring element are added to the system in order to increase the radiochemical yield or even 
to make certain labelling methods possible. This is termed as a carrier-added radiosynthesis. 
In the origin sense, the specific activity As is the activity per unit mass of an element or 
compound containing the radioactive nuclide [35]. But since molar activities are more con-
venient and informative than specific activities, As is usually expressed on a molar basis: 
 
  As = 
n
A
 [Bq/mol]                 Eq. 1.1 
 
where A is the activity and n is the amount of substance. In the absence of stable isotopes of a 
radionuclide, the maximum molar activity As,max is given by: 
 
         As,max = NA 
1/2T
ln2
 [Bq/mol]                Eq. 1.2 
 
where NA is Avogadro’s number and T1/2 the half-life of the radionuclide. Many applications in 
nuclear medicine require high molar activities. For that reason it is useful to know the maximum 
values that are theoretically attainable. For example, the maximum molar activities of the 
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routinely used positron-emitters 18F and 11C are 6.3x1010 GBq/mol and 3.4x1011 GBq/mol, 
respectively. However, the ubiquity of stable elements has to be taken into account and the 
actual molar activities are much smaller than theoretically possible. 
 
As mentioned above, short-lived radionuclides of high specific activity represent micro-
amounts (< 1 µg) of matter. Handling of such minute amounts requires special precautions, 
because their physico-chemical behaviour may be quite different from that observed for 
components present at macroscopic scale. The most prominent difference is the possible 
sorption of a large part of n.c.a. radionuclides and radiolabelled products on the walls of the 
vessel during the reaction and on the exchange material during separation via chromatographic 
methods (e.g. HPLC, GC) or solid-phase systems. Besides, small quantities of impurities even 
in chemicals and solvents of high purity grade may be responsible for unexpected side-
reactions and losses. In consequence, the radiochemical yield may decrease in comparison to 
the yield of the corresponding macroscopic reaction and chemically very similar by-products 
may be produced. 
 
Furthermore, the course of a reaction at the n.c.a. level may strongly differ from that of the 
“classical” case due to the non-stoichiometric ratios and the non-equilibrium conditions. Where-
as in reactions of macroscopic chemistry higher kinetic orders prevail, syntheses at the n.c.a. 
level, on the other hand, normally proceed according to pseudo-first-order kinetics. In the case 
of a reaction of the form A + B → C, the concentration of the precursor A is in great excess over 
the n.c.a. radionuclide B, thus it is a good approximation to take [A] as constant throughout the 
reaction. Assumed the reaction starting with [B]0, the concentration of product C after the 
reaction time t can be written as: 
 
     [C]t = [B]0 (1 – e-kt)    [mol/l]                Eq. 1.3 
 
where k is the rate coefficient of pseudo-first-order type and contains the constant [A] [36]. 
Accordingly, with increasing reaction time t as well as with increasing precursor concentration 
[A] the radiochemical yield of C rises and can be plotted as a hyperbolic curve. The saturation 
yield finally reached corresponds in the ideal case to [B]0 and is often achieved within a few 
minutes due to the high excess of the precursor. Furtheron, consecutive labelling reactions of 
the product can be excluded, since the radionuclide and the radiolabelled product are both 
components at the tracer scale which do not interact for statistical reasons. 
 
Considering the differences between “classical” macroscopic chemistry and radiochemistry 
several further important points have to be taken into account for the development of a 
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synthesis of a radiopharmaceutical at the n.c.a. level. The synthesis, separation and quality 
control of a radiopharmaceutical should be completed within three half-lives of the radionuclide 
used. Because of the sensitivity to impurities, it is necessary to purify reagents and solvents 
with special care. The so-called “last-step labelling”, i.e. the introduction of the radioactive label 
into the compound at the latest possible stage, is desirable for routine production in order to 
avoid complex syntheses with radioactive intermediates which will minimize the radiochemical 
yield and increase the radiation burden. 
 
 
 
1.5 Selenium 
 
Selenium was discovered and isolated in 1817 by J. J. Berzelius and J. G. Gahn, having noticed 
and analyzed a reddish-brown deposit in the lead chambers of a sulfuric acid plant [37]. It was 
named after the Greek selene, the moon, since the new element resembled tellurium (Latin 
tellus, earth), discovered some 35 years before [38]. 
Selenium is a comparatively rare element and has a natural abundance of about 0.05 ppm of 
the earth's crust, similar to that of Ag, Hg and Pd. It is widely but unevenly distributed in rocks 
and soils, often found in association with sulfur. Many sulfides of chalcophilic metals (e.g. Cu, 
Fe, Ag) contain Se as selenide and partly in its oxidized form as selenite [39]. 
Selenium has six stable isotopes, of which the most abundant one is 80Se (49.6 %). They all 
generate distinct lines in mass spectra of selenium compounds, thus forming a characteristic 
group, making it easy to identify selenium-containing fragments. The isotope 77Se has a 
nonzero magnetic moment allowing nuclear magnetic resonance studies on selenium com-
pounds [40]. 
Selenium exists as several structurally definite forms [41, 42]: The red polymorphs     and 
), consisting of Se8 rings, are comparable with sulfur and often deposit during reactions 
involving organoselenium compounds especially by air-oxidation of reduced forms of Se. Grey 
(or “metallic”) selenium (m.p. 217°C, b.p. 685°C) is thermodynamically the most stable form 
showing metallic properties and can be obtained crystalline from molten selenium. Its structure 
of helical polymeric chains contains strong Se-Se bonds between adjacent Se atoms in the 
chain and weak metallic interactions between the neighbouring atoms of different chains. Grey 
selenium is of interest because of its photoconductive properties and therefore used in 
photoelectric devices and xerography. Finally, vitreous black selenium, the ordinary commercial 
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form of the element, comprises an extremely complex and irregular structure of large polymeric 
rings with up to 1000 atoms per ring. 
 
The main source of selenium is the anode slime accumulated during the electrolytic refining of 
Cu. These water-insoluble selenides obtained have to be separated from other components 
(Cu, Ag, Au, Te) of the deposit. The typical sequence for isolation and purification involves 
oxidation by roasting with soda ash in air resulting in water-soluble sodium selenite as well as 
sodium tellurite as by-product. Separation of Se and Te can be achieved by neutralizing the 
alkaline selenite and tellurite leach with sulfuric acid; this precipitates the tellurium as a hydrous 
dioxide and leaves the selenous acid (H2SeO3) in solution from which pure selenium can be 
precipitated by reduction with SO2 [43]. 
Several industrial applications [44] for selenium have been developed since its discovery. 
Glass and ceramic industries need significant quantities of selenium, which is used for 
decolorizing the green tint in glass products, caused by iron impurities. During World War I, this 
was especially practised due to critically shortage of manganese. On the other hand, selenium 
was found to impart a ruby-red colour to glass obtained by incorporating solid particles of 
cadmium sulfoselenide. 
Xerography is another very important application of Se. This invention by C. F. Carlson some 
60 years ago led to a rapid, cheap and dry process for direct document copying using vacuum-
deposited selenium as photoconductor [45]. The use of Se in photoelectric cells and semi-
conductor devices represents related functions. 
As an essential element of life, selenium is added in trace amounts to animal feeds to prevent 
certain diseases and to increase growth and of course utilized as human diet supplement. In 
medicine, a few Se-containing compounds act as fungicides. 
 
 
 
1.5.1 General chemical properties 
 
Selenium, a group VI A element (chalcogen) in the fourth period, exhibits many similarities of 
chemical properties to sulfur and tellurium. In its family it bridges between the nonmetals oxygen 
and sulfur and the metals tellurium and polonium, while in its period it is located between the 
metal (or metalloid) arsenic and the nonmetal bromine. Therefore, Se can be classified as both 
a metal and a nonmetal and occupies a unique position in the Periodic Table [46]. Like sulfur 
and tellurium, Se exists in the valence states –2 to +6 depending on the corresponding 
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compounds. As shown in Scheme 1.1, selenium can be reduced to selenide, oxidized to 
selenite and further oxidized to selenate. 
 
Se2- Se0 SeO32- SeO42- Sch. 1.1
 
 
The most stable compounds are the selenides formed with strongly electropositive elements 
(e.g. Na, K, Ca) as well as the compounds with strongly electronegative elements such as O, F 
and Cl. But compared to sulfur, the higher oxidation states of Se are not that stable and Se 
oxides are relatively strong oxidizing agents. Another property, which distinguishes Se from 
sulfur, is its ability to form compounds with a coordination number greater than four [47]. 
 
 
 
1.5.2 Organoselenium chemistry 
 
Although the first organic compound containing selenium, ethylselenol, was prepared in 1847, 
organoselenium chemistry was a neglected field for many years [48], not at least because of the 
bad odour of Se-containing compounds, which are far more evil-smelling than their thio ana-
logues. It was only in 1931 when the first selenium reagent was introduced into organic syn-
thesis: Riley et al. observed the specific nature of the oxidizing action of selenium dioxide 
(SeO2) on organic compounds [49]. Since that time SeO2 has been used as a versatile oxidant 
for olefins and aldehydes [50]. Apart from selenium dioxide as oxidizing agent, elemental 
selenium and potassium selenocyanate, used for the introduction of Se into organic com-
pounds, were the only selenium containing reagents employed for the next forty years. 
 
The period between 1970 and 1975 represents a turning point in the field of selenium 
chemistry. We can take this time as the birth of modern organoselenium chemistry: In 1970, 
Jones et al. observed that certain steroidal selenoxides rapidly decompose to produce the 
corresponding olefins [51]. Shortly thereafter it was shown that eliminations of selenoxides 
represent a very mild general olefin-forming reaction [52]. A few years later Sharpless et al. 
described a method for the conversion of epoxides to allylic alcohols that utilizes a selenium 
nucleophile [53]. What followed was a worldwide explosion of interest in this new field of organic 
chemistry. Many chemical reactions were described allowing a large variety of synthetically 
useful processes to be accomplished in high yields under mild conditions. In particular, 
transformations such as allylic oxidations, nucleophile-induced cleavage reactions, regiospecific 
alkylations and other manipulations of functional groups can be readily achieved [54, 55]. 
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Often chemists refer to the properties of organosulfur compounds in order to rationalize the 
properties of organoselenium compounds. This is a reasonable approach, considering the 
chemistry of these elements is qualitatively similar. However, their properties often present 
marked differences. Usually, organoselenium compounds are more reactive than their sulfur 
analogues presumably because of the slightly greater polarity and lower bond strength of the 
C-Se σ-bond as well as other σ-bonds such as the N-Se and O-Se bonds [56]. The Se-Se bond 
is less stable than the S-S bond and is easily cleaved in various reversible reactions. When 
exposed to light, selenium compounds are often coloured red by decomposition to the free 
element. 
 
The introduction of selenium into an organic structure can be performed in several ways [40, 
57]. Since the selenium atom is mainly bivalent in organic derivatives and stabilized in the 
oxidation state –2, a widely used method for the preparation of organoselenium compounds 
starts with the reduction of selenium by two equivalents of sodium borohydride [58] yielding 
sodium hydrogen selenide (1), which can be utilized directly in typical nucleophilic displacement 
reactions forming symmetric selenoethers (2) (Scheme 1.2). 
 
Se 2 eq. NaBH4
EtOH
NaHSe
EtOH
RSeR
1 2
RBr
 
 
Sch. 1.2: Preparation of symmetric selenoethers (2) 
 
Furthermore, diselenides, the selenium counterpart of organic peroxides and disulfides, play a 
key role in organoselenium chemistry since they are stable, easily handled and reactive enough 
to produce electrophilic and nucleophilic species [59], thus serving as useful precursors of 
various selenium functional groups. They can be produced by reduction of selenium with one 
equivalent of NaBH4 resulting in sodium diselenide (3) which can be transformed to disele-
nides (4) by reaction with alkylating agents (Scheme 1.3). 
 
Se
1 eq. NaBH4
EtOH
Na2Se2
EtOH
RSeSeR
3 4
RBr
 
 
Sch. 1.3: Preparation of diselenides (4) 
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Other methods for the introduction of selenium into organic molecules use the reaction of 
elemental selenium with organolithium compounds [60], isocyanides [61] or potassium cyanide 
and following nucleophilic displacement [62] to name a few only. 
 
 
 
1.5.3 Selenium biochemistry 
 
First attention to the biochemical properties of selenium and its compounds was turned in the 
1930s when Se was identified as a potent toxic substance for cattle and other livestock. Animal 
diseases known as “blind staggers” and “alkali disease” were put down to grazing on pastures 
with soil of a high Se content, especially in parts of the United States of America [63]. Since that 
time, it has been discovered that selenium produces many toxic events in a wide variety of cell 
types at excessively high levels of intake [64]. This Se toxicity causes severe cases of poisoning 
and may even lead to death. 
On the other hand, in 1957 the biological essentiality of selenium was recognized [65] and we 
now know that it is an essential trace element that serves as an integral component of several 
enzymes and acts as an antioxidant and anticarcinogenic agent [64]. This finding led to the 
recognition that several diseases are actually selenium deficiency syndromes; for example in 
certain parts of China, where an increased risk of heart diseases, bone and joint disorders and 
liver cancer is attributed to Se deficiency [66]. 
The complex and dynamic role, played by selenium in many biological processes has led to a 
very broad spectrum of research since the 1950s, still presenting many interesting problems. An 
effort is stimulated to discover and more thoroughly understand the role of selenium in 
mammalian organisms. 
 
Humans have an estimated dietary intake of selenium of approximately 250 µg/day mainly 
coming from cereals, grain, fish, meat and poultry either in the form of selenoamino acids or Se-
containing proteins and as selenate and selenite. The latter are reduced after ingestion to 
deprotonated hydrogen selenide (HSe-) probably by the same enzymes that metabolize sulfate. 
Selenium exists in biological systems mainly in the anionic form of selenols (R-Se-) or as 
selenoethers analogous to thioamino acids. The highest concentrations of selenium in humans 
are found in liver and pancreas, followed by kidneys. These organs are the sites of the major 
pathways of Se-metabolism [67]. 
The incorporation of Se into selenoproteins stands out due to two general pathways. On the 
one hand, in a highly specific fashion, selenium is incorporated into some functional proteins 
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during their biosynthesis in the form of the amino acid selenocysteine [68]. On the other hand, to 
a lesser degree, unspecific incorporation takes place with selenium replacing sulfur in already 
existing thioproteins. Therefore thioproteins always contain small amounts of Se. This is the 
main reason for the toxicity of selenium: When organisms receive more than micromolar 
concentrations of Se, too much sulfur is substituted. This may lead to inter- and intra-cellular 
dysfunction and eventually to death. 
 
Selenoenzymes play important roles in oxygen metabolism, detoxification processes and the 
immune system. Especially their antioxidant function, primarily associated with glutathione per-
oxidase, suggests that selenium is a significant anticarcinogenic and antimutagenic agent [69]. 
The best-known selenoprotein is the mentioned glutathione peroxidase, which was identified 
as a selenium-containing enzyme in 1973 [70]. Many studies showed that most tissues contain 
this selenoprotein, which catalyzes the reduction of H2O2 and organic hydroperoxides to the 
corresponding alcohols, thus protecting the cells from oxidative damage [71, 72]. The protein is 
a tetramer with four identical subunits each of them possessing one selenium atom (present as 
selenocysteine) at the active site [73]. 
However, the majority of the element is not bound to glutathione peroxidase and in tissues of 
rats at least 12 other Se-containing proteins or protein subunits have been detected [74]. To 
name only a few, selenium was found in the selenoprotein P [75] and W [76] and in deiodinase 
enzymes [77]. 
 
 
 
1.6 Radioselenium in nuclear medicine 
 
1.6.1 General applications 
 
The role of Se in mammals could not have been detected without the use of radioselenium. 
Here, neutron activation analysis benefits from the radioactive nuclide selenium-75 and its 
application has rendered very good service in metabolic studies. Furthermore, 75Se was used as 
a gamma-ray emitting label in a few radiopharmaceuticals despite unsuitable decay charac-
teristics for in vivo medical application. Nowadays, 75Se is mainly used in biochemical in vitro 
studies and for the development of radiosyntheses because of its conveniently long half-life and 
easy availability. 
Apart from 75Se, the positron emitting radionuclide 73Se is an interesting alternative label for 
application in PET. Due to the lack of suitable positron emitters of sulfur for in vivo application in 
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nuclear medicine, foreign radionuclides have to be used for labelling thio compounds. Due to 
the chemical homology of sulfur and selenium, radioselenium lends itself as a possible 
substitute for sulfur to obtain radiotracers for in vivo application. The physical half-life of 
selenium-73 permits PET studies to follow slow metabolism over extended periods. In addition, 
Se-73 would allow enough time for preparation and delivery of 73Se-labelled radiopharma-
ceuticals over long distances. 
 
 
 
1.6.2 Nuclear properties and production of selenium-75 and selenium-73 
 
As mentioned above, selenium-75 and -73 are the relevant radioisotopes of selenium to be 
used for the development of radiosyntheses and for application in nuclear medicine, respec-
tively. Their nuclear properties are shown in Table 1.2. 
 
Tab. 1.2: Nuclear properties of selenium-75 and -73 [from 78] 
 
 
Selenium-75 Selenium-73 
Half-life 120.4 d 7.1 h 
Decay mode EC (100 %)  + (65 %), Emax: 1.3 MeV; 
EC (35 %) 

-ray energy [keV] 265 (58 %) 511 (130 %); 361 (97 %) 
Daughter arsenic-75 arsenic-73 
Decay mode of daughter stable EC (T1/2 = 80 d) 
 
 
 
Selenium-75 decays via electron capture (EC) with a half-life of 120.4 d; selenium-73, on the 
other hand, decays both via positron emission (65 %) and EC (35 %) with a half-life of 7.1 h. 
75Se as a gamma-ray emitting label in various radiopharmaceuticals [79 – 81] proved insufficient 
for in vivo application due to the high internal radiation exposure to the patient when injected for 
diagnostic purpose. Furthermore, only poor-quality images are obtained with conventional 
gamma-cameras due to background interferences [82]. The advantage of 73Se over 75Se for 
application in nuclear medicine is its ability to be used as a PET label with two important 
physical properties. The relatively long half-life of selenium-73 offers the possibility to study 
selenated radiotracers with relatively slow pharmacokinetics. Secondly, its maximum positron 
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energy of 1.3 MeV results in an intrinsic spatial resolution of far less than 2 mm, which is very 
advantageous in PET studies. Besides, an apparently low total absorbed radiation dose is 
maintained in spite of the formation of 73As as radioactive daughter [83]. 
The commercially available radioisotope 75Se is generally produced via the (n, 	 )-reaction on 
natSe or enriched 74Se in a nuclear reactor, yielding c.a. 75Se with low specific activity. Since the 
1970s studies have been carried out to produce Se-75 and Se-73 in the n.c.a. state via a 
cyclotron. The most relevant nuclear reactions for the production of n.c.a. selenium-75 and -73, 
respectively, are given in Table 1.3. 
 
Tab. 1.3: Production routes for selenium-75 and -73 
 
Nuclear Reactions Optimum energy 
range [MeV] 
Yield 
[MBq (mCi)/ 
 Ah] 
Reference 
Selenium-75    
75As(p,n) 17 → 6 2.8 (0.075) [78] 
75As(d,2n) 24 → 10 2.6 (0.07) [78] 
    
Selenium-73    
75As(p,3n) 40 → 30 1406 (38) [78] 
75As(d,4n) 45 → 33 651 (17.6) [78] 
natGe(3He,xn) 36 → 13 37 (1) [84, 85] 
natGe(4He,xn) 28 → 13 26 (0.7) [84] 
natBr(p,x) 62 → 42 81 (2.2) [86] 
 
 
Nuclear data measurements showed that the most suitable method for the production of n.c.a. 
Se-75 is the 75As(p,n) process over the energy range of Ep = 17 → 6 MeV. This radioisotope can 
thus be produced even at a small cyclotron. But generally the production of 75Se in no-carrier-
added form has been handled in the context of 73Se production, i.e. as an impurity rather than 
an isotope of utility. 
First studies on the production of n.c.a. selenium-73 were carried out in the early 1970s using 
the natGe(3He,xn) reaction [85]. Later, 3He- and  -particle induced nuclear reactions on natural 
and enriched germanium were examined in detail and various production routes for 73Se were 
evaluated at medium-sized compact cyclotrons [84, 87]. Besides, the nuclear reaction 
natBr(p,x)73Se was investigated, obtaining 73Se with only minimal impurities [86]. Nevertheless, 
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the method of choice for the production of n.c.a. 73Se is the 75As(p,3n) process over the energy 
range of Ep = 40 → 30 MeV [78]. Although a cyclotron is needed providing higher energies 
compared to the production routes via germanium as target material, the obvious advantage is 
the very high production rate of the 75As(p,3n)73Se reaction. 
The separation of radioselenium from the irradiated target can be performed in general by 
three methods: Solvent extraction [85], anion-exchange chromatography [78] or thermo-
chromatography [88], depending on the specific target used, since very different materials are 
applicable. 
 
 
 
1.6.3 Radioselenium-labelling and radioselenium-labelled tracers 
 
The most common radioselenium-labelled compounds are selenoethers, as the selenium atom 
can form two stable covalent bonds to carbon. Stabilized in this chemical form (oxidation state 
-2) radioselenium may serve in general as an authentic label in selenium-containing bio-
molecules or as a foreign label in thio compounds of interest (e.g. thioamino acids, sulfur-
containing pharmaceuticals). Furthermore, an indirect labelling can be performed by coupling a 
radioselenium-containing moiety (prosthetic group) to an appropriate compound. Only a few 
methods for introducing radioselenium into organic molecules have been developed during the 
past 40 years, which are covered by this chapter. 
 
 
Carrier-added radiosyntheses and tracers 
 
Since the commercially available radioselenium-species is 75Se produced via the (n,  )-reaction 
on highly enriched 74Se, most of the radiosyntheses are based on carrier-added selenium-75 as 
starting material. In case selenium-75 is produced at the n.c.a. level via a cyclotron, natSe-carrier 
is added before beginning of the radiosynthesis. 
The most commonly used method for the preparation of symmetric c.a. [75Se]selenoethers 
starts with the reduction of [75Se]selenious acid or elemental 75Se with an excess of NaBH4 to 
obtain the [75Se]NaHSe nucleophile. This is a versatile reagent for the synthesis of a variety of 
75Se-labelled compounds, since it can readily displace halides and tosyloxy groups (X) attached 
to carbon by SN2 processes, yielding the appropriate 75Se-labelled symmetric selenoethers (1) 
according to Scheme 1.4 [89]. This strong nucleophilicity is mainly due to the softness of 
[75Se]NaHSe, which possesses donor orbitals of quite high energy levels [90]. 
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NaBH4
NaH75Se
RX
1
H275SeO3  /  75Se0 R75SeR
 
 
Sch. 1.4: Preparation of symmetric c.a. [75Se]selenoethers (1) 
 
On the other hand, asymmetric [75Se]selenoethers can be obtained through intermediate 
[75Se]selenols or [75Se]selenolates using two general synthetic pathways. As depicted in 
Scheme 1.5, sodium [75Se]diselenide is formed from NaH75Se by adding an equimolar quantity 
of elemental selenium to the ethanolic solution of NaH75Se. Afterwards, 75Se-labelled dialkyl 
diselenides can be prepared by adding an alkylating agent to Na275Se2. A reduction using 
NaBH4 yields alkyl [75Se]selenols, which may be converted with alkyl halides to asymmetric alkyl 
[75Se]selenides (2) [91]. 
 
NaH75Se SeH275SeO3  /  75Se0 Na275Se2
RX
R275Se2
- R'X R75SeR'
NaBH4
2
R75Se
NaBH4
 
 
Sch. 1.5: Preparation of asymmetric c.a. [75Se]selenoethers (2) via dialkyl [75Se]diselenides 
 
Alternatively, the synthesis of asymmetric [75Se]selenoethers is possible via 1,3-disubstituted 
[75Se]selenoureas as intermediates, resulting from 1,3-disubstituted carbodiimides and hydro-
gen [75Se]selenide, which can be generated from c.a. [75Se]selenite and phosphinic acid as 
reducing agent. 
 
75SeO32-
H3PO2
H275Se
RN C NR
75Se
RHN NHR
R1Br
+
Br - OH-
R175Se-
R2Br R175SeR2
75Se
RHN NHR
R1
2
 
 
Sch. 1.6: Preparation of asymmetric c.a. [75Se]selenoethers (2) via [75Se]selenoureas 
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Treatment of c.a. [75Se]selenoureas with alkyl bromides leads to corresponding [75Se]seleno-
uronium salts. Hydrolysis under basic conditions provides the [75Se]selenolates and a second 
alkylation yields asymmetric [75Se]selenoethers (2) (cf. Scheme 1.6) [92]. 
The irradiation of Se-containing molecules in nuclear reactors in order to obtain directly the 
corresponding 75Se-labelled compounds via (n,  ) reaction represents another possibility of 
radioselenium-labelling [93]. Later observations, however, showed that the (n,  ) process 
involves Se-C bond rupture and Se-Se bond recombination, resulting in several degradation 
products [94]. Thus, this labelling method has never gained any significance, also with respect 
to purification problems. 
 
Three commercially available 75Se-labelled radiopharmaceuticals were earlier used for routine 
in vivo functional imaging [95]: [75Se]selenomethionine, tauro-23-[75Se]selena-25-homocholic 
acid and [75Se]Scintidren. They could be used at the carrier-added level without any problem 
because they did not disturb the physiological systems examined. Since all the following com-
pounds were asymmetric [75Se]selenoethers, their syntheses were performed via diselenides as 
depicted in Scheme 1.5, unless otherwise mentioned. 
The amino acid analogue L-[75Se]selenomethionine (2-amino-4-methylselanyl-butyric acid) 
was the most prominent radioselenium-labelled radiopharmaceutical, being used as a pancre-
atic-imaging agent from the 1960s to the 1980s. That is because the pancreas is the site of high 
amino acid incorporation into proteins, for example digestive enzymes, and storage in secretory 
vesicles. Thus, L-[75Se]selenomethionine was a successful agent for detecting pancreatic tu-
mours [79]. 
The usual method for the preparation of L-[75Se]selenomethionine was via biochemical radio-
synthesis using Baker’s yeast, followed by peptide hydrolysis and isolation by ion-exchange 
chromatography. The procedure takes more than 30 h and gives an overall yield of 20 – 40 % 
[96]. Alternatively, a fast chemical synthesis was developed using 75Se0, methyl lithium and L-  -
amino-  -bromobutyric acid as starting material, giving L-[75Se]selenomethionine (3) in a radio-
chemical yield of more than 80 % in less than 3 h (Scheme 1.7) [97]. 
 
75Se0
MeLi
Me75SeLi
Br COOH
NH2
Me75Se COOH
NH2
3
 
 
Sch. 1.7: Chemical synthesis of L-[75Se]selenomethionine (3) 
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Apart from radioselenium-labelled selenomethionine, various [75Se]selenoamino acids have 
been synthesized as potential pancreatic imaging agents. Those include L-4-selenalysine (2-
amino-3-(2-amino-ethylselanyl)-propionic acid (4)) [98] and  -2/3-selenienylalanine (2-amino-3-
selenophen-2/3-yl-propionic acid (5)) [99] (Scheme 1.8), which were tested in rats. Although the 
pancreas to liver ratio of the latter is twice as good as that for L-selenomethionine, it never 
gained any importance in nuclear medicine. 
 
H2N
Se COOH
NH2
Se
COOH
NH2
4 5
 
 
Sch. 1.8: L-4-selenalysine (4) and  -2/3-selenienylalanine (5) 
 
75Se-labelled compounds have been used in clinical investigations of the enterohepatic 
circulation (gut, liver and biliary tree), thus simplifying the examination of the functional state of 
the terminal ileum. For this purpose, various 75Se-labelled bile acids were synthesized and their 
absorption and excretion were studied in animals [100]. The most promising compound tauro-
23-[75Se]selena-25-homocholic acid (6) (Scheme 1.9) was afterwards evaluated in man and 
showed very good results regarding absorption, secretion into the bile, reabsorption from the 
small intestine and resecretion [80]. This radiopharmaceutical was therefore used in the 1980s 
as a tracer of the complete enterohepatic circulation. 
Further, steroids labelled with selenium-75 have been effective non-invasive probes for the 
diagnosis of many types of adrenal disease. [75Se]Scintidren (6  -[(methyl[75Se]seleno)methyl]-
19-norcholest-5(10)-en-3  -ol (7), Scheme 1.9) was the agent of choice for the clinical diagnosis 
of adrenal pathologies [101]. 
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Sch. 1.9: Tauro-23-[75Se]selena-25-homocholic acid (6) and [75Se]Scintidren (7) 
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Beside these three earlier used and commercially available 75Se-labelled tracers, various 
other radioselenium-labelled compounds were synthesized. Two outstanding examples are 
given below. 
Certain types of central nervous system diseases such as Parkinsonism, Huntington’s Chorea 
and Schizophrenia are associated with changes in the density of dopaminergic receptors. These 
observations have generated considerable interest in the development of techniques for the 
non-invasive detection and quantification of dopaminergic receptor sites, proving ligands with 
high affinity for these receptors and labelled with gamma- or positron-emitting radionuclides as 
ideal agents for mapping dopamine receptor sites [102]. 
In this context, radiolabelled ergoline derivatives were synthesized and studied for some 20 
years. Pergolide, a synthetic, sulfur-containing ergoline, is a potent dopamine agonist in man 
[103]. Since pergolide contains a methylthio-moiety, which can be substituted by a methyl-
[75Se]seleno group, the synthesis of [75  ﬁﬀﬃﬂ "!#ﬀﬃ%$ &(')'+*ﬃ, - -8-[(methyl[75Se]seleno)methyl]-
6-propyl ergoline (8), Scheme 1.10) produced a new dopamine agonist with a gamma-emitting 
radionuclide [104]. 
[75Se]Selenopergolide was evaluated for its ability to cross the blood-brain-barrier of rats and 
showed a high uptake in the brain, adrenal and heart with good organ to blood ratios, so that 8 
might be clinically useful as a brain imaging radiopharmaceutical [102, 104]. 
An example for an authentic labelled tracer is [75Se]Ebselen (2-phenyl-1,2-benziso[75Se]sele-
nazol-3(2H)-one (9), Scheme 1.10). The non-radioactive Ebselen (PZ 51) is a synthetic organo-
selenium drug with low toxicity and anti-inflammatory properties [105]. Synthesis of the 75Se-
labelled compound supported investigations of the metabolism and the pharmacokinetics of 9 in 
animal experiments [106] and first studies showed several similarities between Ebselen and 
glutathione peroxidase, resulting in the in vivo capability of the compound to catalyse the 
conversion of hydroperoxides to alcohols [107]. 
 
N
H
H
75Se
8
75Se
N
O
9
 
 
Sch. 1.10: [75Se]Selenopergolide (8) and [75Se]Ebselen (9) 
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Due to the unsuitable decay characteristics of selenium-75 for in vivo medical application and 
improvements in the field of alternative methods for diagnosis (US, MRT, CT), these 75Se-
labelled radiotracers are no longer in use. 
By taking advantage of the positron-emitter selenium-73 instead of the gamma-emitting label 
75Se, several radioselenium-labelled tracers could be useful as imaging agents for future PET 
studies. For example, first human PET investigations with L-[73Se]selenomethionine, prepared 
by chemical synthesis described above, showed a very good delineation between liver and 
pancreas and this radiotracer may prove to be clinically valuable [82]. Moreover, it has been 
suggested that the use of L-[73Se]selenomethionine may even be appropriate to measure brain 
protein incorporation in humans with PET [108]. 
Apart from L-[73Se]selenomethionine, radioselenium-labelled steroids were studied as adrenal 
imaging agents [81] and these investigations showed that the use of several Se-73-labelled 
steroids would be a potentially powerful tool for the diagnosis of adrenal disease using PET. 
 
 
No-carrier-added radiosyntheses and tracers 
 
The drawback of the radiosynthetic pathways mentioned above is the indispensable addition of 
natSe-carrier, resulting in products of low specific activity and the risk of possible selenium 
toxicity. All attempts made to perform these radiosyntheses at the n.c.a. level failed either 
because of poor reaction kinetics at subnanomolar levels [86] or because the necessary 
formation of intermediate diselenide-species during the reaction is not possible without natSe-
carrier [92]. Two completely new labelling approaches have been developed recently to achieve 
no-carrier-added radioselenium-tracers. In these studies, 75Se was only used as model-nuclide 
for the development of radiolabelling methods. Possible future in vivo application for PET 
studies requires the use of Se-73. 
Schmaljohann reported the first synthesis of n.c.a. D/L-[75Se]selenomethionine (3) by a solid 
phase approach (Scheme 1.11) [109]. The reaction of elemental n.c.a. selenium-75 with 
polymer-supported triphenylphosphine led to the formation of the corresponding [75Se]triphenyl-
phosphineselenide. An alkylation with methyl triflate formed the [75Se]methylselenotriphenyl-
phosphonium salt. This phosphonium salt was hydrolized under alkaline conditions yielding the 
[75Se]methylselenide anion. Alkylation using D/L-2-tert.-butoxycarbonylamino-4-bromobutyric 
acid ethylester as precursor led to the formation of protected D/L-[75Se]selenomethionine. Acid 
hydrolysis gave the n.c.a. labelled D/L-selenomethionine in a radiochemical yield of 30 %. 
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Sch. 1.11: Preparation of n.c.a. D/L-[75Se]selenomethionine (3) [cf. 109] 
 
In 2001, Ermert et al. prepared n.c.a. homocysteine [75Se]selenolactone (L-3-amino-dihydro-
[75Se]selenophen-2-one (10)) by using sulfur as non-isotopic carrier (Scheme 1.12) [110]. This 
labelling method is based on the original chemical synthesis of c.a. [75Se]selenomethionine, 
described by Plenevaux et al. [97], substituting the selenium carrier by elemental sulfur. The 
reduction of n.c.a. [75Se]selenite under acidic conditions with sodium thiosulfate led to the pre-
cipitation of sulfur, inserting n.c.a. 75Se in the elemental form. This sulfur matrix was transformed 
with methyl lithium into a mixture of lithium methyl [75Se]selenide and lithium methyl mercaptide. 
Subsequent reaction with L-2-tert.-butoxycarbonylamino-4-bromobutyric acid ethylester resulted 
in the formation of the protected L-[75Se]selenomethionine and the corresponding methionine 
derivative. Following Birch reduction and consecutive cleavage of the protective groups under 
simultaneous lactonisation in presence of hydrochloric acid led to the formation of n.c.a. 
L-homocysteine [75Se]selenolactone hydrolchloride (10) with a RCY of 5 – 10 % and L-homo-
cysteine thiolactone hydrochloride. L-homocysteine [73Se]selenolactone could be used as a 
longer-lived alternative of [11C]homocysteine thiolactone, a sensitive indicator of adenosine 
production in ischemic myocardial tissue [111]. 
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Sch. 1.12: Radiosynthesis of n.c.a. L-homocysteine [75Se]selenolactone hydrochloride (10) with 
sulfur as non-isotopic carrier 
 
 
 
1.7 Radioligands for cerebral adenosine receptors 
 
1.7.1 Synaptic transmission 
 
The central nervous system (CNS) consists of a highly complex aggregation of cells, part of 
which is a communication network and another part a supportive matrix (glial cells). The 
communication network is formed by neurons, which are the functional cellular units consisting 
of a cell body (soma) with extensions (dendrites and an axon). Axons and dendrites emerging 
from different neurons intercommunicate by means of specialized junctional complexes known 
as synapses which are clefts (gaps) of between 15 and 20 nm separating the presynaptic and 
the postsynaptic sites [112, 113]. 
Almost all the synapses used for signal transmission in the CNS are chemical synapses. 
Whereas information is transmitted in a neuron by conduction of an electrical signal (also 
referred to as nerve impulse or action potential) from the soma or dendritic region along the 
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axon to the synaptic ending, a chemical neurotransmitter serves to signal information from the 
presynaptic end to the next cell. On release from nerve terminals, neurotransmitters act on 
receptor proteins at the postsynaptic membranes to produce either excitation, inhibition or 
modification of sensitivity of the target cell. Chemically mediated transmission involves the 
following processes (cf. Scheme 1.13): 
 
1. synthesis of the neurotransmitter in the soma of the presynaptic cell, 
2. storage of the neurotransmitter or its precursor in vesicles in the presynaptic terminal, 
3. release of the substance into the synaptic extracellular space in response to an appropriate 
electrical signal coming from the soma, 
4. recognition and binding of the compound by postsynaptic receptors and 
5. termination of the action of the neurotransmitter by inactivation, degradation or re-uptake. 
 
 
Sch. 1.13: Schematic depiction of a chemically mediated synaptic transmission 
 
More than 120 transmitter substances have been discovered thus far. Some of them (e.g. 
amino acids, acetylcholine) have an “inherent” biological activity. They bind to ligand-activated 
ion channels at the postsynaptic membrane, thus causing a direct increase in conductance of 
certain ions into the postsynaptic neuron. Other neurotransmitters are referred to as neuro-
modulators (e.g. biogenic amines, peptides); they have no direct activity but act indirectly via 
second messenger systems (e.g. G protein-coupled receptors) to bring about the postsynaptic 
28  Introduction 
 
 
response, mostly being slower but longer-lasting in their effects compared with those of the 
former [114]. 
Receptors, which can be classified in several types and subtypes, are those constituents of a 
cell that have the ability to recognize a drug, a hormone or a neurotransmitter. The membrane 
of the postsynaptic neuron contains large numbers of those receptor proteins. The molecules of 
these receptors have two important components: (1) a binding component that protrudes out-
ward from the membrane into the synaptic cleft and (2) an ionophore component that passes all 
the way through the membrane to the interior of the postsynaptic neuron. The protein surface of 
the binding component is a complicated shape containing hollows, ravines and ridges and 
somewhere amidst this complicated geography there is an area which has the correct shape to 
accept the incoming messenger. When the chemical messenger fits into this site, either the 
neurotransmitter acts as an agonist and “switches on” the receptor molecule and a postsynaptic 
action is induced, or the substance acts as an antagonist thus inhibiting a postsynaptic action. 
The binding of the neurotransmitter to its receptor is not based on a chemical reaction to obtain 
a completely new molecule, but rather on other interactions (ionic bonding, hydrogen bonding, 
van der Waals interactions, dipole-dipole interactions and induced dipole interactions). These 
specific binding interactions between messenger and receptor result in a change of the shape of 
the receptor protein and, in the case of an agonistic transmitter, subsequently affect other com-
ponents of the cell membrane (e.g. ion channels, G proteins) leading to a biological effect [115]. 
 
 
 
1.7.2 Binding assays with radioligands 
 
Though the basic principles governing the binding of neurotransmitters and drugs to receptors 
were elucidated many years ago, it was not until the 1960s that binding processes were studied 
directly. This was only possible by the use of radioactive labelled drugs. In the early 1960s, the 
binding of atropine to muscarinic receptors in smooth muscles was measured in this way. Over 
the next years, quantitative radioligand binding assays were developed for receptors for a 
variety of drugs and neurotransmitters, and ligands radiolabelled with 3H, 14C or 125I are now 
available for the study of many classes of receptors. This widespread availability of suitable 
ligands has led to a rapid expansion in the use of binding assays with radioligands to charac-
terize receptors and receptor subtypes [116]. 
Radioligands provide precise probes that permit specific examinations of the initial interaction 
between a drug and its binding site. For example, the kinetics of association and dissociation of 
a receptor-radioligand complex can be accurately determined by using simple tissue homo-
Introduction  29 
 
genates. A pharmacological profile of the radioligand that is based on the equilibrium disso-
ciation constants of a series of unlabelled ligands can be defined by measuring the inhibition of 
the binding of a radioligand by these unlabelled compounds. The use of radioligands also 
permits characterization of receptors in the absence of a measurable biological response. This 
is important in the study of CNS receptors, where the effects of neurotransmitters are complex 
and isolated tissue preparations are difficult to obtain. The use of binding assays with radio-
ligands can result in meaningful estimates of the number or density of receptors in a particular 
tissue. Consequently, changes in the density of receptors resulting from pathological conditions 
or pharmacological interventions can be monitored. Binding assays can also be used to dis-
criminate multiple classes of receptors in a single tissue and to estimate their relative pro-
portions [117]. 
Two basic types of assays utilize radioligands. The first, direct binding assay, measures the 
direct interaction of a radioligand with a receptor. Direct binding assays permit determination of 
both kinetic and equilibrium properties and provide estimates of the receptor density. They are 
also used to choose appropriate conditions and radioligands to determine the properties of 
receptors. 
The second, indirect binding assay, measures the inhibition of the binding of a radioligand by 
an unlabelled ligand to deduce indirectly the affinity of receptors for the unlabelled ligand. This 
approach is particularly useful in the characterization of receptors and, vice versa, of drugs. 
 
 
 
1.7.3 Purinergic system 
 
Purines such as adenosine 5’-triphosphate (ATP) (11) and adenosine (12) (Scheme 1.14) play a 
central role in the energy metabolism of all life forms, but it is also recognized that purines are 
released from neurons and produce widespread effects on multiple organ systems by binding to 
cell-surface purinergic receptors. ATP is a classical neurotransmitter that is packaged into 
neuronal secretory granules and released in quanta in response to action potentials. In addition, 
ATP is released from non-neuronal sources such as platelets, and large amounts escape from 
damaged cells. A number of ectoenzymes are involved in the rapid catabolism of ATP to 
adenosine in the extracellular space. 
Adenosine is not a classical neurotransmitter because it is not stored in neuronal synaptic 
vesicles. It is generally thought of as a neuromodulator that gains access to the extracellular 
space in part from the breakdown of extracellular ATP, and in part by translocation from the 
cytoplasm of cells by nucleoside transport proteins. Adenosine thus acts as a metabolic 
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messenger that imparts information about the intracellular metabolism of a particular cell to 
extracellular-facing receptors on the same and adjacent cells. Extracellular adenosine is rapidly 
removed, in part by reuptake into cells and in part by degradation to inosine. Receptors for both 
ATP and adenosine are widely distributed in the central and in the peripheral nervous system as 
well as in other tissues [118]. 
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Sch. 1.14: ATP (11) and adenosine (12) 
 
Based on physiological responses of various tissues to purines, Burnstock deduced that there 
are distinct receptors that bind adenosine (and analogues) or ATP (and analogues), designated 
P1 and P2 purinergic receptors, respectively [119]. It is known that there are families of both 
adenosine and ATP receptors, and these subtypes produce physiological responses in various 
organ systems upon activation by adenosine and ATP analogues, respectively [120]. 
 
 
Adenosine receptors 
 
One of the criteria initially used to distinguish P1 and P2 receptors was selective blockade of the 
former by xanthines such as caffeine (13) and theophylline (14) (Scheme 1.15). These xan-
thines occur naturally in coffee, tea and chocolate, and their well-known stimulant action has 
been attributed to blockade of P1 receptors in the CNS [121]. In addition, adenosine produces 
effects on cellular function, some of which are opposite to those produced by ATP. Thus, ATP 
functions as an excitatory transmitter in the CNS, whereas adenosine inhibits CNS excitability. 
Four P1 receptors, A1, A2A, A2B and A3 have been defined pharmacologically and cloned. All 
adenosine receptors are G protein-coupled, activated by adenosine and antagonized by 
xanthines [122]. 
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Sch. 1.15: Caffeine (13) and theophylline (14) 
 
A1 adenosine receptors are widely distributed in the CNS. These receptors have been 
extensively characterized in brain where they are expressed in high density (0.5 – 1 pmol/mg 
membrane protein). In the periphery, adenosine A1 receptors are found in the heart, in adipose 
tissue and in kidney. A1 receptor activation leads to inhibition of adenosine 3’,5’-cyclic mono-
phosphate (cAMP) formation and N-channel-mediated calcium-conductances. 
A2 adenosine receptors are divided into A2A and A2B subtypes based on substantial differences 
in tissue distribution and in binding affinity for adenosine, the former having high, the latter lower 
affinity to adenosine. In the CNS, A2A receptors are restricted to the striatum, nucleus accum-
bens and olfactory tubercle, whereas A2B adenosine receptors are distributed more ubiquitously 
throughout the CNS and the periphery. Both A2A and A2B are functionally coupled to activation of 
cAMP formation. 
The A3 receptor is present in the cerebral cortex, striatum and olfactory bulb with the highest 
concentration in the testis. It is negatively coupled to cAMP formation. 
 
Ligands for the adenosine receptors have a broad therapeutic potential because of the wide 
organ and tissue distribution of adenosine receptor subtypes [121]. Agonists for the adenosine 
receptors could, for example, be useful as sedatives and in the diagnosis of diseases of 
coronary arteries [123]. However, severe cardiovascular side effects can be expected, caused 
by the strong hypotensive effects of the adenosine agonists [124]. These side effects are major 
drawbacks in the therapeutic use of adenosine receptor agonists. Partial agonists could have 
less pronounced cardiovascular effects and may act more selectively [125]. Another advantage 
of partial agonists would be that they probably induce less receptor downregulation and 
desensitization. 
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1.7.4 Adenosine receptor ligands in medical imaging 
 
The discovery of adenosine receptor subtypes opened up new avenues for potential drug 
treatment of a variety of conditions such as neurodegenerative disorders, psychosis, anxiety 
and many other pathophysiological states that are believed to be associated with changes of 
adenosine levels [126 – 128]. Selective and potent agonists and antagonists at the human 
adenosine receptor subtypes are needed for such therapeutic intervention. Thus, the particular 
clinical importance of the A1 and the A2A adenosine receptors makes them attractive targets for 
radionuclide in vivo imaging. 
Whereas the radioligand binding assays described in subchapter 1.7.2 are in vitro methods, 
which require biopsy samples or post-mortem tissue in the case of human receptor studies, the 
technique of in vivo receptor imaging permits both, the detection of receptor abnormalities in 
various disease states and the control of drug treatment. PET is the imaging procedure of 
choice, offering the opportunity to study not only the distribution of the receptors via suitable 
radioligands, but also to obtain a pharmacological information equivalent, for example, to the 
in vitro measurement of Bmax (total number of binding sites). 
Though, there are several limiting factors for the use of radioligands of cerebral receptors 
[129]. Basic requirement is the possibility to label a suitable molecule with a positron-emitter 
(e.g. carbon-11, fluorine-18). The labelled compound has to be stable in vivo and should be 
transported to the target receptor without being metabolized. The logP-value should be ideally in 
the range of 2.2 – 2.4 to cross the blood-brain barrier, if the compound is not actively trans-
ported into the brain via a carrier-mediated system. The ratio of specific to non-specific binding, 
the (subtype) selectivity and the affinity to the target receptor (subtype) should be high. In 
addition, the specific activity of the radioligand should be as high as necessary (mostly at the 
n.c.a. level) in order to avoid a saturation of the receptor system by the compound administered. 
 
The adenosine receptor ligands under development for PET are all antagonists. There are 
mainly two reasons why adenosine antagonists, but not agonists, are used in PET. The first is 
that high affinity agonist binding requires that the receptor is coupled to a G protein. Since 
usually only a fraction of the receptors are coupled, labelled antagonists serve as better 
radioligands, because they bind to both, coupled and uncoupled receptors. Second, and 
perhaps most important, several metabolic pathways exist for adenosine and its analogues, 
possibly reducing the amount of radioligand available for binding to extracellular receptors, thus 
diminishing the ability of PET to detect specific binding to receptors. 
 
Introduction  33 
 
At present, both A1 and A2A adenosine receptors antagonists are under evaluation as PET 
ligands, all labelled with 11C or 18F [130]. The first A1 receptor ligand developed for PET was 
[11C]KF15372 (8-dicyclopropylmethyl-1-(1-[11C]propyl)-3-propylxanthine (15), Scheme 1.16), 
which was synthesized with a radiochemical yield of 5 % within 45-55 min [131]. Several studies 
in mice and monkeys [131 – 133] showed that the radioligand distribution in the brain was 
heterogeneous, predominantly to the cerebellum, striatum, thalamus and cerebral cortex, sites 
of known high adenosine A1 receptor density. The specific binding of [11C]KF15372 to A1 
receptors supports the use of this ligand for imaging CNS receptors, although a few drawbacks 
like rapid metabolism, high unspecific binding to organs such as the heart and the short half-life 
of 11C indicate that [11C]KF15372 is not the ideal radioligand. 
[18F]CPFPX (8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine (16), Scheme 1.16) has 
subnanomolar affinity to the bovine adenosine A1 receptor [134] and can be synthesized in 
radiochemical yields of about 55 % [135]. Quantitative autoradiography showed that distribution 
of [18F]CPFPX within the brain was to regions which were reported [136] to have a high density 
of A1 receptors. This radioligand is more advantegeous for the use in PET studies because of its 
longer half-life. 
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Sch. 1.16: [11C]KF15372 (15) and [18F]CPFPX (16) 
 
The first A2A adenosine receptor ligand for PET was [11C]KF17837 ((E)-8-(3,4-dimethoxy-
styryl)-1,3-dipropyl-7-[11C]methylxanthine (17), Scheme 1.17), which can be synthesized in 
radiochemical yields ranged between 19 and 50 % [137]. Biodistribution studies in mice and ex 
vivo autoradiography of rat brain showed that the accumulation of the radioligand in the striatum 
was higher than in cerebellum or cortex [138]. A comprehensive comparison of KF17837 and 
three other styrylxanthines in mice and rats identified [11C]KF18446 ((E)-8-(3,4,5-trimethoxy-
styryl)-7-[11C]methylcaffeine (18), Scheme 1.17) as a ligand with superior ability to label the 
striatum [139]. 
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Sch. 1.17: [11C]KF17837 (17) and [11C]KF18446 (18) 
 
There is some question about whether styrylxanthines such as [11C]KF17837 or [11C]KF18446 
specifically label adenosine A2A receptors in central neurons, because in primate brain regional 
distribution does not match receptor densities measured by other methods, notably quantitative 
autoradiography. Another recently developed potential radioligand for A2A receptors is 
[11C]MSX-2 (3-(3-hydroxypropyl)-8-(m-methoxystyryl)-7-(methyl-1-propargylxanthine), which 
binds to A2A receptors but also shows very high unspecific binding [140]. Several non-xanthine 
compounds are therefore at the beginning of evaluation. 
 
The main clinical application of PET studies of receptors is the determination of the density 
and pathophysiological changes of those receptors. Since the adenosine A1 receptor is 
neuromodulatory, it plays a critical role in the regulation of CNS activity, which explains its high 
density in areas such as the cerebral and cerebellar cortices, the basal ganglia and the 
thalamus. Accordingly, PET could be a useful tool in testing the hypothesis that defects of 
neuromodulation such as epilepsy owe to a decreased density of adenosine A1 receptors [141]. 
Since experimental models show that cerebral ischemia rapidly decreases A1 receptor density in 
brain [142], PET might have a role in mapping the extent of ischemic injury, for example, that is 
caused by stroke. 
The adenosine A2A receptor is found in high density in the basal ganglia of the brain, where 
substantial evidence indicates they act reciprocally with the dopamine D2 receptor in the control 
of movement [143]. Accordingly, A2A adenosine receptor PET ligands might be useful 
investigational or even diagnostic tools in Parkinsonism and other movement disorders [144 –
 146]. Preliminary evidence [147, 148] suggests that the A2A adenosine receptor may play a role 
in the pathogenensis of schizophrenia; PET could play a role in testing that hypothesis and in 
given case be of diagnostic help. 
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Chapter 2 
 
Aims and Scope 
 
Selenium-73 is considered as a candidate for application in positron emission tomography as 
already outlined in the Introduction (cf. subchapter 1.6). This positron-emitting radionuclide 
(65 % . +) can be produced in sufficient amounts via the 75As(p,3n)73Se nuclear reaction. Its half-
life of 7.1 h enables to perform PET studies over extended periods in order to follow slow 
kinetics in a given case. Due to a lack of a suitable radioisotope of sulfur for in vivo medical 
application in nuclear medicine, 73Se may serve as a possible substitute for sulfur in thio com-
pounds of interest according to the chemical homology of sulfur and selenium. Moreover, 
selenium-containing biomolecules could be labelled and utilized as radiotracers for PET studies. 
 
The toxicity of selenium compounds on the one hand, and conceivable future applications of 
73Se-labelled molecules, e.g. as radioligands for the determination of receptor density and 
occupancy, on the other hand, require the use of no-carrier-added products. The availability of 
potential 73Se-labelled radiopharmaceuticals at the n.c.a. level, though, is quite limited because 
only two methods for introducing n.c.a. radioselenium into organic compounds have been 
developed thus far. The disadvantage of these radiosyntheses, however, is their limitation to the 
class of n.c.a. labelled methyl selenoethers. 
 
The aim of this work was to enlarge the range of available n.c.a. 73Se-labelled compounds to 
a wide variety of asymmetric alkyl and aryl selenoethers, in which selenium is stabilized in the 
oxidation state –2 and forms two stable covalent bonds to carbon. For convenience, the de-
velopment and optimization of the radiosyntheses were to be performed using the longer-lived 
selenium-75 (T1/2 = 120.4 d). Some of the labelling routes developed were to be repeated with 
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selenium-73 afterwards in order to compare the radiochemistry of selenium-73 and selenium-
75. 
 
The main focus should be on the development of straightforward synthetic strategies leading 
to n.c.a. radioselenoethers within the shortest possible time and with high radiochemical yield. 
Based on a recent research project, in which carrier-added 1,3-disubstituted [75Se]seleno-
ureas served as intermediates for the preparation of c.a. asymmetric radioselenoethers, a new 
radiosynthesis should be developed in order to obtain radioselenium-labelled products at the 
no-carrier-added level. The conversion of n.c.a. elemental 75Se to an appropriate n.c.a. 1,3-di-
substituted [75Se]selenourea is the key step of the underlying radiosynthetic strategy and should 
be investigated in detail using an alkyl isocyanide and an alkyl amine. Subsequent reaction 
steps, including alkylation of the [75Se]selenourea, hydrolysis and a final alkylation were to be 
examined, thus generating various asymmetric n.c.a. [75Se]selenoethers. Furthermore, in con-
sideration of a future automated synthesis for clinical routine use, a polymer-supported radio-
synthesis was to be developed using the outlined pathway. 
Alternatively, a route via alkyl [75Se]selenocyanates as intermediates, their effective synthesis 
using n.c.a. 75Se0, sodium cyanide and alkylating agents as starting materials was to be 
investigated. The conversion of alkyl [75Se]selenocyanates to the desired n.c.a. radioselenium-
labelled products was to be performed via suitable reagents. 
 
Special emphasis should be on the optimization of every single reaction step of each radio-
synthesis regarding various reaction conditions in order to obtain labelled products in a highly 
efficient manner. Preparation of different [75Se]selenoethers as model compounds should show 
the versatility of the radiosynthetic strategies developed. 
In addition, two more complex, physiologically relevant radioselenium-labelled compounds 
should be prepared to demonstrate the utility of the radiosyntheses developed. The first one, L-
homocysteine [75Se]selenolactone, is a potential in vivo indicator for ischemic myocardial tissue 
and is of great interest as a longer-lived alternative of [11C]homocysteine thiolactone. The 
second one is 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine, which is a radioligand with high 
affinity for the adenosine A1 receptor. The evaluation of the no-carrier-added radiochemistry is 
particularly important for future labelling with selenium-73. 
 
In order to identify 73,75Se-labelled intermediates and products, suitable conditions for radio 
high performance liquid chromatography and radio thin layer chromatography needed to be 
developed. In addition, standard compounds and precursors had to be synthesized. 
   37 
 
Chapter 3 
 
Results and Discussion 
 
Selenoethers, sometimes also referred to as selenides, are one of the most stable classes of 
selenium-containing organic compounds [54]. They do not decompose in dilute acids or strongly 
alkaline solutions and are resistant to mild oxidizing or reducing agents. Furthermore, they 
possess a satisfactory in vivo stability [89]. Of particular interest are asymmetric selenoethers, 
since they cover a broad range of Se-containing compounds. Therefore, a potential approach 
for labelling of organic, pharmacologically effective substances with radioselenium is the 
synthesis of appropriate asymmetric radioselenoethers, which may possibly act as tracers in 
nuclear medicine. Special emphasis is laid on the preparation of radioselenium-labelled com-
pounds at the no-carrier-added level to obtain products of high specific activity. This is due to 
the fact that, firstly, in vivo toxic effects can be excluded and, secondly, suitable selenoethers 
can be used as radioligands for the determination of receptor occupancy and density. 
 
Several synthetic strategies have been developed for the preparation of asymmetric seleno-
ethers [40, 46, 54, 56]. Some of the more important of these are outlined in Scheme 3.1. The 
direct application to radiolabelling, especially at the n.c.a. level, though, is not possible for all of 
them. 
The commonly used synthetic pathways A-C do not seem suitable for the preparation of n.c.a. 
radioselenoethers, since they require the use of dimeric or trimeric selenium species as starting 
material (A, B) or as intermediate (C). For statistical reasons, a reaction between two compo-
nents at the n.c.a. level can be excluded [149]. Thus, a formation of n.c.a. radioseleno 
oligomers is not likely. 
Therefore, alternative reaction sequences for introducing n.c.a. radioselenium into organic 
compounds appear necessary. The first synthesis of a n.c.a. 75Se-labelled organic compound 
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([75Se]selenomethionine) was reported by Schmaljohann using n.c.a. selenium-75 in its 
elemental form as starting material (synthetic pathway D) [109]. However, using strategy E, 
repeated attempts to prepare n.c.a. [75Se]selenomethionine failed [82, 97]. 
The use of a selenourea as intermediate for the synthesis of asymmetric selenoethers seems 
to be another promising approach (concepts F, G). The reduction of selenite to hydrogen 
selenide, however, does not occur directly, but proceeds via the intermediates Se0 and Se22-. 
The first reduction step from selenite to elemental selenium can be carried out without any 
problem. Further reduction from Se0 to hydrogen selenide most probably requires the interim 
formation of diselenide-species. Since these cannot be formed at the n.c.a. level, the 
preparation of n.c.a. hydrogen [75Se]selenide does not appear possible, and n.c.a. selenoureas 
cannot be obtained via the synthetic pathway F [92]. 
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Sch. 3.1: Synthetic concepts for the preparation of asymmetric selenoethers 
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Alternatively, the strategies G and H offer principally the possibility to synthesize asymmetric 
n.c.a. radioselenoethers via selenoureas and selenocyanates, respectively, which is examined 
in this work in detail. 
 
Both, selenium-73 and selenium-75 are the relevant radioisotopes in this study. They were 
produced in the no-carrier-added state at appropriate cyclotrons using the 75As(p,3n)73Se and 
the 75As(p,n)75Se nuclear reactions, respectively [78, 88]. Thermochromatographic workup of 
the target, following reduction by sulfur dioxide and extraction provided n.c.a. 73Se0 and n.c.a. 
75Se0, respectively, in benzene [88]. The alternative method for the reduction of n.c.a. 
[73,75Se]selenite to 73,75Se0 via sodium thiosulfate [110] was only used in few preliminary studies 
of the development of radiosyntheses, because the presence of thio compounds could have 
undesired effects on the radiosyntheses. 
Throughout this work selenium-75 served as a model-nuclide for the development of radio-
syntheses because of its more suitable physical properties for this purpose than Se-73: 
 
• longer half-life (120.4 d vs. 7.1 h), 
• easier accessibility (20 MeV protons vs. 45 MeV protons), 
• lower radiation exposure to the experimentalist (265 keV / -ray vs. 1.3 MeV 0 +-particles), 
• non-radioactive daughter nuclide (75As vs. 73As). 
 
In view of the fact that selenium-73 is the required radionuclide for PET studies, several 73Se-
labelled model compounds were prepared after development and optimization of the radio-
synthetic strategies with selenium-75 in order to compare the radiochemical yields of the 
corresponding 73Se- and 75Se-labelled compounds, thus confirming that the radiosyntheses 
developed are also suitable for the preparation of n.c.a. [73Se]selenoethers. 
 
 
 
3.1 No-carrier-added radioselenoethers via 1,3-disubstituted 
[73,75Se]selenoureas 
 
Recently, it was shown that carrier-added (c.a.) 1,3-disubstituted [75Se]selenoureas, which were 
obtained by reaction of c.a. [75Se]H2Se and carbodiimides, are attractive intermediates for the 
synthesis of various asymmetric c.a. [75Se]selenoethers [92]. The drawback of this synthesis, 
however, is the indispensible addition of natSe-carrier, resulting in products of low specific 
activity. Using the concept of selenoureas as radioselenium-labelled intermediates as basis, this 
project led to a new labelling method at the n.c.a. level [150]. 
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It is known that the reaction of selenium with alkyl isocyanides produces alkyl isoseleno-
cyanates (1), which can be converted to the desired selenoureas (2) by adding corresponding 
amines [61, 151]. The alkylation of 2 can be done by various alkylating agents due to the highly 
polarized carbon-selenium bond [152] yielding corresponding selenouronium salts (3). Hydro-
lysis under basic conditions provides the alkyl selenolates (4) [153] and subsequent in situ 
alkylation yields asymmetric selenoethers (5) [40] (Scheme 3.2). 
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Sch. 3.2: Synthesis of selenoethers (5) via substituted selenoureas (2) 
(R1 = R2 = cyclohexyl; R3 = methyl, ethyl, propyl; X = triflate; R4 = various alkyl 
moieties; Y = bromine) 
 
In the preliminary stages of the development of the radiosynthesis, this synthetic pathway was 
followed using natSe0 as starting material in order to check for general feasibility of this concept. 
It also served to synthesize the standard compounds used as reference for radio high 
performance liquid chromatography (radio-HPLC) and radio thin layer chromatography (radio-
TLC). All non-radioactive seleno compounds 1-5 were obtained in satisfactory yields (cf. 
subchapter 4.2.1). 
 
The development and optimization studies of the n.c.a. radiosynthesis via 1,3-disubstituted 
[75Se]selenoureas using n.c.a. 75Se0 as starting material are described in the following. 
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3.1.1 Cyclohexyl iso[75Se]selenocyanate via cyclohexyl isocyanide 
 
According to resonance theory, the carbon atom of an alkyl isocyanide bears a lone electron 
pair and may act as a nucleophile. The radiosynthetic strategy to be developed takes 
advantage of this property by performing a nucleophilic attack on n.c.a. 75Se0 to give an alkyl 
iso[75Se]selenocyanate ([75Se]1). This introduction of n.c.a. radioselenium into an organic 
compound is the initial key-step of the radiosynthesis; the investigation of this reaction 
sequence is therefore essential. Optimization studies regarding solvent and temperature were 
performed using commercially available cyclohexyl isocyanide as precursor yielding the model 
compound cyclohexyl iso[75Se]selenocyanate ([75Se]1a) (Scheme 3.3). 
 
N
75Sen.c.a. 75Se0
[75Se]1a
C
benzene, 80°C
N C
 
 
Sch. 3.3: Synthesis of cyclohexyl iso[75Se]selenocyanate ([75Se]1a) 
 
Since the nucleophilic attack of the carbon atom on [75Se]selenium takes place only at higher 
temperatures according to literature [154], the impact of various solvents on this reaction was 
examined at 80°C. As graphically depicted in Figure 3.1 the maximum radiochemical yield 
(RCY) of [75Se]1a (all RCYs given in subchapter 3.1.1 are related to n.c.a. 75Se0) was obtained 
within 45 min using ethanol, benzene or acetonitrile as the solvent (with 57 ± 6 %, 54 ± 5 % and 
47 ± 7 %, respectively). The subsequent slight decrease of the RCYs can be attributed to 
decomposition of [75Se]1a due to further heating. Ethanol as a protic, benzene as a relatively 
unpolar and acetonitrile as a dipolar aprotic solvent have the same effect on the RCY of 
[75Se]1a. They are equally suitable solvents, whereas the use of dimethyl sulfoxide led to a 
maximum RCY of 19 ± 4 % only within 15 min. Apparently, interactions between dimethyl 
sulfoxide and the product led to a rapid decomposition of [75Se]1a, yielding unidentified 75Se-
labelled byproducts, as shown by radio-TLC. 
Although ethanol appeared as the most suitable solvent because of the largest RCY obtained, 
benzene was used in subsequent optimization studies in order to avoid a change of solvent 
after extraction of elemental selenium-75 into benzene during isolation. 
 
42  Results and Discussion 
 
 
0 20 40 60 80
0
10
20
30
40
50
60
70
 
 
 ethanol
 benzene
 acetonitrile
 methyl sulfoxide
R
CY
 [%
]
time [min]
 
Fig. 3.1: Radiochemical yield of cyclohexyl iso[75Se]selenocyanate ([75Se]1a) as a function of 
time and solvent 
 Reaction conditions: 370 kBq n.c.a. 75Se0, cyclohexyl isocyanide (10 µL, 80 µmol), 
0.5 mL solvent, 80°C. 
 
The data given in Figure 3.2 show that the RCY of [75Se]1a decreased with decreasing 
reaction temperature. The maximum RCYs were obtained within 45 min and reached 54 ± 5 %, 
47 ± 5 % and 32 ± 3 % at 80, 60 and 40°C, respectively. Since there is no detectable reduction 
of the RCY of [75Se]1a at 60 or 40°C after reaching the saturation yield of about 50 and 30 %, 
respectively, the process of decomposition of [75Se]1a seems to be effective only at tempera-
tures above 60°C. 
 
The concentration of the precursor cyclohexyl isocyanide was also optimized. Such studies 
showed that the reagent is needed in an amount of at least 80 µmol per 0.5 mL benzene to 
provide [75Se]1a with an optimum RCY of 54 ± 5 %. These optimization studies showed that the 
reaction sequence illustrated in Scheme 3.3 is best carried out in 0.5 mL benzene at 80°C within 
45 min using at least a 160 mM solution of cyclohexyl isocyanide. 
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Fig. 3.2: Radiochemical yield of cyclohexyl iso[75Se]selenocyanate ([75Se]1a) as a function of 
time and temperature 
 Reaction conditions: 370 kBq n.c.a. 75Se0, cyclohexyl isocyanide (10 µL, 80 µmol), 
0.5 mL benzene, various reaction temperatures (80, 60, 40°C). 
 
 
 
3.1.2 Formation of 1,3-dicyclohexyl [75Se]selenourea using a one-pot 
procedure 
 
Primary amines easily add to alkyl isoselenocyanates (1) to give 1,3-disubstituted seleno-
ureas (2) by forming a new C-N bond between the nitrogen of the amino group and the carbon 
atom of the isoselenocyanate group [61, 151]. This reaction sequence was used to synthesize 
1,3-dicyclohexyl [75Se]selenourea ([75Se]2a) as model compound starting from [75Se]1a and 
cyclohexylamine. Using the optimal reaction conditions described above for the preparation of 
[75Se]1a, it was demonstrated by radio-TLC that [75Se]2a was obtained immediately upon 
adding cyclohexylamine to the reaction mixture. Accordingly, a one-pot procedure was 
examined as model reaction for the preparation of [75Se]2a with interim formation of [75Se]1a 
starting from a mixture of n.c.a. 75Se0, cyclohexyl isocyanide and cyclohexylamine (Scheme 
3.4). 
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Sch. 3.4: One-pot synthesis of 1,3-dicyclohexyl [75Se]selenourea ([75Se]2a) 
 
For convenience, this reaction step was optimized in benzene as explained in subchap-
ter 3.1.1. An optimal RCY of [75Se]2a (92 ± 5 %; RCYs given in subchapter 3.1.2 are related to 
n.c.a. 75Se0) was obtained via the one-pot synthesis at 80°C within 90 min as graphically 
depicted in Figure 3.3. 
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Fig. 3.3: Radiochemical yield of 1,3-dicyclohexyl [75Se]selenourea ([75Se]2a) as a function of 
time 
 Reaction conditions: 370 kBq n.c.a. 75Se0, cyclohexyl isocyanide (10 µL, 80 µmol), 
cyclohexylamine (10 µL, 90 µmol), 0.5 mL benzene, 80°C. 
 
Surprisingly, the plot shows that the reaction rate of the synthesis of [75Se]2a was much faster 
than that of [75Se]1a. This unexpected observation can be explained as follows. Firstly, the 
radiosynthesis of [75Se]1a is the rate-determining step of the one-pot procedure. Apparently, 
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[75Se]1a, once formed, is immediately converted to [75Se]2a. In this case, the rate of the 
synthesis of [75Se]2a should be identical with that of the synthesis of [75Se]1a. A possible 
explanation of the difference between the reaction rate of [75Se]1a and [75Se]2a is, that the rapid 
conversion of [75Se]1a to [75Se]2a prevents the decomposition of [75Se]1a, which is much 
slower. Therefore, one can suggest that the reaction rate of [75Se]2a is also the actual rate of 
the formation of [75Se]1a, while the experimentally determined reaction rate of [75Se]1a is the 
overall rate of both, formation and decomposition of [75Se]1a and is therefore smaller. Due to 
the fact that the intermediate [75Se]1a, once formed, is immediately transformed to [75Se]2a, the 
decomposition does not affect the RCY of [75Se]2a, which explains the larger RCY of [75Se]2a 
than that of [75Se]1a at any reaction time. 
 
As outlined in subchapter 1.4, n.c.a. syntheses of the form A + B 1  C proceed according to 
pseudo-first-order kinetics and thus, the concentration (or activity) of the labelled target 
molecule can be written as: 
     [C]t = [B]0 (1 – e-kt)    [mol/l]                Eq. 3.1 
 
with k: rate constant, [B]0: initial activity of 75Se0 and [C]t: activity of [75Se]1a and [75Se]2a, 
respectively, at reaction time t. 
Both, the synthesis of [75Se]1a as well as the synthesis of [75Se]2a are of the form A + B 1  C. 
The former is straightforward and contains A (cyclohexyl isocyanide), B (n.c.a. 75Se0) and C 
([75Se]1a); the latter is more complex and can be written as A + B 1  C + D 1  E with A: 
cyclohexyl isocyanide, B: n.c.a. 75Se0, C: [75Se]1a, D: cyclohexylamine and E: [75Se]2a. Since 
the first stage of this sequence is rate-determining and C and D were converted immediately to 
E after formation of C, this synthesis can roughly be simplified by leaving out the intermediate C 
and the second precursor D, which is in large excess. Thus, the synthesis can be written as 
“A + B 1  E”, now representing a pseudo-first-order reaction. 
In order to determine the rate constants k of [75Se]1a and [75Se]2a, one can convert 
Equation 3.1 to the formula ln([B]0/([B]0-[C]t)) = kt. The corresponding plots of this term as a 
function of time can be seen in Figure 3.4. Only the first 20 min were taken into account. As 
expected for reactions which proceed according to pseudo-first-order kinetics the plots can be 
fitted resulting in corresponding straight lines. The slopes of these regression lines give the rate 
constants k, being 0.048 min-1 and 0.024 min-1 for the synthesis of [75Se]2a and [75Se]1a, 
respectively. 
From these k-values one can suggest that the decomposition reaction considerably affects 
the overall reaction rate of the formation of [75Se]1a and that the consecutive step from [75Se]1a 
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to [75Se]2a seems to prevent the decomposition of [75Se]1a by the instant conversion to 
[75Se]2a. 
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Fig. 3.4: Plot of ln([B]0/([B]0-[C]t)) as a function of time for the determination of the relative rate 
constant k for the synthesis of [75Se]2a and [75Se]1a 
 Reaction conditions: see Fig. 3.3. 
 
After additional optimization studies with respect to the amount of precursor, the radio-
selenium-labelled intermediate [75Se]2a was conveniently generated in benzene at 80°C via a 
one-pot procedure with a RCY of 92 ± 5 % within 90 min using cyclohexyl isocyanide and 
cyclohexylamine each with a concentration of at least 0.16 mol/L. 
 
 
 
3.1.3 Alkylation of 1,3-dicyclohexyl [75Se]selenourea 
 
The nature of the selenourea group and in particular the position of its double-bond is 
responsible for the advantegeous use of selenoureas as suitable intermediates for the pre-
paration of selenoethers. Resonance structures of the selenourea group can be depicted by I 
and II in Scheme 3.5. From experimental [155] and semi-theoretical [156] investigations it is 
concluded that II is the more important resonance form. The increased contribution of II is 
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explained as due to a decrease in orbital overlap between the carbon 2p and the selenium 4p 
orbitals, which leads to a reduction of the C=Se double-bond character, thus polarizing the 
selenium atom by imparting a negative charge. 
 
N C
Se
N
N C
Se
N
I II
 
 
Sch 3.5: Resonance structures of the selenourea group 
 
Therefore, alkylation of selenoureas never occurs at the N atom but rather at the Se atom 
[157] to give the corresponding selenouronium salts (3) [152], which are sometimes also 
referred to as isoselenouronium salts or selenopseudourea salts. They show ionic character, 
the cation containing the tetravalent selenium atom, and are more stable than the selenourea 
precursor [40]. Commonly used agents for the alkylation of selenoureas are alkyl halides or 
tosylates. For reasons of slow reaction kinetics, this alkylation step takes place only at high 
reaction temperature and a prolonged reaction time [92]. 
In this study, attempts to obtain n.c.a. [75Se]selenouronium salts ([75Se]3) using alkyl halides 
or tosylates failed under a variety of different reaction conditions because of an unexpectedly 
rapid decomposition of n.c.a. [75Se]2a to elemental selenium-75. Therefore, trifluoromethane-
sulfonic acid alkyl esters (R3OTf) were used as much stronger alkylating agents, which reacted 
even at room temperature (Scheme 3.6). 
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Sch. 3.6: Synthesis of [75Se]selenouronium salts ([75Se]3) 
(R3 = methyl ([75Se]3a), ethyl ([75Se]3b) and propyl ([75Se]3c)) 
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For optimization of the RCY of this alkylating reaction, the synthesis of [75Se]3a was used as 
model reaction and it was optimized with respect to the amount of methyl triflate and to reaction 
time. 
As expected, the effect of the amount of methyl triflate on the RCY of [75Se]3a initially shows 
pseudo-first-order kinetics, as can be seen in Figure 3.5. A quantitative yield of [75Se]3a was 
obtained with 0.1 mmol methyl triflate. Increasing amounts of alkylating agent led to a slight 
decrease of the RCY of [75Se]3a, which is probably due to side reactions between [75Se]3a 
formed and the increasing excess of methyl triflate. 
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Fig. 3.5: Radiochemical yield of methyl selenouronium salt ([75Se]3a) as a function of amount 
of methyl triflate 
 Reaction conditions: 185 kBq [75Se]2a, various amounts of methyl triflate, 0.5 mL 
benzene, 1 min, r.t. 
 
The dependence of the RCY of [75Se]3a as a function of time shows that the reaction is 
quantitatively finished within 1 min at room temperature (Figure 3.6). Using longer reaction 
times the RCY decreased, probably due to the same side reactions that occurred with amounts 
of more than 0.1 mmol methyl triflate (see above). 
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Fig. 3.6: Radiochemical yield of methyl selenouronium salt ([75Se]3a) as a function of time 
 Reaction conditions: 185 kBq [75Se]2a, methyl triflate (10 µL, 0.1 mmol), 0.5 mL 
benzene, r.t. 
 
Therefore, an instant and complete separation of [75Se]3 formed from surplus alkyl triflate was 
extremely important in order to avoid side reactions. Furthermore, even minor traces of this 
strong alkylating agent could lead to undesired byproducts in the following stages of the 
radiosynthesis. Small scale silica gel column chromatography proved to be the most effective 
method for purification, and [75Se]3a-c were separated with a recovery rate of 87 ± 3 % (related 
to [75Se]2a). 
 
 
 
3.1.4 Synthesis of asymmetric dialkyl [75Se]selenoethers 
 
Treatment of selenouronium salts (3) with hydroxide yields the corresponding free seleno-
late (4) [153, 158]. The tentative mechanism, leading to the displacement of the alkylseleno 
group from 3 by the hydroxide ion, is presented in Scheme 3.7. 
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Sch. 3.7: Tentative mechanism for the formation of selenolate (4) 
 
A C-O single-bond is formed through a nucleophilic attack of the hydroxide anion on the 
positively polarized selenourea group, as can be seen in the transition state (structure III). It is 
likely that the second stage of the reaction is an internal electron movement, thus strengthening 
the C-O bond and weakening the C-Se bond. Subsequently, the proton is transferred to a 
second hydroxide anion and the carbon-selenium bond is cleaved heterolytically, resulting in 
the corresponding selenolate (4), an urea (IV) and water. 
 
Selenols (also referred to as selenomercaptans) are the selenium analogues of alcohols and 
thiols (mercaptans). They are quite acidic (pKa = 3.73) and are deprotonated in basic solvent, 
forming selenolates (4). This species is a strong nucleophile and is rapidly oxidized by atmos-
pheric oxygen [46]. In order to obtain selenoethers (5), in situ alkylation of 4 can be performed 
using appropriate alkylating agents [54]. This last step can be considered as a modified William-
son ether synthesis, since 4 is the seleno-analogue of the alkoxide ion used in Williamson 
syntheses. 
The transfer of this reaction sequence to the n.c.a. level was investigated as described in this 
subchapter. As already mentioned in literature [92], tetrabutylammonium hydroxide (TBAH) is a 
suitable base for hydrolysis of [75Se]3, since the tetrabutylammonium cation acts as phase 
transfer catalyst that makes the hydroxid anion soluble in organic solvent systems. Using TBAH 
in tetrahydrofuran (THF) the corresponding [75Se]selenolates ([75Se]4) were liberated and 
subsequently alkylated in situ, yielding the desired [75Se]selenoethers ([75Se]5) (Scheme 3.8). 
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Sch. 3.8: Synthesis of asymmetric [75Se]selenoethers ([75Se]5) via one-pot procedure starting 
from [75Se]3 
 (R3 = methyl, ethyl, propyl; R4 = various alkyl moieties; Y = bromine, tosylate) 
Results and Discussion  51 
 
Further investigations showed again that this reaction step was most effective using a one-pot 
procedure with simultaneous addition of TBAH and the alkylating agent. Attempts to perform 
hydrolysis and alkylation in separate steps resulted in poorer yields of [75Se]5. This is because 
[75Se]4 is not stable and is very reactive. Thus, the liberation of [75Se]4 always yielded [75Se]5 as 
well as an unidentified polar 75Se-labelled byproduct, probably an oxidized species of [75Se]4. 
This observation illustrates the reactivity-selectivity principle, which states that the greater the 
reactivity of a species, the less selective it will be, in other words [75Se]4 reacted with all 
possible electrophilic “precursors” and not only with the added alkylating agent. 
 
The effect of the concentration of TBAH on the formation of [75Se]4 is an important parameter 
of the synthesis of [75Se]5. On the one hand, the hydroxide anions are necessary to liberate 
[75Se]4 from [75Se]3, but on the other hand, OH- is a nucleophile and can therefore act as a 
competitor of [75Se]4, which may lead to a decrease of precursor R4Y. For optimization studies, 
the synthesis of benzylmethyl[75Se]selenide ([75Se]5a) was used as model reaction starting from 
[75Se]3a, various concentrations of TBAH and benzyl bromide as precursor. 
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Fig. 3.7: Radiochemical yield of benzylmethyl[75Se]selenide ([75Se]5a) as a function of con-
centration of TBAH 
 Reaction conditions: 185 kBq [75Se]3a, various concentrations of TBAH, benzyl 
bromide (12 µL, 0.1 mmol), 0.6 mL THF, 5 min, 70°C. 
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As can be seen in Figure 3.7 the larger the concentration of TBAH in the range of 0.025 –
 
0.1 mol/L, the more methyl [75Se]selenolate ([75Se]4a) was formed, which was instantly con-
verted to benzylmethyl[75Se]selenide ([75Se]5a). The maximum RCY of [75Se]5a (61 ± 5 %, 
related to methyl selenouronium salt ([75Se]3a)) was obtained using a concentration of 0.1 mol/L 
TBAH. Above 0.1 mol/L of TBAH the RCY of [75Se]5a decreased. Since the amount of the 
precursor obviously dropped due to its increased conversion to the corresponding alcohol as 
demonstrated by TLC, the liberation of [75Se]4a led to an increased formation of the unidentified 
polar 75Se-labelled byproduct. 
 
Since the reaction of [75Se]4a with an alkyl halide proceeds according to an SN2 mechanism, 
polar, aprotic solvents other than THF are expected to favour the synthesis of [75Se]5a probably 
leading to an increase of the maximum RCY of [75Se]5a and to a decrease of the polar 
byproduct. Therefore, N,N-dimethylformamide and dimethyl sulfoxide instead of THF were used 
as solvents. However, a drastic decline of RCY of the model compound [75Se]5a was observed. 
The 75Se-labelled byproduct mentioned above now represented the major product and was 
obtained in yields of 60 –
 
90 % (related to [75Se]3a). 
These and further investigations showed that maximum radiochemical yields of [75Se]5 (up to 
61 % related to [75Se]3) were obtained using concentrations of at least 0.1 mol/L TBAH and 
0.17 mol/L alkylating agent in THF at 70°C. In particular, studies regarding the time dependence 
showed that the optimum RCY was reached within 5 min. 
 
To sum up subchapters 3.1.1 to 3.1.4, the time schedule of the radiosynthesis developed and 
optimized is depicted in Scheme 3.9. Starting from n.c.a. 75Se0, cyclohexyl isocyanide and 
cyclohexylamine 1,3-dicyclohexyl [75Se]selenourea ([75Se]2a) was obtained via one-pot pro-
cedure within 90 min with a RCY of 92 ± 5 %. Subsequent alkylation of [75Se]2a via alkyl triflates 
gave rise to a quantitative yield of [75Se]selenouronium salts ([75Se]3) which were purified using 
silica gel column chromatography. Hydrolysis of purified [75Se]3 under basic conditions and in 
situ alkylation provided asymmetric [75Se]selenoethers ([75Se]5) within a total reaction time of 
130 min in RCYs of 15 to 48 % (related to n.c.a. 75Se0), depending on the nature of the alkyl 
groups R3 and R4. 
 
A survey of n.c.a. [75Se]selenoethers prepared as model compounds via the radiosynthetic 
pathway described above is given in subchapter 3.1.7. 
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N
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i
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purified [75Se]3
R375SeR4
[75Se]5
iii
iv
0 min
90 min
91 min
125 min
130 min
92 ± 5 % (related to n.c.a. 75Se0)
100 % (related to [75Se]2a)
87 ± 3 % (related to [75Se]3)
19 - 61 % (related to purified [75Se]3)
15 - 48 % (related to n.c.a. 75Se0)
 
 
Sch. 3.9: Radiosynthesis of [75Se]selenoethers ([75Se]5) 
 Reaction conditions: i) cyclohexyl isocyanide (0.08 mmol), cyclohexylamine 
(0.08 mmol), benzene (0.5 mL), 80°C; ii) methyl, ethyl or propyl triflate (0.1 mmol), 
benzene (0.5 mL), r.t.; iii) separation via silica gel column chromatography; iv) TBAH 
(0.06 mmol), various alkyl bromine or tosylate compounds (0.1 mmol), THF (0.6 mL), 
70°C. 
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3.1.5 Polymer-supported preparation of n.c.a. [75Se]selenoethers 
 
The method of radioselenoether synthesis described above is extremely time-consuming 
because of the tedious intermediate purification step required. Further, for routine application it 
would be desirable to achieve a general pathway for a fully automated synthesis of n.c.a. 
[73Se]selenoethers in order to prevent undue product handling thus decreasing exposure of 
personnel. Therefore, the reaction sequence described in Scheme 3.9 was modified for a 
polymer-supported synthesis in order to separate and purify radioselenium labelled inter-
mediates in a very convenient way while decreasing the overall reaction time. 
 
Starting from n.c.a. elemental selenium-75, cyclohexyl isocyanide and aminomethylated poly-
styrene, the corresponding polymer-bound [75Se]selenourea ([75Se]2resin) was synthesized in 
benzene at 80°C within 10 min with a radiochemical yield of 80 ± 5 % (related to n.c.a. 75Se0) 
(Scheme 3.10). The use of toluene as solvent and increased reaction temperature and time, as 
well as larger amounts of the precursors and previous swelling of the resin, did not improve the 
RCY. Surprisingly, the maximum RCY of [75Se]2resin was obtained within a much shorter time 
compared to the preparation of free [75Se]2a (10 min vs. 90 min), which is probably due to the 
high density of amino groups on the resin. The intermediate [75Se]2resin was purified by washing 
with benzene in order to separate starting material not transformed and any byproduct. The 
RCY was determined as activity bound on the resin of purified [75Se]2resin, since it is likely that 
75Se was present on the polymer in no other form than as in the corresponding selenourea 
group. 
Subsequent alkylation in benzene via alkyl triflates yielded the corresponding [75Se]seleno-
uronium salt ([75Se]3resin) within 5 min with a radiochemical yield of 92 ± 3 % (activity bound on 
the purified resin, related to [75Se]2resin), which was independent from the alkyl triflate used 
(Scheme 3.10). Reaction time was extended in comparison to the homogenous radiosynthesis 
of [75Se]3 (5 min vs. 1 min) to guarantee that most of [75Se]2resin was converted to [75Se]3resin. 
Purification of [75Se]3resin was carried out by repeated washing with benzene and tetrahydro-
furan in order to get rid of surplus alkyl triflate and to determine the RCY of the purified 
[75Se]3resin. 
Using the optimized reaction conditions for the formation of [75Se]5 described in subchap-
ter 3.1.4, basic hydrolysis of the purified [75Se]3resin and in situ alkylation of the intermediate 
anion [75Se]4 yielded asymmetric radioselenoethers in radiochemical yields of 18 – 76 % 
(related to [75Se]3resin) and 13 – 56 % (related to n.c.a. 75Se0), respectively, within a total 
reaction time of 35 min (Scheme 3.10). Thus, the overall reaction time was reduced by a factor 
of almost four while the RCYs remained unchanged. 
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Sch. 3.10: Polymer-supported radiosynthesis of [75Se]selenoethers ([75Se]5) 
 Reaction conditions: i) cyclohexyl isocyanide (0.08 mmol), aminomethylated 
polystyrene (40 mg), benzene (0.5 mL), 80°C; ii) washing with benzene; iii) methyl, 
ethyl or propyl triflate (0.1 mmol), benzene (0.5 mL), r.t.; iv) separation via washing 
with benzene and tetrahydrofuran; v) TBAH (0.06 mmol), various alkyl bromine or 
tosylate compounds (0.1 mmol), THF (0.6 mL), 70°C. 
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A survey and a comparison of RCYs of the various n.c.a. [75Se]selenoethers prepared as 
model compounds via the polymer-supported and the homogenous radiosynthesis are given in 
subchapter 3.1.7. 
 
 
 
3.1.6 Labelling experiments with n.c.a. selenium-73 
 
After the development and optimization of the homogenous and polymer-supported 
radiosyntheses of [75Se]5, the positron-emitter selenium-73 was used as radiolabel. The prepa-
ration of [73Se]selenoethers ([73Se]5) was performed via the reaction strategies described in 
Scheme 3.9 (subchapter 3.1.4) and Scheme 3.10 (subchapter 3.1.5) using n.c.a. 73Se0 as 
starting material. 
Repeated experiments with Se-73 showed no differences in radiochemical yields, and 73Se-
labelled compounds were obtained under the same reaction conditions as their corresponding 
75Se-labelled counterparts (listed in subchapter 3.1.7). It was confirmed that there is no 
difference in the radiochemistry of selenium-73 and selenium-75. Possible radiolytic effects due 
to higher energies of the 2 -rays or the 3 +-particles of the decaying selenium-73 were not 
observed. 
In this empirical way it was demonstrated that selenium-75 is a suitable model-nuclide for 
selenium-73 and that radiosyntheses developed via selenium-75 may serve as well for the pre-
paration of 73Se-labelled compounds without any necessity of modifying the reaction conditions. 
 
 
 
3.1.7 Comparative discussion of results 
 
Several asymmetric alkyl [73,75Se]selenoethers ([73,75Se]5a-g) were prepared as model com-
pounds (cf. Table 3.1) in order to demonstrate the versatility of the polymer- and non-polymer-
supported syntheses described above. Labelling of these compounds resulted in radiochemical 
yields of up to 56% related to elemental radioselenium. Using ethyl or propyl [73,75Se]seleno-
lates, the yields decreased in comparison to methyl [73,75Se]selenolate, using both the homo-
genous and the polymer-supported method. The radiochemical yields decreased also when 
using a secondary bromide as second alkylating agent. 
Furthermore, the radioselenium labelled alkylating agent methyl[73,75Se]selenopropanyl 
toluenensulfonate ([73,75Se]5g) was obtained with a RCY of 15 ± 4 %. It may serve as a small 
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longer-lived prosthetic group for labelling of suitable nucleophilic functional groups via 
[73,75Se]selenoalkylation. 
The yields of the homogenous and the polymer-supported syntheses are similar, whereas the 
total reaction time can be reduced from more than two hours to about half an hour using the 
polymer-supported method. 
 
 
Tab. 3.1: Comparison of radiochemical yields* [%] of various asymmetric n.c.a. [73,75Se]seleno-
ethers via homogenous and polymer-supported synthesis 
 
R473,75Se R3
73,75Se
73,75Se
Me
Et
Me
Et
73,75Se MeTsO
56 ± 5
39 ± 4
Prop 32 ± 3
36 ± 4
24 ± 2
Prop 17 ± 2
homogenous+ polymer-supported++
48 ± 5
41 ± 4
39 ± 4
37 ± 4
31 ± 3
21 ± 2
13 ± 2
* related to 73,75Se0;  + 130 min and ++ 35 min total reaction time, respectively
15 ± 4
Compound No.
 [73,75Se]5a
[73,75Se]5b
 [73,75Se]5c
 [73,75Se]5d
 [73,75Se]5e
[73,75Se]5f
[73,75Se]5g
 
 
 
Although a wide variety of asymmetric n.c.a. alkyl [73,75Se]selenoethers could be obtained 
demonstrating the versatility of both radiosynthetic pathways via [73,75Se]selenoureas, all 
attempts made to synthesize aryl radioselenoethers failed. Nucleophilic aromatic substitution 
(SNAr) using various aryl bromine or aryl tosylate compounds with strong electron-withdrawing 
substituents to be attacked by n.c.a. [75Se]selenolates did not occur, and the target molecules 
(R375SeAr) were not obtained (Scheme 3.11). Experiments using more nucleofugic groups, e.g. 
fluorine, NR3+ or NO2, as leaving groups in aryl derivatives with strong electron-withdrawing 
substituents may possibly lead to arylalkylselenides. 
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R375SeAr[75Se]4
Ar: various aryl moieties
Y: bromine, tosylate
 
 
Sch. 3.11: Unsuccessful experiments for the preparation of n.c.a. aryl [75Se]selenoethers 
 
 
 
3.1.8 Homocysteine [75Se]selenolactone 
 
L-Homocysteine [73Se]selenolactone ([73Se]6) is of great interest as a longer-lived alternative of 
[11C]homocysteine thiolactone ([11C]7) (Scheme 3.12). The latter, so far, could only be obtained 
as racemic mixture due to the short half-life of carbon-11 [159]. 
 
73Se
NH2
O
S
11C O
[73Se]6 [11C]7
NH2
 
 
Sch. 3.12: L-Homocysteine [73Se]selenolactone ([73Se]6) and D/L-[11C]homocysteine thiolactone 
([11C]7) 
 
In order to image regional cardiac adenosine production by PET, D/L-[11C]homocysteine 
thiolactone was used as a sensitive indicator for ischemic myocardial tissue [111], where an 
increased formation of adenosine is due to the breakdown of adenine nucleotides. The 
accumulation of adenosine in hypoxic cells can be detected by an excess of homocysteine in 
presence of [11C]homocysteine thiolactone which leads to an increased formation of intracellular 
S-adenosyl homocysteine catalyzed by the enzyme SAH hydrolase. 
According to the chemical homology of sulfur and selenium, it is the aim to substitute sulfur by 
radioselenium to get a longer-lived radiotracer, to test the possibility of enzymatic conversion of 
adenosine into [73Se]selenoadenosine homocysteine for future radiopharmacological studies. 
 
Since homocysteine [75Se]selenolactone can be prepared by reductive demethylation of 
[75Se]selenomethionine via an appropriate [75Se]selenolate as intermediate [110] (cf. subchap-
ter 1.6.3), a method was developed in this study to generate the appropriate [75Se]seleno-
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late ([75Se]4d) via basic hydrolysis of the corresponding [75Se]selenouronium salt ([75Se]3d). 
Consecutive cyclization yielded the target molecule [75Se]6 as depicted in Scheme 3.13. 
 
N
H
75Se
N
H
[75Se]2a
N
H
75Se
N
H
[75Se]3d
X COOEt
NHBoc
8
COOEt
NHBoc
X
(X = leaving group)
OH
75Se COOEt
NHBoc HCl
75Se
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Sch. 3.13: Homocysteine [75Se]selenolactone ([75Se]6) via the corresponding [75Se]seleno-
uronium salt ([75Se]3d) 
 
As examined in subchapter 3.1.3, the alkylation of [75Se]2a at the n.c.a. level is only success-
ful using appropriate trifluoromethanesulfonic acid alkyl esters as very strong alkylating agents. 
Unfortunately, all attempts to generate the precursor 8 with X = triflate failed, and only ethyl 
N-tert.-butoxycarbonyl-2-amino-4-bromobutyrate (X = Br) could be obtained. Obviously, the 
triflate compound was too reactive and unstable. Starting from the corresponding alcohol and 
trifluoromethanesulfonic anhydride according to literature methods [160], all attempts to synthe-
size this compound failed. Due to the lack of an appropriate triflate precursor, it was not possible 
to alkylate n.c.a. [75Se]2a. 
Instead, carrier-added 1,3-dicyclohexyl [75Se]selenourea was produced starting from c.a. 
75Se0, cyclohexyl isocyanide and cyclohexylamine. This radiosynthesis of c.a. disubstituted 
[75Se]selenoureas is more advantageous than that recently reported via carbodiimides and 
hydrogen [75Se]selenide [92], since the use of a volatile radioselenium-labelled compound 
([75Se]H2Se) is avoided. The subsequent alkylation with 8 (X = Br) led to a nearly quantitative 
formation of the desired c.a. [75Se]selenouronium salt ([75Se]3d), which was purified according 
to subchapter 3.1.3. Hydrolysis in presence of TBAH and consecutive acidification with 
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concentrated hydrochloric acid yielded c.a. homocysteine [75Se]selenolactone by cyclization and 
simultaneous cleavage of the protecting groups. 
The total RCY starting from c.a. selenium-75 was 20 – 30 %, being three times higher 
compared to the radiosynthetic strategy via lithium methyl [75Se]selenide by using sulfur as non-
isotopic carrier [110] (cf. subchapter 1.6.3). In addition, the selenourea strategy is more con-
venient because it is easier to handle since the demethylation step (Birch reduction) on 
[75Se]selenomethionine (cf. Scheme 1.11) is avoided. Furthermore, it offers the possibility of 
automated radiosynthesis. The indispensable addition of natSe-carrier limits the maximum 
possible specific activity. However, the use of [73Se]6 in nuclear medicine does not absolutely 
require that this tracer is administered at the n.c.a. level, provided that the toxicity of this 
compound is no problem. 
 
 
 
3.2 No-carrier-added alkyl and aryl [75Se]selenoethers 
via [75Se]selenocyanates 
 
With regard to the unsuccessful experiments to obtain aryl radioselenoethers via the selenourea 
strategy (cf. subchapter 3.1.7), the development of another attractive reaction sequence was 
performed in order to enlarge the scope of available n.c.a. radioselenium-labelled compounds to 
aryl selenoethers [161]. This class is of particular interest, because aryl selenoethers are 
expected to be even more stable than their alkyl analogues. This represents an advantage if 
appropriate radioselenium-labelled compounds are applied for in vivo studies. 
 
The potassium salt of selenocyanic acid (KSeCN (9a)) is one of the best-established reagents 
for the introduction of selenium into organic molecules [40]. The compound is readily prepared 
from elemental selenium and potassium cyanide [162, 163] and commercially available. 
Potassium selenocyanate is soluble in water, the lower aliphatic alcohols, acetonitrile and many 
other polar organic solvents. This high solubility in organic solvent systems earns 9a a unique 
position among the readily accessible inorganic selenium derivatives. Like thiocyanate, the 
selenocyanate anion (9) is considered to be a pseudohalide because of resemblance of its 
chemical behaviour to that of halide ions. With regard to the reactivity of 9, it was found that it is 
ten times more nucleophilic than the thiocyanate ion and lies between chloride and bromide 
anions for substitution reactions on haloacetophenones [57]. The major mode of application of 
9a takes advantage of this high nucleophilicity towards aliphatic halides, yielding alkyl seleno-
cyanates (10) [164] as illustrated in Scheme 3.14. 
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Alkyl selenocyanates have occupied a privileged position in organoselenium chemistry [57] 
and represent stable compounds which are transformed to valuable organoselenium derivatives 
[165]. In particular, the selenium atom of alkyl selenocyanates is the preferential site of attack by 
different nucleophiles due to its electrophilicity. Therefore, selenocyanates react with organo-
metallic compounds producing chemoselectively, in a single step and in almost quantitative 
yields, aliphatic and aromatic selenoethers (5) [40] as depicted in Scheme 3.14. 
 
KSeCN
R1X
R1SeCN
R2Y
R1SeR2
9a 10 5
 
 
Sch. 3.14: Synthesis of selenoethers (5) via alkyl selenocyanates (10) 
(R1 = alkyl moieties, R2 = alkyl or aryl moieties, X = halides, Y = Li or MgBr) 
 
In the preliminary stages of the development of the radiosynthesis, this synthetic pathway was 
followed using natSe0 as starting material to check for general feasibility of this concept and to 
synthesize the standard compounds used as reference for radio-HPLC and radio-TLC. All non-
radioactive seleno compounds (10 and 5) prepared via this route were obtained in satisfactory 
yields (cf. subchapter 4.2.2). 
The application of this reaction sequence to the n.c.a. level was examined and optimized in 
order to prepare n.c.a. alkyl and aryl radioselenoethers as described in the following sections. 
 
 
 
3.2.1 Alkyl [75Se]selenocyanates via sodium [75Se]selenocyanate 
 
The reaction of elemental selenium with potassium cyanide is well-known, resulting in pot-
assium selenocyanate. In this study here sodium cyanide was used for the preparation of the 
[75Se]selenocyanate anion ([75Se]9) due to the easier availability of NaCN in comparison with 
KCN. 
Since the SeCN- anion is a very nucleophilic agent, it appeared promising to develop a one-
pot procedure with interim formation of sodium [75Se]selenocyanate ([75Se]9b) and in situ con-
version to an alkyl [75Se]selenocyanate ([75Se]10). 
The formation of n.c.a. 1-phenylethyl-1-[75Se]selenocyanate ([75Se]10a) was used as a model 
reaction starting from n.c.a. 75Se0, sodium cyanide and (1-bromoethyl)benzene (cf. Scheme 
3.15). As demonstrated by radio-TLC, the synthesis of sodium [75Se]selenocyanate was the 
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rate-determining step in this one-pot reaction sequence, since [75Se]10a was formed imme-
diately upon adding benzyl bromide to a solution of [75Se]9b, being synthesized using n.c.a. 
75Se0 and NaCN as starting material. 
 
Na75SeCN
Br
n.c.a. 75Se0
75SeCN
[75Se]9b
NaCN
[75Se]10a
EtOH / H2O
     80°C
 
 
Sch. 3.15: Synthesis of 1-phenylethyl-1-[75Se]selenocyanate ([75Se]10a) 
 
The formation of [75Se]10a was optimized with respect to the effects of solvent, amount of 
water, time, temperature and concentration of sodium cyanide and of the precursor (1-bromo-
ethyl)benzene, as detailed below. 
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Fig. 3.8: Radiochemical yield of 1-phenylethyl-1-[75Se]selenocyanate ([75Se]10a) in various 
solvents 
 Reaction conditions: 370 kBq n.c.a. 75Se0, sodium cyanide (10 µmol in 0.1 mL H2O), 
(1-bromoethyl)benzene (73 µmol), 0.5 mL solvent, 5 min, 80°C. 
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Synthesis of [75Se]10a was equally successful in either ethanol or acetonitrile with a radio-
chemical yield of 69 ± 3 % and 68 ± 4 %, respectively. However, the use of ethanol as solvent 
gave rise to 70 ± 5 % recovery rate after the subsequent purification step, compared to only 
50 ± 6 % recovery rate using acetonitrile. Other solvents like N,N-dimethylformamide, acetone 
and benzene did not prove as suitable since the RCY of [75Se]10a reached only 29, 14 and 0 %, 
respectively, as can be seen in Figure 3.8. Therefore, of those examined ethanol was the 
solvent of choice in which [75Se]10a was obtained in a satisfactory yield and, in addition, which 
was suitable for the subsequent purification step via reversed phase cartridges. 
 
The effect of water on this labelling step is graphically depicted in Figure 3.9. Working in the 
presence of some amount of water appeared advantageous for this initial reaction step, since 
sodium cyanide can be easily added to the reaction mixture if dissolved in H2O. 
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Fig. 3.9: Radiochemical yield of 1-phenylethyl-1-[75Se]selenocyanate ([75Se]10a) as a function 
of added water 
Reaction conditions: 370 kBq n.c.a. 75Se0, sodium cyanide (10 µmol), (1-bromo-
ethyl)benzene (73 µmol), 0.6 mL solvent (ethanol/water mixture), 5 min, 80°C. 
 
As illustrated in Figure 3.9, the amount of water was a crucial factor for obtaining a high RCY 
of [75Se]10a. The cyanide- and [75Se]selenocyanate-anion as ionic species seem to prefer an 
aqueous solution as reaction solvent. The maximum RCY of [75Se]10a was observed with 
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69 ± 3 % at 15 ± 2 vol.% H2O. The reaction step tolerated a water-amount between 10 and 
20 vol.% with no significant decrease of the RCY. Utilization of less than 10 vol.% H2O led to 
considerably lower yields, probably because of the lower solubility of sodium cyanide in ethanol. 
Treatment of n.c.a. 75Se0 with NaCN and (1-bromoethyl)benzene in ethanol containing more 
than 20 vol.% H2O resulted in lower RCY as well. This decrease can be possibly explained by a 
growing suppression of the nucleophilic substitution reaction on the alkyl halide caused by 
increasing inhibition of an SN2-type exchange by NC75Se- due to the more protic reaction 
solvent. 
 
In order to examine the influence of the reaction temperature on the [75Se]selenocyanate 
formation, the synthesis of [75Se]10a was performed at 60°C and 80°C under otherwise stable 
conditions. The data given in Figure 3.10 indicate that the optimum temperature for the 
formation of [75Se]10a in ethanol was 80°C. The time dependences of the RCY represent 
hyperbolic curves with a saturation yield, which is typical for pseudo-first-order reactions. 
0 2 4 6 8 10 12 14 16
0
10
20
30
40
50
60
70
80
 
 80°C
 60°CR
C
Y 
[%
]
time [min]
 
Fig. 3.10: Radiochemical yield of 1-phenylethyl-1-[75Se]selenocyanate ([75Se]10a) as a function 
of temperature and time 
Reaction conditions: 370 kBq n.c.a. 75Se0, sodium cyanide (10 µmol in 0.1 mL H2O), 
(1-bromoethyl)benzene (73 µmol), 0.5 mL ethanol. 
 
The saturation yield was obtained for [75Se]10a after a very short reaction time of only 4 min, a 
fact which is favourable in view of a short radiosynthesis. Although the curves of the time 
Results and Discussion  65 
 
dependences are very similar and the saturation yields are approximately the same whether the 
reactions were carried out at 60 or 80°C, the reaction rate is faster at the higher temperature. 
As demonstrated by radio-TLC, 75Se-labelled byproducts were formed in amounts of about 
30 % independent on the temperatures, which explains the equal saturation yield for both 
reaction temperatures. 
 
In order to compare the effect of the reaction temperature on the synthesis of [75Se]10a, the 
relative rate constants k of [75Se]10a were determined at 60°C and 80°C. As can be seen in 
Figure 3.11, the term ln([B]0/([B]0-[C]t)) (with [B]0: initial activity of 75Se0 and [C]t: activity of 
[75Se]10a at reaction time t) is plotted as a function of time. The slopes of the fitted straight lines 
give the rate constants k, being 0.28 min-1 and 0.2 min-1 for the synthesis of [75Se]10a at 80°C 
and 60°C, respectively. From these k-values one can see that an increase of reaction 
temperature of 20°C increases the rate of reaction by 40 %. 
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Fig. 3.11: Plot of ln([B]0/([B]0-[C]t)) as a function of time for the determination of the relative rate 
constants k for the synthesis of [75Se]10a at 80°C and 60°C 
 Reaction conditions: see Fig. 3.10. 
 
The dependence of the RCY of [75Se]10a on the amount of sodium cyanide is shown in Figure 
3.12 and was determined not only for maximizing the radiolabelling yield but also for minimizing 
precursor concentration in order to facilitate product separation and purification. With regard to a 
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future in vivo application of a radioselenium-labelled compound being synthesized via seleno-
cyanate, it is extremely important to obtain the target molecule without any traces of sodium 
cyanide because of its high toxicity. Use of at least 10 µmol sodium cyanide was necessary to 
obtain the optimum RCY of [75Se]10a of about 70 %. A smaller amount of NaCN led to a 
reduction. In this case, a semilogarithmic amount-RCY plot shows a sigmoidal curve, which 
represents the typical course of the RCY for a pseudo-first-order reaction. 
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Fig. 3.12: Radiochemical yield of 1-phenylethyl-1-[75Se]selenocyanate ([75Se]10a) as a function 
of the amount of sodium cyanide 
Reaction conditions: 370 kBq n.c.a. 75Se0, sodium cyanide (various amounts in 
0.1 mL H2O), (1-bromoethyl)benzene (73 µmol), 0.5 mL ethanol, 5 min, 80°C. 
 
Furthermore, the concentration of the precursor (1-bromoethyl)benzene was optimized 
keeping all conditions except the one examined as constant. An amount of at least 73 µmol of 
the alkylating agent per 0.6 mL of solvent proved to be useful for obtaining a high RCY of 
69 ± 3 % for [75Se]10a, while higher amounts did not lead to a significant increase of the RCY. 
 
These optimization studies showed that the reaction sequence illustrated in Scheme 3.15 is 
best carried out within 5 min at 80°C using 10 µmol NaCN (dissolved in 0.1 mL H2O) and 
73 µmol alkylating agent in 0.5 mL ethanol. 
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In order to demonstrate the versatility of this labelling sequence, reactions using the alkylating 
agents benzyl bromide and methyl trifluoromethanesulfonate (MeOTf) were carried out under 
the conditions described above, yielding benzyl [75Se]selenocyanate ([75Se]10b) and methyl 
[75Se]selenocyanate ([75Se]10c) with a RCY of 15 ± 4 % and 73 ± 8 %, respectively. 
 
The disappointingly low yield of [75Se]10b can be probably explained by an isomerization of 
[75Se]10b to its corresponding iso[75Se]selenocyanate as demonstrated by radio-TLC. This 
assumption bases on the knowledge of the properties of thiocyanates [166]. In general, the 
isomerization of alkyl thiocyanates to corresponding isothiocyanates is practically complete in 
the vast majority of cases, and only traces of thiocyanate may be detected at equilibrium. 
Selenocyanates isomerize more rapidly than the corresponding thiocyanates, but the 
equilibrium at macroscopic scale is much more shifted towards the “normal” compound, i.e. 
selenocyanate, than in the case of sulfur [167]. This was particularly confirmed in the case of 
benzyl selenocyanate via IR spectra. It was found that the reaction of potassium selenocyanate 
and benzyl bromide resulted in both, benzyl selenocyanate and, to a lesser degree, benzyl 
isoselenocyanate. 
A proposed mechanism of this isomerization reaction is portrayed in simplified terms in 
Scheme 3.16. 
 
RSeCN
Se C N
SeCNRR     +
10 V 9 VI
Se C N
 
 
Sch. 3.16: Simplified mechanism for the isomerization reaction of organic selenocyanates (10) 
 
This isomerization mechanism is a simple dissociation of organic selenocyanates. The seleno-
cyanate group acts as a good leaving group from aliphatic carbon, thus generating a transition 
state in which an alkyl cation V and the selenocyanate anion 9 are formed by heterolysis. Since 
9 can act as a selenium as well as a nitrogen nucleophile, subsequent rearrangement yields 
isoselenocyanates VI. Tracer and stereochemical studies, though, indicate that the dissociation 
and formation of this simple transition state is only a rough approximation of reality. Detailed 
68  Results and Discussion 
 
 
studies rather suggest a more complex internal ion-pair mechanism without complete heterolytic 
cleavage [167]. 
In case of n.c.a. benzyl [75Se]selenocyanate ([75Se]10b), this isomerization seems to be 
favoured without reaching an equilibrium as in the macroscopic scale. This preferred isomeri-
zation may be due to the fact that the benzyl cation is relatively stable and thus more easily 
formed than other aliphatic cations due to the fact that it has delocalized electrons and five 
resonance contributors. In addition, the benzyl-nitrogen bond is more stable than the benzyl-Se 
bond, so the iso-derivative is more abundant resulting in the decrease of the RCY of [75Se]10b. 
In the case of [75Se]10a and [75Se]10c, on the other hand, satisfactory RCYs were obtained, 
which can be explained by the fact that these compounds isomerize only to a small degree as 
demonstrated by radio-TLC. 
Surprisingly, [75Se]10a does not favour isomerization, although the transition state contains a 
benzylic cation, which is even more stable than the benzyl cation. Apparently, the mechanism 
depicted in Scheme 3.16 is too simplified and needs to be more thoroughly studied. 
An alternative explanation for the formation of isoselenocyanate derivatives bases on the 
property of the selenocyanate anion to act directly as a nitrogen nucleophile due to its ambident 
nucleophilicity. So it is also likely that the bidentate anion 9 reacts with the alkylating agent to 
give the isoselenocyanate derivative without “detour” via the aliphatic selenocyanate. 
 
 
Tab. 3.2: Preparative RCY of alkyl [75Se]selenocyanates ([75Se]10) after separation via 
reversed phase cartridges (related to n.c.a. 75Se0) 
 
ProductPrecursor RCY [%]
75SeCNBr 48 ± 5[
75Se]10a
[75Se]10b75SeCNBr 11 ± 5
[75Se]10cMe75SeCNMeOTf 69 ± 8
Compound No.
 (a)                 (b)
69 ± 3
15 ± 4
73 ± 8
(a) substitution yield, (b) after Sep-Pak / LiChrolut purification
 
 
Results and Discussion  69 
 
A separation of the n.c.a. alkyl [75Se]selenocyanates from their aqueous/ethanolic solvent 
system was indispensable due to the following reaction step involving organic lithium or 
Grignard compounds. Furthermore, it must be taken into account that the starting material 
sodium cyanide is highly toxic and must completely be removed before use of an appropriate 
73Se-labelled target molecule as in vivo radiotracer. 
For simple performance, reversed phase cartridges were used for the purification of [75Se]10. 
Maximum recovery rates were reached with ethanol as eluant for [75Se]10a and [75Se]10b using 
Sep-Pak Plus C18 cartridges (70 ± 5 %) and for [75Se]10c using LiChrolut EN cartridges 
(95 ± 3 %), resulting in a total RCY after separation, which is given in Table 3.2 for the various 
reagents. 
 
 
 
3.2.2 Synthesis of asymmetric alkyl and aryl [75Se]selenoethers 
 
Due to its properties as a pseudohalide, the cyano group in alkyl selenocyanates acts as a good 
leaving group upon nucleophilic attack on the positively polarized selenium-atom. Apparently, 
the weak cyanocarbon-selenium bond is the reason of the high reactivity of the selenocyanato-
substituted compound [168]. 
Therefore, the direct reaction of [75Se]10 with alkyl or aryl lithium derivatives according to 
Scheme 3.17 leads to asymmetric [75Se]selenoethers ([75Se]5). Grignard reagents may be used 
in place of lithium compounds. This conversion was carried out in anhydrous diethyl ether with 
typical RCYs of 80 –
 
90 %. The reaction appears to be quite general, not being impaired by 
various aromatic or aliphatic compounds used. Optimization studies showed that this reaction 
step is most effective while using Li- or Grignard-compounds in amounts of 0.1 mmol in 0.5 mL 
anhydrous diethyl ether, taking place at room temperature within 1 min. 
 
R175SeCN
R2Li / R2MgBr
[75Se]10 [75Se]5
R175SeR2
 
 
Sch. 3.17: Synthesis of asymmetric [75Se]selenoethers ([75Se]5) via organic [75Se]seleno-
cyanates ([75Se]10) 
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Several asymmetric aliphatic and aromatic [75Se]selenoethers were prepared as model com-
pounds (Table 3.3) in order to prove the versatility of the method. 
 
 
Tab. 3.3: RCY of some asymmetric n.c.a. aryl and alkyl [75Se]selenoethers ([75Se]5) formed via 
[75Se]selenocyanates ([75Se]10) 
 
Product   (R1-75Se-R2)Precursor RCY [%]
Me
R1
Me
Bu
F
[75Se]10a   +   MeLi
[75Se]10a   +   BuLi
[75Se]10a  +   PhLi
[75Se]10a  +   p-FPhMgBr
40 ± 5
39 ± 5
44 ± 5
43 ± 5
Me[75Se]10b   +   MeLi
[75Se]10b   +   PhLi 9 ± 5
9 ± 5
[75Se]10c   +   PhLi 55 ± 8
(related to 75Se0)
Compound No.
 [75Se]5a
 [75Se]5d
 [75Se]5h
 [75Se]5i
 [75Se]5j
 [75Se]5k
 [75Se]5l
R2
 
 
 
When benzyl bromide was used as alkyl halide to be reacted with [75Se]selenocyanate, the 
radiochemical yield decreased significantly due to an isomerization to the iso-derivative. 
Accordingly, the RCYs of [75Se]5a and [75Se]5k were very low. The overall RCYs of the other 
model compounds were similar and quite satisfactory. Both, alkyl and aryl organometallic 
agents added readily to the [75Se]selenocyanates. The use of Grignard compound instead of 
lithium derivatives had no effect on the RCY.  
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To sum up Chapter 3.2, the radiosynthesis developed and optimized is depicted in Scheme 
3.18. Starting from n.c.a. 75Se0, sodium cyanide and various alkyl bromine or triflate compounds, 
several alkyl [75Se]selenocyanates were obtained via a one-pot procedure within 5 min and with 
a RCY of 15 – 73 %. Subsequent purification using reversed phase cartridges gave rise to 
recovery rates of 70 – 95 %. Reaction of purified [75Se]10 with organometallic compounds 
yielded asymmetric [75Se]selenoethers ([75Se]5) within a total reaction time of 20 min in RCYs of 
9 to 55 % (related to n.c.a. 75Se0). 
 
RCY
n.c.a. 75Se0
time
i
ii
iii
0 min
5 min
19 min
20 min
15 - 73 % (related to n.c.a. 75Se0)
70 - 95 % (related to [75Se]10)
80 - 90 % (related to purified [75Se]10)
R175SeCN
[75Se]10
purified [75Se]10
[75Se]5
R175SeR2
9 - 55 % (related to n.c.a. 75Se0)
 
 
Sch. 3.18: Radiosynthesis of [75Se]selenoethers ([75Se]5) via [75Se]selenocyanates 
 Reaction conditions: i) sodium cyanide (10 µmol in 0.1 mL H2O), various alkyl 
bromine or triflate compounds (73 µmol), 0.5 mL ethanol, 80°C; ii) purification via 
reversed phase cartridges, iii) alkyl or aryl lithium or Grignard compounds 
(0.1 mmol), 0.5 mL anhydrous diethyl ether, r.t. 
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3.3 Comparison and evaluation of the n.c.a. radiosyntheses 
developed 
 
Two new radiosynthetic pathways were developed to prepare various aliphatic and aromatic 
[75Se]selenoethers at the no-carrier-added level, both based on the initial formation of radio-
selenium labelled intermediates. 
The radiosyntheses developed take advantage of the large nucleophilicity of a negatively 
charged or polarized terminal carbon atom adjacent to a nitrogen via multiple bond. Mainly two 
compounds exhibit this property: on the one hand alkyl isocyanides and on the other hand the 
inorganic cyanide anion. In both cases, elemental radioselenium is attacked by the carbon 
nucleophile, yielding a labelled alkyl isoselenocyanate (RNC75Se) or the inorganic [75Se]seleno-
cyanate anion (NC75Se-), respectively. Apparently, these initial reaction steps for introducing 
75Se0 into an organic or inorganic compound proceed very similar, and they represent the rate-
determining steps in their corresponding radiosyntheses. 
 
Both products were prepared and converted in situ to give the desired radioselenium labelled 
intermediates in corresponding one-pot procedures. 
In the former case, the alkyl iso[75Se]selenocyanate and a primary amine react to give the 
corresponding labelled 1,3-disubstituted selenoureas and in the latter case, the [75Se]seleno-
cyanate anion adds to an appropriate alkyl halide, yielding alkyl [75Se]selenocyanates 
(R75SeCN). These intermediates belong to two completely different classes with regard to the 
reactivity of the selenium atom. Whereas on the one hand the substituted [75Se]selenourea 
contains the Se atom as a nucleophile, in alkyl [75Se]selenocyanate, on the other hand, it is an 
electrophile. However, both of these organic derivatives of selenium have in common that they 
offer the general possibility for the formation of new C-Se bonds. 
In case of [75Se]selenoureas, one can consider the organic moiety as an activating as well as 
a protecting group, that facilitates the further synthetic sequence and which is removed after-
wards by a suitable procedure. While many selenium nucleophilic reagents contain a selenium 
anion and are generally used in alkaline media, the neutral [75Se]selenourea is readily alkylated 
in organic solvents to give [75Se]selenouronium salts. After purification, these salts are hydro-
lyzed under basic conditions to the corresponding selenolates, which are alkylated by various 
alkylating agents (R’X) in situ, yielding the desired asymmetric radioselenoethers (R75SeR’). 
On the other hand, the alternative intermediate product R75SeCN offers the possibility to 
obtain the target molecules more straightforward. Since the cyano moiety of this derivative is a 
good leaving group, a nucleophilic attack of an appropriate organometallic compound (R’Li or 
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R’MgBr) on the electrophilic selenium atom displaces the cyano group by the organic moiety R’, 
thus obtaining asymmetric radioselenoethers (R75SeR’). 
Both of these radiosyntheses developed in this work have proved to be valuable methods for 
the preparation of a broad range of asymmetric radioselenoethers at the no-carrier-added level, 
but there are some individual differences in their applicability and in their handling. 
 
Of particular interest are the overall reaction times of the respective radiosynthetic strategies. 
The entire synthesis for the preparation of the desired asymmetric [75Se]selenoether via a free 
[75Se]selenourea-derivative (i.e. homogenous phase synthesis) as intermediate takes more than 
two hours, which is due to the long reaction time for the formation of the disubstituted 
[75Se]selenourea and the tedious purification required. 
The use of a polymer-supported primary amine as precursor for the [75Se]selenourea 
synthesis reduces the total reaction time to about half an hour, being only a quarter of the 
original reaction time, while the same RCYs are attained. This saving of time is caused firstly by 
the more rapid formation of polymer-supported [75Se]selenoureas in comparison to the free 
substituted [75Se]selenourea and, secondly, by a much shorter purification procedure. 
An even larger decrease of the total reaction time is achieved using alkyl [75Se]seleno-
cyanates as intermediates. This more straightforward synthesis of asymmetric [75Se]seleno-
ethers is performed within only 20 min, since 75Se0 is introduced directly into a part of the target 
molecule, and no “detour” via an activating or protecting group is necessary. 
 
Since the alkylation of n.c.a. labelled selenourea derivatives can only be carried out using 
trifluoromethanesulfonic acid alkyl esters as alkylating agents, which are in general unstable 
compounds and which cannot be synthesized with several more complex alkyl moieties, the 
range of achievable radioselenoethers is limited. 
A disavantage of the radiosynthetic pathway using alkyl [75Se]selenocyanates is the possible 
isomerization of these intermediates to the corresponding iso[75Se]selenocyanate, which can 
lead to a drastic decrease of the radiochemical yield in some cases (cf. subchapter 3.2.1). 
 
The huge advantage of the latter radiosynthesis is that asymmetric alkyl as well as aryl 
[75Se]selenoethers can be obtained, since aliphatic and aromatic lithium or Grignard compounds 
can be used in the last reaction step. 
The radiosynthetic strategy via 1,3-disubstituted [75Se]selenoureas, on the other hand, only 
offers the possibility to prepare asymmetric dialkyl [75Se]selenoethers. All attempts made to 
obtain aryl [75Se]selenoethers failed. 
 
74  Results and Discussion 
 
 
The radiochemical yields of the labelled target molecules are similar in both cases and 
amount up to about 50 – 55 % (related to n.c.a. 75Se0). 
Thus, the spectrum of available n.c.a. radioselenium labelled compounds has been enlarged 
via these presented reaction sequences to a wide range of asymmetric alkyl and aryl 
[75Se]selenoethers, which were obtained at the n.c.a. level for the first time. 
Furthermore, due to the successful application to a solid-phase synthetic route, the pathway 
via polymer-supported labelled selenourea-derivatives appears very attractive for automation. In 
addition, this radiosynthetic strategy avoids the use of highly toxic sodium cyanide as reagent. 
 
 
Tab. 3.4: Comparison of radioselenation methods 
 
Synthesis of           total  RCY      References 
       reaction time 
 
 n.c.a. alkyl [73,75Se]selenoethers 
  via 1,3-disubstituted [73,75Se]selenoureas 
  in solution      130 min         15 – 48 %      this work 
 polymer-supported       35 min         13 – 56 %      this work 
 
 n.c.a. alkyl / aryl [75Se]selenoethers 
 via alkyl [75Se]selenocyanates      20 min           9 – 55 %      this work 
 
 n.c.a. [75Se]selenomethionine 
 via triphenylphosphine[75Se]selenide     60 min                 30 %         [109] 
 
 n.c.a. homocysteine [75Se]selenolactone 
 via lithium methyl [75Se]selenide 
 using sulfur as non-isotopic carrier   180 min           5 – 10 %         [110] 
 
 c.a. alkyl [75Se]selenoethers 
 via 1,3-disubstituted [75Se]selenoureas    90 min         10 – 60 %          [92] 
 
 c.a. alkyl / aryl [75Se]selenoethers 
 via sodium hydrogen [75Se]selenide  > 60 min         up to 86 %       [89, 91] 
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As listed in Table 3.4, previously described methods for radioselenation only lead either to 
n.c.a. methyl selenoethers and related compounds [109, 110] or to carrier-added alkyl and aryl 
radioselenoethers [89, 91, 92]. 
 
 
 
3.4 Synthesis of a radioselenated ligand for the adenosine A1 
receptor 
 
As already outlined in the Introduction (cf. subchapter 1.7.3) partial agonists for the adenosine 
A1 receptor could have an attractive broad therapeutic potential. Previously, van der Wenden et 
al. [169] have synthesized such partial agonists by substituting the 5’-position of N6-cyclo-
pentyladenosine (CPA). Studies showed that inter alia 5’-(methylseleno)-CPA (19) (Scheme 
3.19) proved selective for the adenosine A1 receptors, displaying an affinity in the nanomolar 
range. 
 
N
N N
N
NH
O
MeSe
OHHO
19
 
 
Sch. 3.19:
 5’-(Methylseleno)-N6-cyclopentyladenosine (19) 
 
The application of the longer-lived positron emitter selenium-73 could be useful in particular 
for neuroreceptor work. It has been argued that the only feasible means of accurately studying 
receptor sites present in low concentrations is by using very high affinity ligands labelled with 
long-lived radionuclides that permit the “wash-out” phase to be analysed [170]. In late images of 
long-lived radiotracers the receptor-bound tracer should dominate the images, while with 
shorter-lived positron-emitters (e.g. 11C, 18F) the non-specific binding and the influence of 
perfusion on the local distribution may be considerable, thus both must be accounted for. 
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In order to obtain a 73Se-labelled radioligand, which could be useful for PET studies of the 
adenosine A1 receptor system, compound 19 was selected for labelling at the n.c.a level; first 
with selenium-75 to check for general feasibility of appropriate radioselenation methods. 
 
 
 
3.4.1 Standards and precursor 
 
The standard compound 5’-(methylseleno)-CPA (19) and the precursor for radioselenation 5’-
bromo-2’,3’-isopropylidenedioxy-CPA (23) were synthesized in five and three steps, respec-
tively, starting from 6-chloropurine riboside (20) (Scheme 3.20). 
 
N
N N
N
NH
O
MeSe
OHHO
19
N
N N
N
Cl
O
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OHHO
20
i N
N N
N
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O
HO
OHHO
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N
N N
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O
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O O
iii
N
N N
N
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O
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O O
iv
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N N
N
NH
O
MeSe
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O O
v
 
 
Sch. 3.20: Synthesis of 5’-(methylseleno)-CPA (19) 
 i) cyclopentylamine, EtOH, reflux; ii) sulfuric acid (conc.), acetone, 0°C; iii) triphenyl-
phosphine, carbon tetrabromide, CH2Cl2, r.t.; iv) dimethyldiselenide, sodium 
borohydride, EtOH, r.t.; v) acetic acid, reflux. 
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CPA (21) was obtained by reacting 20 with cyclopentylamine in ethanol to substitute the 
chlorine atom [171]. To obtain a 5’-group that is selectively reactive with respect to the other two 
(2’- and 3’-) positions, the cis vicinal 2’- and 3’-hydroxyl groups of CPA were selectively 
protected with an isopropylidene moiety by sulfuric acid-catalytic reaction in acetone [172], 
yielding 2’,3’-isopropylidenedioxy-CPA (22). Subsequently, the 5’-hydroxyl group of 22 was 
replaced by a bromine atom as leaving group, by reaction with carbon tetrabromide and 
triphenylphosphine in CH2Cl2 [173], resulting 5’-bromo-2’,3’-isopropylidenedioxy-CPA (23). This 
compound was quite unstable and was therefore used directly after purification. A reaction 
between 23 and methyl selenolate, which was obtained by reductive cleavage of dimethyl-
diselenide via sodium borohydride [174], yielded 5’-(methylseleno)-2’,3’-isopropylidenedioxy-
CPA (24). Deprotecting the 2’- and 3’-position of 24 with acetic acid [175] gave the final product 
5’-(methylseleno)-CPA (19) with an overall yield of about 20 % (related to 20). 
 
Results of radioligand binding studies for 5’-(methylseleno)-CPA (19) in literature [169] are 
promising regarding selectivity for the adenosine A1 receptor, since they showed a 150 fold 
better affinity for the A1 vs. the A2A receptor, which is probably due to to the presence of the N6-
cyclopentyl substituent. Though, the Ki value of 19 for the adenosine A1 receptor was not very 
satisfactory with only 76 nM; the Ki value for the A2A receptor amounted to 11 µM. These 
literature data were obtained using membranes of rat brain cortex with [3H]DPCPX as the 
radioligand and using rat striatal membranes with [3H]CGS21680 as the radioligand, respec-
tively. 
Nevertheless, 19 seems to be a very attractive selective ligand for the A1 receptor, therefore 
radioligand binding studies were carried out in context with this thesis by the Pharmacology 
Group of the Institute of Nuclear Chemistry under different conditions (cf. subchapter 4.5). Its 
affinity for the adenosine A1 receptor was determined by competition with [3H]CPFPX on pig 
cortical membranes. The Ki value of 19 for the adenosine A1 receptor was 0.9 nM (0.8 – 1.1 nM, 
95 % confidence interval). On the other hand, 19 had a Ki value of 1.3 µM (0.3 – 5.5 µM, 95 % 
confidence interval) for the adenosine A2A receptor measured by displacement of [3H]CGS21680 
from pig striatal membranes. These results suggest, that 5’-(methylseleno)-CPA (19) is selective 
for the adenosine A1 vs. the A2A receptor with a 1500 fold better affinity. The differences of this 
study and literature data can be explained by the altered conditions of the radioligand binding 
studies, i.e. by a different radioligand competitor in case of the A1 receptor study and by tissues 
of different animals in the studies. 
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3.4.2 Synthesis of n.c.a. 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine 
 
Since the specific activity of a potential radioligand for in vivo studies is a crucial factor and 
should be as high as possible in order to avoid a saturation of the receptor system by the 
compound administered, appropriate n.c.a. labelling methods are required. The n.c.a. radio-
selenation strategies developed in this work were tested for the preparation of n.c.a. 5’-(methyl-
[75Se]seleno)-CPA ([75Se]19). 
Attempts to obtain n.c.a. [75Se]19 via the selenocyanate method were not successful probably 
due to isomerization (cf. subchapter 3.2.1) of 5’-[75Se]selenocyanato-2’,3’-isopropylidenedioxy-
CPA to 5’-iso[75Se]selenocyanato-2’,3’-isopropylidenedioxy-CPA. 
Using instead the first radiosynthetic concept via free methyl [75Se]selenouronium salt 
([75Se]3a), 5’-(methyl[75Se]seleno)-2’,3’-isopropylidenedioxy-CPA ([75Se]24) was obtained in a 
RCY of 70 % (related to [75Se]3a) after hydrolysis of [75Se]3a and alkylation of the resulting 
methyl [75Se]selenolate ([75Se]4a) with 5’-bromo-2’,3’-isopropylidenedioxy-CPA (23) under the 
optimized reaction conditions given in subchapter 3.1.4. The corresponding reaction sequence 
utilizing the polymer-supported methyl [75Se]selenouronium salt ([75Se]3aresin) as starting 
material (cf. subchapter 3.1.5) gave rise to a RCY of [75Se]24 of about 70 % (related to 
[75Se]3aresin) as well. Subsequent deprotection of [75Se]24 using hydrochloric acid at 80°C 
yielded the final n.c.a. product [75Se]19 within 5 min and with a RCY of 55 % (related to 
[75Se]24). Thus, 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine was obtained at the n.c.a. 
level with an overall RCY of approximately 30 % (related to 75Se0) within a total reaction time of 
135 and 40 min using the free and the polymer-supported selenourea method, respectively. 
The specific activity of n.c.a. [75Se]19 was determined to be more than 300 GBq/mmol 
(8 Ci/mmol) (cf. subchapter 4.4.3). In consideration of this relatively low value and a theoretically 
As,max of 40 TBq/mmol (1 Ci/µmol) for carrier-free selenium-75, the actual specific activity will 
amount to a value in the range between these two limits. Provided production of higher starting 
activities would not increase the dilution with stable selenium, i.e. the amount of carrier will still 
remain below 1 nmol, which is the limit of detection (cf. subchapter 4.4.3), one can suggest that 
the actual specific activity would increase with the same factor as the starting activity. In case of 
the positron emitter selenium-73, the theoretically As,max amounts to 1600 TBq/mmol 
(400 Ci/µmol). Therefore one can suggest that an even higher specific activity will be obtained if 
the starting activity is in the GBq-range. Thus, it should be possible to obtain a specific activity, 
which is sufficient to perform in vivo receptor studies with 73Se-labelled ligands using PET. 
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Chapter 4 
 
Experimental 
 
4.1 General 
 
All chemicals and solvents were purchased from Aldrich (Germany), Fluka (Switzerland) and 
Merck (Germany). They were reagent grade or better and used without further purification. 
LiChrolut EN cartridges were obtained from Merck; Sep-Pak Plus C18 cartridges were ob-
tained from Waters (USA) and aminomethylated polystyrene was obtained from Novabiochem 
(Germany). All selenocompounds were prepared under a slight positive pressure of argon. 
Gravity column chromatography was done with Merck silica gel 60 (0.063 – 0.200 mm). Flash 
chromatography was done with Fluka silica gel 60 (220 –
 
440 mesh). Mixtures of elution 
solvents are given as V:V ratios. 
 
Melting point determinations employed a Mettler FP 61 apparatus. Melting points (m.p.) and 
boiling points (b.p.) are uncorrected. Analytical thin-layer chromatography (TLC) was performed 
with precoated silica gel plates (5 x 7.5 cm plates Type F254S, Merck, Germany). Visualization of 
TLC slides was by either iodine, UV or ninhydrin. Infrared spectra (IR) were recorded as KBr 
pellets on a Shimadzu IR-460 spectrophotometer. 1H, 13C and 19F nuclear magnetic resonance 
(NMR) spectra were recorded at 200, 50 and 188 MHz, respectively, on a Bruker DPX Avance 
200 spectrometer with samples dissolved in CDCl3, CD2Cl2 or d6-DMSO. 13C NMR were 
routinely run with broad band decoupling. All chemical shifts are reported in 4  ppm using the 
signals of the solvent as a reference. Mass spectra (MS) were obtained using a Thermoquest 
Automass Multi mass spectrometer using the ionization method indicated for each single 
compound. High-resolution mass spectra (HR-MS) served as additional identification of 
compounds prepared for the first time and were determined with electron ionization (EI) using 
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standard methods on a Finnigan MAT 900 ST apparatus (University of Cologne, Germany). HR-
MS was used in place of elemental analysis, since it provided results which were sufficient for 
this work. 
 
 
 
4.2 Standards and precursors 
 
Most of the syntheses described below were carried out as modified versions of the correspon-
ding original literature. In few cases the syntheses were taken directly from the literature without 
any alteration, and in some cases completely new syntheses were elaborated. 
 
 
4.2.1 Syntheses via 1,3-dicyclohexyl selenourea 
 
Cyclohexyl isoselenocyanate (1a) [following 154] 
 
Selenium (0.19 g, 2.4 mmol) was added to a solution of cyclohexyl isocyanide (0.25 mL, 
2 mmol) in EtOH (20 mL). The mixture was stirred under reflux for 4 h. After cooling, 
undissolved selenium was removed by filtration, the solvent evaporated, and the residue was 
purified via gravity column chromatography (hexane/diethyl ether 20:1) to give the product [176] 
as an oil after evaporation of the eluent. 
 
Yield: 113 mg (30 %). 
 
Rf: 0.35 (hexane/diethyl ether 100:3). 
 
IR: 5 max (KBr): 2120 cm-1 (NCSe). 
 
1H-NMR (d6-DMSO): 6 798;:<>=)?A@ﬃBﬁCD@ﬁEFCHGI@BJ8K<J7(=)?L@BM:CD@ﬁEFC 2). 
 
13C-NMR (d6-DMSO): N OQPROJSKTVUXWZYﬃ[DYﬃ\]^I_ﬁ`aTbS c(U"[Fd -N), 32.9 (CH2), 25.3 (CH2), 23.4 (CH2). 
 
MS (EI): m/e 189 (M, 18 %), 66 (75), 55 (100). 
 
 
1,3-Dicyclohexyl selenourea (2a) [following 61] 
 
Selenium (0.95 g, 12 mmol) was added to a solution of cyclohexyl isocyanide (1.24 mL, 
10 mmol) and cyclohexyl amine (1.14 mL, 10 mmol) in EtOH (100 mL). The mixture was stirred 
under reflux for 16 h. After cooling, undissolved selenium was removed by filtration, the solvent 
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evaporated, and the residue was purified via gravity column chromatography (hexane/diethyl 
ether 2:3) to give the product [92] as colourless solid after evaporation of the eluent. 
 
Yield: 2.53 g (88 %). 
 
M.p.: 172°C. 
 
Rf: 0.52 (hexane/diethyl ether 2:3). 
 
IR: e max (KBr): 3250 cm-1 (NH), 2930 cm-1 (CH), 1560 cm-1 (NH). 
 
1H-NMR (CD2Cl2): f  5.85 (bs, 2H, NH), 3.85 (bs, 2H, CH), 1.65 (m, 10H, CH2). 
 
13C-NMR (d6-DMSO): f  173.0 (C=Se), 54.3 (CH-N), 32.0, 25.0, 24.5 (CH2). 
 
MS (EI): m/e 288 (M, 25 %), 207 (10), 125 (30), 98 (29), 83 (23), 43 (100). 
 
HR-MS calculated for C13H24N2Se: 289.118, found 289.117. 
 
 
Trifluoromethanesulfonic acid propyl ester [following 160] 
 
A solution of 1-propanol (1.8 mL, 24 mmol) in CH2Cl2 (10 mL) was added dropwise with stirring 
over a 30-min period to a solution of 2,6-lutidine (3.6 mL, 30 mmol) and trifluoromethanesulfonic 
anhydride (4.8 mL, 30 mmol) in CH2Cl2 (30 mL) at –70°C. After warming to r.t., the solvent was 
evaporated, and the residue was distilled to give the product as colourless liquid. 
 
Yield: 3.41 g (74 %). 
 
B.p.: 75°C at 20 mbar. 
 
1H-NMR (CDCl3): f  4.58 (t, 2H, CH2-O), 1.91 (m, 2H, CH2-CH3), 1.09 (t, 3H, CH3). 
 
13C-NMR (CDCl3): f ggMhi"gkj"lFm 3), 79.6 (CH2-O), 23.1 (CH2-CH3), 9.8 (CH3). 
 
19F-NMR (CDCl3): n –75.4 (CF3). 
 
 
Selenouronium salts (3) 
 
1,3-Dicyclohexyl selenourea (2a) (575 mg, 2 mmol) was suspended in benzene (50 mL) and 
heated to 70°C, resulting in a grey solution. The appropriate trifluoromethanesulfonic acid alkyl 
ester (2.1 mmol) was added and the mixture further stirred for 1 h at room temperature. The 
solvent was evaporated and the crude product obtained was purified via gravity column 
chromatography. Byproducts and starting material were removed (hexane/diethyl ether 1:1) and 
the appropriate purified selenouronium salts were eluted from the column with acetone yielding 
grey solids after evaporation: 
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(Biscyclohexylaminomethylene)methylselenouronium trifluoromethanesulfonate (3a) 
 (“methyl selenouronium salt”) 
 
Yield: 750 mg (83 %). 
 
M.p.: 122°C. 
 
Rf: 0.1 – 0.2 (hexane/diethyl ether 2:3). 
 
MS (ESI): m/e 303 (M-OTf, 100 %). 
 
(Biscyclohexylaminomethylene)ethylselenouronium trifluoromethanesulfonate (3b) 
 (“ethyl selenouronium salt”) 
 
Yield: 820 mg (88 %). 
 
M.p.: 95°C. 
 
Rf: 0.1 – 0.2 (hexane/diethyl ether 2:3). 
 
MS (ESI): m/e 317 (M-OTf, 100 %). 
 
(Biscyclohexylaminomethylene)propylselenouronium trifluoromethanesulfonate (3c) 
 (“propyl selenouronium salt”) 
 
Yield: 776 mg (81 %). 
 
M.p.: 95°C. 
 
Rf: 0.1 – 0.2 (hexane/diethyl ether 2:3). 
 
MS (ESI): m/e 331 (M-OTf, 100 %). 
 
 
Methylselenoethers (5a, 5d) 
 
An aqueous solution (1.5 M) of tetrabutylammonium hydroxide (0.53 mL, 0.8 mmol) was added 
to a mixture of 3a (352 mg, 0.78 mmol) and selected alkylbromides/tosylates (0.8 mmol) in 
acetonitrile (30 mL). The mixture was stirred for 0.5 h at room temperature. The solvent was 
evaporated and the residue was purified via gravity column chromatography (hexane/diethyl 
ether 100:2) to give 5a and 5d as pale yellow oils after evaporation of the eluent: 
 
Benzylmethylselenide (5a) [177] 
 
Yield: 106 mg (73 %). 
 
nD
20: 1.5962 (lit.: 1.5969). 
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Rf: 0.41 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3 oqpr sbt;uuAvXwLxyzDx|{F} -H), 3.77 (s, 2H, CH2-Ph), 1.95 (s, 3H, CH3). 
 
13C-NMR (CDCl3): ~  136.8 (Cq), 128.3 (=CH), 25.3 (CH2), 6.3 (CH3). 
 
MS (EI): m/e 186 (M, 7 %), 169 (1), 91 (100). 
 
1-Phenyl-1-(methylseleno)ethane (5d) [92] 
 
Yield: 103 mg (66 %). 
 
nD
20: 1.5783. 
 
Rf: 0.40 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3 q ~ bKAXLŁD|F -H), 4.16 (q, 1H, CH), 1.90 (s, 3H, Se-CH3), 1.73 (d, 3H, CH-
CH3). 
 
13C-NMR (CDCl3):   144.7 (Cq), 128.0 (=CH), 38.2 (Ar-CH), 22.5 (CH-CH3), 4.9 (Se-CH3). 
 
MS (EI): m/e 200 (M, 5 %), 105 (100), 95 (24), 77 (82). 
 
 
3-(Methylseleno)-1-propanol [following 60] 
 
Selenium powder (450 mg, 5.7 mmol) was suspended in tetrahydrofuran (20 mL), and methyl 
lithium in diethyl ether (4.3 mL, 6.9 mmol) was added with stirring. The selenium dissolved to 
give a pale yellow solution. 3-Bromo-1-propanol (0.52 mL, 5.7 mmol) was added and the 
mixture stirred for 1 h. The solution was hydrolyzed with water (10 mL), the organic phase 
separated, washed with NaHCO3 and NaCl solutions and dried (Na2SO4). The solvent was 
removed by distillation and the residue fractionated in vacuo to give the product as a pale yellow 
oil. 
 
Yield: 0.4 g (45 %). 
 
B.p.: 100°C at 7 mmHg (lit.: 100°C at 8 mmHg). 
 
Rf: 0.40 (hexane/diethyl ether 1:1). 
 
1H-NMR (CDCl3):   3.80 (t, 2H, CH2-OH), 2.70 (t, 2H, CH2-Se), 2.05 (s, 3H, CH3), 1.93 (m, 2H, 
CH2-CH2-CH2). 
 
MS (EI): m/e 154 (M, <1 %), 93 (11), 57 (15), 28 (100). 
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3-(Methylseleno)-1-propanyl p-toluenesulfonate (5g) [following 178] 
 
Toluene-4-sulfonyl chloride (285 mg, 1.5 mmol) in acetonitrile (1 mL) was added to a stirred 
solution of 3-(methylseleno)-1-propanol (153 mg, 1 mmol), triethylamine (0.3 mL, 2 mmol) and 
trimethylamine hydrochloride (80 mg, 0.1 mmol) in acetonitrile (1 mL) at 0°C, and the mixture 
was stirred for 1 h. Water was added to the mixture, which was extracted with ethyl acetate. The 
organic phase was washed with brine, dried (Na2SO4) and concentrated. The obtained crude 
product was purified by gravity column chromatography (hexane/diethyl ether 1:1) to give 5g 
[109] as a pale yellow oil after evaporation of the eluent. 
 
Yield: 295 mg (96 %). 
 
nD
20: 1.5506. 
 
Rf: 0.60 (hexane/diethyl ether 1:1). 
 
1H-NMR (CDCl3):   7.75 (m, 2H, Ar-H), 7.35 (m, 2H, Ar-H), 4.15 (t, 2H, CH2-OTos), 2.53 (t, 2H, 
Se-CH2), 2.40 (s, 3H, Ph-CH3), 1.95 (m, 2H, CH2-CH2-CH2), 1.90 (s, 3H, Se-CH3). 
 
MS (EI): m/e 308 (M, 38 %), 213 (8), 155 (2), 95 (21), 91 (100). 
 
 
Ethylselenoethers (5b, 5e) 
 
Ethylselenoethers 5b and 5e were prepared from 3b (365 mg, 0.78 mmol), appropriate 
alkylbromides (0.8 mmol) and an aqueous solution (1.5 M) of tetrabutylammonium hydroxide 
(0.53 mL, 0.8 mmol) in acetonitrile (30 mL) in the same way as described for methyl-
selenoethers. Workup as described above afforded pale yellow oils: 
 
Benzylethylselenide (5b) 
 
Yield: 85 mg (50 %). 
 
nD
20: 1.5777. 
 
Rf: 0.39 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3):   7.30 (m, 5H, Ar-H), 3.84 (s, 2H, Ar-CH2), 2.56 (q, 2H, Se-CH2-CH3), 1.41 (t, 
3H, CH3). 
 
13C-NMR (CDCl3):   140.0 (Cq), 128.1 (=CH), 27.0 (Ar-CH2), 17.8 (Se-CH2-CH3), 15.9 (CH3). 
 
MS (EI): m/e 200 (M, 30 %), 91 (100), 65 (30). 
 
HR-MS calculated for C9H12Se: 200.010, found: 200.010. 
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1-Phenyl-1-(ethylseleno)ethane (5e) 
 
Yield: 82 mg (49 %). 
 
nD
20: 1.5623. 
 
Rf: 0.37 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3):   7.31 (m, 5H, Ar-H), 4.25 (q, 1H, CH), 2.46 (q, 2H, CH2), 1.77 (d, 3H, CH-
CH3), 1.34 (t, 3H, CH2-CH3). 
 
13C-NMR (CDCl3):   145.1 (Cq), 128.0 (=CH), 37.1 (Ar-CH), 23.0 (CH-CH3), 18.4 (CH2), 16.0 
(CH2-CH3). 
 
MS (EI): m/e 214 (M, 22 %), 105 (100), 79 (18), 77 (24), 51 (27). 
 
HR-MS calculated for C10H14Se: 214.026, found: 214.026. 
 
 
Propylselenoethers (5c, 5f) 
 
Propylselenoethers (5c and 5f) were prepared from 3c (374 mg, 0.78 mmol), appropriate alkyl-
bromides (0.8 mmol) and an aqueous solution (1.5 M) of tetrabutylammonium hydroxide 
(0.53 mL, 0.8 mmol) in acetonitrile (30 mL) in the same way as described for methyl-
selenoethers. Workup as described above afforded pale yellow oils: 
 
Benzylpropylselenide (5c) 
 
Yield: 68 mg (41 %). 
 
nD
20: 1.5639. 
 
Rf: 0.45 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3):   7.29 (m, 5H, Ar-H), 3.81 (s, 2H, Ar-CH2), 2.52 (t, 2H, Se-CH2-CH2), 1.69 (m, 
2H, CH2-CH3), 1.00 (t, 3H, CH3). 
 
13C-NMR (CDCl3):   140.1 (Cq), 129.1 (=CH), 27.3 (CH2-CH3), 26.7 (Ar-CH2), 24.0 (Se-CH2-
CH2), 15.0 (CH3). 
 
MS (EI): m/e 214 (M, 27 %), 91 (100), 65 (25). 
 
HR-MS calculated for C10H14Se: 214.026, found: 214.026. 
 
1-Phenyl-1-(propylseleno)ethane (5f) 
 
Yield: 76 mg (43 %). 
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nD
20: 1.5532. 
 
Rf: 0.39 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3):   7.31 (m, 5H, Ar-H), 4.21 (q, 1H, CH), 2.44 (t, 2H, Se-CH2), 1.77 (d, 3H, CH-
CH3), 1.58 (m, 2H, CH2-CH3), 0.96 (t, 3H, CH3). 
 
13C-NMR (CDCl3):   145.1 (Cq), 128.0 (=CH), 37.4 (Ar-CH), 27.1 (CH2-CH3), 24.1 (Se-CH2), 
23.1 (CH-CH3), 15.1 (CH2-CH3). 
 
MS (EI): m/e 228 (M, 17 %), 105 (100), 79 (14), 77 (20), 51 (17). 
 
HR-MS calculated for C11H16Se: 228.041, found: 228.042. 
 
 
Ethyl N-tert.-butoxycarbonyl-2-amino-4-bromobutyrate (8) [from 109] 
 
L-  -Amino-  -butyrolactone hydrobromide (3.5 g, 22.5 mmol) was dissolved in a solution of 
hydrobromic acid (5.7 M) in acetic acid (40 mL) and heated at 100°C for 6 h in an autoclave. 
The mixture was cooled overnight, the precipitate was filtered off and washed with diethyl ether 
to give 2-amino-4-bromobutyric acid hydrobromide as colourless crystals, which were used 
without further purification. 
2-Amino-4-bromobutyric acid hydrobromide (3.3 g, 12.6 mmol) was dissolved in ethanol 
(50 mL), and gaseous HCl was introduced at 0°C for 2 h. The solvent was evaporated to give 
ethyl 2-amino-4-bromobutyrate as a brown oil, which was used without further purification. 
A solution of ethyl 2-amino-4-bromobutyrate, di-tert.-butyl dicarbonate (2.75 g, 12.6 mmol) and 
NaHCO3 (1.05 g, 12.6 mmol) in ethanol (50 mL) was treated with ultrasound for 2 h. The solvent 
was evaporated, and the residue was purified via gravity column chromatography (hexane/ethyl 
acetate 7:3) to give ethyl N-tert.-butoxycarbonyl-2-amino-4-bromobutyrate as colourless crystals 
after evaporation of the eluent. 
 
Yield: 2.8 g (40 % related to L-  -amino-  -butyrolactone hydrobromide). 
 
M.p.: 65°C (lit.: 69.5°C). 
 
Rf: 0.78 (hexane/diethyl ether 2:3). 
 
IR:  max (KBr): 3375 cm-1 (NH), 1749 cm-1 (CO), 1682 cm-1 (CO). 
 
1H-NMR (CDCl3):  QRﬁ ¡¢H£q¤9 ¤¥¦9ZﬁD¨§FH£Ib¤9K©ª¦R9©D¨« -CH2), 3.50 (t, 2H, Br-
CH2), 2.30 (m, 2H, CH2-CH2-CH), 1.50 (s, 3H, CH3), 1.35 (t, 3H, CH2-CH3). 
 
13C-NMR (CDCl3): ¬ ­M®a¯b°;¯±"²³±+´¶µX´·µI¸Z­M¹ºb°;®¥±+²³±"´¶µI»HµI¸9¼½°;¾¥± C(CH3)3), 62.2 (O-CH2), 54.9 (Ctert), 
28.7 (Br-CH2), 28.7 (C(CH3)3), 27.8 (CH2-CH2-Ctert), 14.6 (CH2-CH3). 
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MS (EI): m/e 311 (M, <1 %), 236 (22), 210 (10), 182 (11), 136 (18), 57 (100). 
 
 
Homocysteine selenolactone hydroiodide (6) [from 179] 
 
Selenomethionine (100 mg, 0.51 mmol) was added to hydrogen iodide (5 mL, 57 %) and the 
mixture was refluxed at 140°C for 4 h. The resulting solution was extracted several times with 
diethyl ether, the aqueous phase was diluted with water and then dried by lyophilization. The 
product was dissolved in hot ethanol and then precipitated by addition of three volumes of 
diethyl ether. The final product 6 was recovered by centrifugation and was further washed with 
diethyl ether. 
 
Yield: 94 mg (63 %). 
 
Rf: 0.68 (n-butanol/ethanol/formic acid 5:1:1). 
 
1H-NMR (d6-DMSO): ¿  4.38 (t, 1H, CH), 2.34 (t, 2H, CH2-Se), 1.65 (m, 2H, CH2-CH2-CH). 
 
MS (ESI): m/e 164 (M-HI, 100 %). 
 
 
 
4.2.2 Syntheses via alkyl selenocyanates 
 
Alkyl selenocyanates (10) [following 180] 
 
Potassium selenocyanate (9a) (1.44 g, 10 mmol) and an appropriate alkylbromide (10 mmol) 
were heated under reflux in ethanol (50 mL) for 2 h. The solvent was evaporated and the 
residue was purified via flash chromatography (hexane/diethyl ether 1:4) to give 10 after 
evaporation of the eluent: 
 
Benzyl selenocyanate (crystalline) (10a) [181] 
 
Yield: 1.45 g (74 %). 
 
M.p.: 71.7°C (lit.: 72°C). 
 
Rf: 0.66 (hexane/diethyl ether 2:3). 
 
IR: À max (KBr): 2140 cm-1 (Se-C≡N). 
 
1H-NMR (CDCl3): Á  7.38 (m, 5H, Ar-H), 4.35 (s, 2H, CH2). 
 
13C-NMR (CDCl3): Á  135.8 (Cq), 129.4 (=CH), 102.5 (Se-C≡N), 33.2 (CH2). 
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MS (EI): m/e 197 (M, 2 %), 91 (100), 65 (76). 
 
1-Phenylethyl-1-selenocyanate (yellow oil) (10b) [182] 
 
Yield: 1.66 g (79 %). 
 
nD
20: 1.5833. 
 
Rf: 0.77 (hexane/diethyl ether 2:3). 
 
IR: Â max (KBr): 2145 cm-1 (Se-C≡N). 
 
1H-NMR (CDCl3): Ã  7.43 (m, 5H, Ar-H), 4.96 (q, 1H, Ar-CH), 2.10 (d, 3H, CH3). 
 
13C-NMR (CDCl3): Ã  139.9 (Cq), 128.6 (=CH), 103.1 (Se-C≡N), 48.8 (CH), 23.3 (CH3). 
 
MS (EI): m/e 211 (M, 1 %), 105 (100), 77 (44). 
 
 
Methyl selenocyanate (10c) was obtained by reaction of 9a (0.014 g, 0.1 mmol) and trifluoro-
methanesulfonic acid methyl ester (11 µL, 0.1 mmol) in refluxing ethanol (10 mL) within 30 min. 
It was not separated due to its instability. 
 
Rf: 0.91 (hexane/diethyl ether 2:3). 
 
 
Alkylselenoethers (5a, 5d, 5h) [following 183] 
 
Alkylselenoethers (5a, 5d and 5h) were prepared from 10 (1 mmol) and the appropriate alkyl 
lithium compound (1 mmol) in anhydrous diethyl ether (20 mL) by stirring this mixture for 10 min 
at r.t. The solvent was evaporated, and the residue was purified via flash chromatography 
(hexane/diethyl ether 100:2) to give 5a, 5d and 5h as pale yellow oils after evaporation of the 
eluent: 
 
Benzylmethylselenide (5a) [177] 
 
Yield: 154 mg (83 %). 
 
Analytical data see above. 
 
1-Phenyl-1-(methylseleno)ethane (5d) [92] 
 
Yield: 172 mg (86 %). 
 
Analytical data see above. 
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1-Phenyl-1-(butylseleno)ethane (5h) 
 
Yield: 193 mg (80 %). 
 
nD
20: 1.5361. 
 
Rf: 0.47 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3): Ä  7.31 (m, 5H, Ar-H), 4.21 (q, 1H, Ar-CH), 2.44 (t, 2H, Se-CH2-CH2), 1.76 (d, 
3H, CH-CH3), 1.60 (m, 2H, CH2-CH2-CH2), 1.36 (m, 2H, CH2-CH3), 0.89 (t, 3H, CH2-CH3). 
 
13C-NMR (CDCl3): Ä  145.1 (Cq), 128.0 (=CH), 37.4 (Ar-CH), 32.9 (Se-CH2), 24.7 (CH2-CH2-CH2), 
23.6 (CH-CH3), 23.1 (CH2-CH3), 14.0 (CH2-CH3). 
 
MS (EI): m/e 242 (M, 10 %), 105 (100), 77 (18). 
 
HR-MS calculated for C12H18Se: 242.057, found: 242.057. 
 
 
Arylselenoethers (5i-k) [following 183 and 184] 
 
Arylselenoethers (5i-k) were prepared from 10 (1 mmol) and the appropriate aryl lithium or 
Grignard compound (1 mmol) in anhydrous diethyl ether (20 mL) in the same way as described 
for alkylselenoethers. Workup as described above afforded pale yellow oils: 
 
Benzylphenylselenide (5k) [185] 
 
Yield: 220 mg (89 %). 
 
nD
20: 1.6277. 
 
Rf: 0.42 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3): Ä  7.39 (m, 10H, Ar-H), 4.19 (s, 2H, CH2). 
 
13C-NMR (CDCl3): Ä  144.9 (Cq), 136.1 (Cq), 130.7 (=CH), 32.7 (CH2). 
 
MS (EI): m/e 248 (M, 12 %), 157 (3), 91 (100), 65 (16). 
 
1-Phenyl-1-(phenylseleno)ethane (5i) [186] 
 
Yield: 209 mg (80 %). 
 
nD
20: 1.6183. 
 
Rf: 0.50 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3): Ä  7.44 (m, 10H, Ar-H), 4.57 (q, 1H, Ar-CH), 1.86 (d, 3H, CH3). 
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13C-NMR (CDCl3): Å  144.1 (Cq), 136.0 (Cq), 128.9 (=CH), 42.7 (Ar-CH), 22.7 (CH3). 
 
MS (EI): m/e 262 (M, 5 %), 157 (5), 105 (100), 77 (21). 
 
1-Phenyl-1-(4-fluorophenylseleno)ethane (5j) 
 
Yield: 244 mg (87 %). 
 
nD
20: 1.5988. 
 
Rf: 0.42 (hexane/diethyl ether 100:3). 
 
1H-NMR (CDCl3): Å  7.18 (m, 9H, Ar-H), 4.45 (q, 1H, Ar-CH), 1.79 (d, 3H, CH3). 
 
13C-NMR (CDCl3): Å  160.9 (C-F), 143.8 (Cq), 138.4 (Cq), 122.4 (=CH), 43.3 (Ar-CH), 22.3 (CH3). 
 
19F-NMR (CDCl3): Å  -113.9. 
 
MS (EI): m/e 280 (M, 13 %), 175 (3), 105 (100), 77 (83). 
 
HR-MS calculated for C14H13FSe: 280.017, found: 280.016. 
 
 
 
Phenylmethylselenide (5l) [following 187] 
 
A mixture of diphenyl diselenide (0.4 g, 1.3 mmol) and sodium borohydride (0.1 g, 2.7 mmol) in 
EtOH (50 mL) was stirred at r.t. for 10 min. After adding of methyl iodide (0.17 mL, 2.7 mmol), 
the solution was refluxed for 30 min. The solvent was evaporated and the residue was purified 
via flash chromatography (hexane/diethyl ether 100:2) to give phenylmethylselenide [188] as a 
pale yellow oil after evaporation of the eluent. 
 
Yield: 164 mg (74 %). 
 
nD
20: 1.602. 
 
Rf: 0.46 (hexane/diethyl ether 100:2). 
 
1H-NMR (CDCl3): Å  7.38 (m, 5H, Ar-H), 2.40 (s, 3H, CH3). 
 
13C-NMR (CDCl3): Å  129.4 (=CH), 7.7 (CH3). 
 
MS (EI): m/e 172 (M, 100 %), 157 (95). 
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4.2.3 Synthesis of 5’-(methylseleno)-N6-cyclopentyladenosine 
 
N6-Cyclopentyladenosine (21) [from 171] 
 
A mixture of 6-chloropurine ribonucleoside (5.7 g, 20 mmol), cyclopentylamine (11.8 mL, 
120 mmol) and EtOH (100 mL) was refluxed for 15 h, and it was evaporated in vacuo to 
dryness. The residue was triturated with a small amount of EtOH, and colourless crystals of N6-
cyclopentyladenosine were obtained. 
 
Yield: 4.56 g (68 %) (lit.: 75 %). 
 
M.p.: 78.8°C (lit.: 77 – 81°C). 
 
Rf: 0.68 (CH2Cl2/MeOH 1:4). 
 
1H-NMR (d6-DMSO): Æ ÇÈ;ÉaÊÌËÍÎÏﬁÐDÎ9ÐÑÇaÒIÎﬃÇÈKÓ9ÏAËÍÎÔÏﬁÐDÎbÐÑÓÒIÎ#ÕbÈ;ÇÖ×Ë"ØbÎ¨ÏﬁÐ ÎbÙ 6H), 5.91 (d, 1H, H1’), 
5.47 (m, 2H, OH-2’/OH-3’), 5.21 (m, 1H, OH-5’), 4.62 (m, 1H, H2’), 4.56 (bs, 1H, HCN6), 4.17 
(m, 1H, H3’), 3.99 (m, 1H, H4’), 3.67 (m, 2H, H5’), 1.78 (m, 8H, Hcyclopentyl). 
 
13C-NMR (d6-DMSO): Ú ÛMÜÜbÝ;Þàß+áZâaã+áåäæIçFÛQÜÞÝÛß"áåèæqç³Ûéââ¨Ý;êëß"áDìaæIç³ÛíâﬃîÝ âïß"á¢ÜaæIçZììÝ;ìàß"á·ÛQð æqçÑìaäbÝñì
(C4’), 74.3 (C2’), 71.5 (C3’), 62.6 (C5’), 56.9 (C1 cyclopentyl), 33.0 (C2/5cyclopentyl), 24.3 
(C3/4cyclopentyl). 
 
MS (ESI): m/e 336 (M+1, 100 %). 
 
 
2’,3’-Isopropylidenedioxy-N6-cyclopentyladenosine (22) [from 172] 
 
N6-cyclopentyladenosine (21) (4.36 g, 13 mmol) dissolved in acetone (50 mL) was added drop-
wise to a stirred mixture of acetone (50 mL) and concentrated sulfuric acid (1.3 mL, 26 mmol) at 
0°C. After complete addition, the mixture was stirred at r.t. for 90 min. The solution was cooled 
again to 0°C and was neutralized with NaOHaq (20 mL, 20 %). The mixture was concentrated 
and partitioned between H2O and CH2Cl2. The aqueous layer was extracted several times with 
CH2Cl2. The combined organic layers were dried (Na2SO4), and the solvent was evaporated. 
The residue was purified via flash chromatography (CH2Cl2/MeOH 100:2) to give 2’,3’-
isopropylidenedioxy-N6-cyclopentyladenosine as colourless crystals after evaporation of the 
eluent. 
 
Yield: 3.79 g (78 %). 
 
M.p.: 96°C. 
 
Rf: 0.35 (CH2Cl2/MeOH 25:1). 
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1H-NMR (d6-DMSO): ò óô;õaöÌ÷øùúﬁûDù9ûÑóaüIùﬃóôKýõþ÷øùÔúﬁûDùbûÑýüIù#ßbô;óRúL÷ bù¨úﬁû ù 6H), 6.15 (d, 1H, H1’), 
5.32 (m, 2H, H2’/OH-5’), 4.99 (m, 1H, H3’), 4.56 (bs, 1H, HCN6), 4.24 (m, 1H, H4’), 3.57 (m, 2H, 
H5’), 1.77 (m+s, 11H, Hcyclopentyl/CH3, isopropylidene), 1.34 (s, 3H, CH3, isopropylidene). 
 
13C-NMR (d6-DMSO):  
	 
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(Cq, isopropylidene), 90.6 (C1’), 87.3 (C4’), 84.1 (C2’), 82.3 (C3’), 62.5 (C5’), 57.0 (C1 cyclopentyl), 33.0 
(C2/5cyclopentyl), 27.9 (CH3, isopropylidene), 26.0 (CH3, isopropylidene), 24.3 (C3/4cyclopentyl). 
 
MS (ESI): m/e 375 (M, 100 %), 204 (35). 
 
 
5’-Bromo-2’,3’-isopropylidenedioxy-N6-cyclopentyladenosine (23) [from 173] 
 
Triphenylphosphine (2.36 g, 9 mmol) in dry CH2Cl2 (20 mL) was added dropwise to a stirred 
solution of 22 (3.38 g, 9 mmol) and CBr4 (5 g, 15 mmol) in dry CH2Cl2 (20 mL) at r.t. After 15 h 
the solvent was evaporated and the residue was purified via flash chromatography 
(CH2Cl2/MeOH 100:2) to give 5’-bromo-2’,3’-isopropylidenedioxy-N6-cyclopentyladenosine as an 
oil after evaporation of the eluent. 
 
Yield: 2.09 g (53 %). 
 
Rf: 0.81 (CH2Cl2/MeOH 25:1). 
 
1H-NMR (d6-DMSO): ( )
*+)-,/.02143!0536)70$)
*%89):,/.0;143!036870=<*<>?,@0143A0B 6H), 6.22 (d, 1H, H1’), 
5.51 (m, 1H, H2’), 5.02 (m, 1H, H3’), 4.58 (bs, 1H, HCN6), 4.48 (m, 1H, H4’), 3.68 (m, 2H, H5’), 
1.75 (m+s, 11H, Hcyclopentyl/CH3, isopropylidene), 1.24 (s, 3H, CH3, isopropylidene). 
 
13C-NMR (d6-DMSO): C DEFGH IJKLJFMNDE4K5G%F IJOMﬁNﬂDﬃK$EGP IJ!HMNﬂD"K$Q
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(Cq, isopropylidene), 91.7 (C1’), 86.2 (C4’), 85.0 (C2’), 80.8 (C3’), 57.8 (C1cyclopentyl), 32.6 
(C2/5cyclopentyl), 32.5 (C5’), 26.7 (CH3, isopropylidene), 25.2 (CH3, isopropylidene), 24.5 (C3/4cyclopentyl). 
 
MS (ESI): m/e 440 (M, 100 %). 
 
 
5’-(Methylseleno)-2’,3’-isopropylidenedioxy-N6-cyclopentyladenosine (24) [following 174] 
 
5’-Bromo-2’,3’-isopropylidenedioxy-N6-cyclopentyladenosine (23) (1.75 g, 4 mmol) dissolved in 
EtOH (20 mL) was added dropwise to a stirring mixture of dimethyl diselenide (1.07 mL, 
8 mmol) and sodium borohydride (2 g) in EtOH (20 mL). After complete addition, the mixture 
was stirred at r.t. for 30 min. The solution was concentrated and partitioned between H2O and 
CH2Cl2. The aqueous layer was extracted several times with CH2Cl2. The combined organic 
layers were dried (Na2SO4), and the solvent was evaporated. The residue was purified via flash 
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chromatography (CH2Cl2/MeOH 100:2) to give 5’-(methylseleno)-2’,3’-isopropylidenedioxy-N6-
cyclopentyladenosine as oil after evaporation of the eluent. 
 
Yield: 1.5 g (83 %). 
 
Rf: 0.35 (CH2Cl2/MeOH 25:1). 
 
1H-NMR (d6-DMSO): R S
TUV-W/XY2Z4[!Y5[6S\Y$S
T%]9V:W/XY;Z4[!Y[6]\Y=^T^_:W`YZ4[AYa 6H), 6.20 (d, 1H, H1’), 
5.54 (m, 1H, H2’), 5.05 (m, 1H, H3’), 4.56 (bs, 1H, HCN6), 4.33 (m, 1H, H4’), 2.80 (m, 2H, H5’), 
1.78 (m+2s, 14H, Hcyclopentyl/SeCH3/CH3, isopropylidene), 1.35 (s, 3H, CH3, isopropylidene). 
 
13C-NMR (d6-DMSO): b cdd
e%f ghijhfklcdm
ed ghnkﬁlﬂcﬃiie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e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(Cq, isopropylidene), 90.1 (C1’), 87.2 (C4’), 84.7 (C2’), 84.2 (C3’), 58.1 (C1 cyclopentyl), 33.0 
(C2/5cyclopentyl), 27.8 (C5’), 27.5 (CH3, isopropylidene), 26.0 (CH3, isopropylidene), 24.3 (C3/4cyclopentyl), 5.0 
(SeCH3). 
 
MS (ESI): m/e 454 (M, 100 %), 360 (97). 
 
 
5’-(Methylseleno)-N6-cyclopentyladenosine (19) [from 175] 
 
A solution of 24 (1.36 g, 3 mmol) in acetic acid (60 mL, 65 %) was refluxed for 4 h. The solvent 
was evaporated and the residue was purified via flash chromatography (CH2Cl2/MeOH 100:2) to 
give 5’-(methylseleno)-N6-cyclopentyladenosine [169] as a colourless solid. The product recrys-
tallized from EtOH. 
 
Yield: 1.08 g (87 %). 
 
M.p.: 71.3°C (lit.: 66 – 72°C). 
 
Rf: 0.22 (CH2Cl2/MeOH 25:1). 
 
1H-NMR (d6-DMSO): r s
tuv-w/xy2z4{!y5{6s|y$s
t%}~w/xy;z4{!y{6}|y=vt%9?wyz4{Ay 6H), 5.94 (d, 1H, H1’), 
5.54 (m, 1H, OH-2’), 5.42 (m, 1H, OH-3’), 4.80 (m, 1H, H2’), 4.62 (bs, 1H, HCN6), 4.20 (m, 2H, 
H3’/H4’), 2.91 (m, 2H, H5’), 1.77 (m+s, 11H, Hcyclopentyl/SeCH3). 
 
13C-NMR (d6-DMSO):  %Ł9
 Łﬁﬃ$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(C4’), 74.1 (C2’), 73.7 (C3’), 56.9 (C1cyclopentyl), 33.1 (C2/5cyclopentyl), 28.2 (C5’), 24.3 
(C3/4cyclopentyl), 5.4 (SeCH3). 
 
MS (ESI): m/e 414 (M+1, 100 %). 
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4.3 Radiosyntheses 
 
4.3.1 Production of n.c.a. radioselenium [from 78, 88, 189] 
 
For routine production of n.c.a. [73,75Se]selenium the following established procedure was used. 
A Cu3As-layer (0.75 mm thick, As content: 28 %) on a watercooled Cu-backing was irradiated 
with 20 MeV protons at the compact cyclotron CV-28 of the Forschungszentrum Jülich GmbH. 
75Se was produced via the 75As(p,n) process in batch yields of about 37 MBq within 4 h at a 
nominal beam current of 20 µA. 
The n.c.a. selenium-73 was produced through the 75As(p,3n) process on a solid high-current 
Cu3As-target using 45 MeV protons in the internal beam of the high energy isochronous 
cyclotron (COSY Injector) of the Forschungszentrum Jülich GmbH. 
 
 
 
4.3.2 Preparation of elemental n.c.a. selenium-75 [from 87, 88, 110] 
 
The following preparations are methods already established and can be performed with Se-73 
without any alteration. 
 
Thermochromatography 
 
The chemical processing started two days (one hour in case of 73Se) after irradiation in order to 
allow the decay of short-lived activities. A two-step thermochromatographic method using O2 as 
the purging gas was performed to separate radioselenium from the Cu3As-target (cf. Figure 4.1). 
The irradiated Cu3As-target was placed in a quartz tube (15 mm diameter) located in an oven. 
In the first step, thermochromatography was done in an O2 stream (85 mL/min) at 660°C for 
40 min whereby arsenic was removed from the target and the As2O3 formed was deposited 
about 7 cm away from the end of the oven. Thereafter, the quartz tube was shifted back till the 
As2O3 zone was in the middle of the oven. The temperature of the oven was then raised to 
750°C for about 5 min whereby As2O3 was shifted further by 12 cm. The quartz tube was now 
moved to its original position and the second stage of thermochromatography started. The 
temperatures used gradually were: 900°C (7 min), 1000°C (15 min) and 1100°C (10 min). A 
stepwise increase in temperature was mandatory to avoid silicate formation which would lead to 
a decreased volatility of radioselenium. The radioselenium was deposited as 75SeO2 about 
11 cm away from the end of the oven. At the end of the thermochromatographic process the 
Experimental  95 
 
quartz tube was cooled to r.t. and rinsed with warm hydrochloric acid (6 mL, 6 M) whereby 
>98 % of the radioselenium was dissolved. The radionuclidic purity of the separated 75Se was 
>99 %, and >95 % of the radioactivity existed as [75Se]selenite as demonstrated via  -ray 
spectrometry and radio-TLC, respectively. 
 
 
 
Fig. 4.1: Thermochromatographic procedure for separation of 75Se from the target [from 88] 
(A) Removal of [74As]As2O3 at 660°C to zone (a). 
(B) Shift of zone (a) to the middle of the oven; transfer of [74As]As2O3 at 750°C to 
zone (b), thereby purification of zone (a). 
(C) Shift of the quartz tube to original position. 
(D) Removal of 75Se at 900-1100°C to zone (a). 
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Reduction of [75Se]selenite to elemental selenium-75 
 
Since elemental selenium-75 was used as starting material for the radiosyntheses developed, 
the thermochromatographically separated n.c.a. [75Se]SeO32- was reduced to 75Se0 in dilute 
hydrochloric acid by bubbling SO2 for 5 min. The solution was then heated to 85°C for 30 min. 
The subsequent extraction of elemental selenium-75 into benzene was performed using the 
apparatus shown in Figure 4.2. 
 
 
Fig. 4.2: Apparatus for extraction of radioselenium in benzene [from 88] 
 
It consisted of a round bottom distillation flask connected to an extractor in the form of a 
perforator. The benzene was distilled, condensed in the Dimroth cooler and fell through a funnel 
into the dropping tube having a frit at the end. While stirring, the reduced radioselenium solution 
was injected into the extractor. With a benzene dropping rate of 5 mL/min, the elemental 75Se 
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was extracted quantitatively in the organic phase within 30 min. Thereafter, the aqueous phase 
was separated via the waste removal part and the radioselenium concentrated in benzene. 
 
Alternatively, n.c.a. [75Se]selenite was reduced to n.c.a. 75Se0 with sodium thiosulfate. An 
aqueous solution of Na2S2O3 (2 mL, 0.5 mol/L) was added to n.c.a. [75Se]SeO32- in dilute hydro-
chloric acid. The precipitate was centrifuged for 15 min. The water phase was decanted and the 
sulfur matrix washed three times with THF. The dry sulfur matrix containing the elemental 
radioselenium was then dissolved in CS2 (2 mL). 
 
All experiments with n.c.a. elemental selenium-73,75 mentioned below were conducted under 
argon in conical 5 mL reaction vessels equipped with a magnetic stirring bar and a teflon rubber 
septum. 
 
 
 
4.3.3 Radiosyntheses via disubstituted n.c.a. [73,75Se]selenoureas 
 
Cyclohexyl iso[75Se]selenocyanate ([75Se]1a) 
 
Studies on the formation of n.c.a. cyclohexyl iso[75Se]selenocyanate ([75Se]1a) were performed 
using the reaction of n.c.a. [75Se]Se0 (370 kBq, 10 µCi) and various amounts of cyclohexyl 
isocyanide in selected solvents (0.5 mL) at various temperatures. Aliquots were analyzed for 
[75Se]1a by radio-HPLC and radio-TLC under conditions given below. 
 
 
1,3-Disubstituted [73,75Se]selenoureas ([73,75Se]2) 
 
The preparation of n.c.a. 1,3-dicyclohexyl [73,75Se]selenourea ([73,75Se]2a) was performed at 
80°C within 90 min after adding cyclohexyl isocyanide (10 µL, 0.08 mmol) and cyclohexylamine 
(10 µL, 0.09 mmol) to a solution of n.c.a. [73,75Se]Se0 in benzene (0.5 mL, typically containing 
370 kBq (10 µCi)). Aliquots were analyzed for [73,75Se]2a by radio-HPLC and radio-TLC under 
conditions given below. The solution obtained was used in the following reaction step without 
any purification. 
Alternatively, aminomethylated polystyrene (40 mg) was used instead of cyclohexylamine for 
polymer-supported formation of N-cyclohexyl [73,75Se]selenourea-N’-methyl polystyrene 
([73,75Se]2resin), which was purified by washing with benzene (2 mL) before use in the following 
reaction step. 
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[73,75Se]Selenouronium salts ([73,75Se]3) 
 
The [73,75Se]selenouronium salts ([73,75Se]3) were prepared in benzene (0.5 mL) by reaction of 
[73,75Se]2a with the appropriate trifluoromethanesulfonic acid alkyl ester (0.1 mmol) at r.t. within 
1 min. The alkylation reactions were monitored by radio-TLC. The surplus of triflate was 
removed by silica gel column chromatography (10 x 1 cm) using diethyl ether, and the purified 
[73,75Se]selenouronium salt was eluted from the column with acetone. 
Using [73,75Se]2resin the alkylation step was performed as described above within 5 min. 
Purification of [73,75Se]3resin was carried out by washing the resin with benzene (2 mL) and 
tetrahydrofuran (2 mL). 
 
 
[73,75Se]Selenoethers ([73,75Se]5a-g) 
 
The asymmetric [73,75Se]selenoethers ([73,75Se]5a-g) were prepared by treatment of [73,75Se]3a-c 
or [73,75Se]3resin with tetrabutylammonium hydroxide (0.06 mmol) in the presence of the selected 
bromine- or tosylate-compounds (0.1 mmol) in 0.6 mL tetrahydrofuran at 70°C within 5 min. The 
[73,75Se]selenoethers ([73,75Se]5a-g) obtained were analyzed by radio-HPLC and radio-TLC. 
 
 
Homocysteine [75Se]selenolactone ([75Se]6) 
 
C.a. 1,3-dicyclohexyl [75Se]selenourea ([75Se]2a) was synthesized by reaction of c.a. 75Se0 
(containing 2 mg (0.025 mmol) natSe0), cyclohexyl isocyanide (10 µL, 0.08 mmol) and cyclo-
hexylamine (10 µL, 0.09 mmol) in acetonitrile (0.5 mL) and used without further purification. The 
c.a. [75Se]selenouronium salt ([75Se]3d) was prepared in acetonitrile (0.5 mL) by reaction of c.a. 
[75Se]2a with 8 (31 mg, 0.1 mmol) at 80°C within 40 min. The alkylation reaction was monitored 
by radio-TLC. Surplus of 8 and byproducts were removed by silica gel column chromatography 
as described above. 
Hydrolysis of purified [75Se]3d with TBAH (0.1 mmol) in methanol (2 mL) was done within 
5 min at 70°C. After removal of the solvent, concentrated hydrochloric acid (5 mL) was added to 
the residue and heated for 30 min at 100°C. The solvent was removed, the residue was 
suspended in ethanol and filtered over a Sep-Pak Plus C18 cartridge. Homocysteine 
[75Se]selenolactone was analyzed on radio-TLC as detailed below. 
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4.3.4 Radiosyntheses via alkyl [75Se]selenocyanates 
 
Alkyl [75Se]selenocyanates ([75Se]10) 
 
The preparation of n.c.a. alkyl [75Se]selenocyanates ([75Se]10) was performed at 80°C within 
5 min after adding sodium cyanide (10 µmol in 0.1 mL H2O) and the appropriate alkylating agent 
(73 µmol) to a solution of n.c.a. [75Se]Se0 in ethanol (0.5 mL, typically containing 370 kBq 
(10 µCi)). Aliquots were analyzed for [75Se]10 by radio-HPLC and radio-TLC. 
Purification of [75Se]10 was carried out using reversed phase cartridges: 10 mL of water were 
added to the reaction mixture and then passed through an appropriate reversed phase cartridge 
prewashed with 3 mL of ethanol followed by 10 mL of water. The products adsorbed on the solid 
phase were eluted with 2 mL of anhydrous diethyl ether and passed through a Na2SO4-
cartridge. 
 
 
Alkyl and aryl [75Se]selenoethers ([75Se]5a, 5d, 5h-l) 
The asymmetric alkyl- and aryl[75Se]selenoethers were prepared within 1 min by treatment of 
purified [75Se]10 with a selected lithium or Grignard compound (0.1 mmol) in 0.5 mL anhydrous 
diethyl ether at room temperature. The [75Se]selenoethers obtained were analyzed by radio-
HPLC and radio-TLC. 
 
 
 
4.3.5 Radiosynthesis of n.c.a. 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine 
 
The labelled adenosine-derivative was prepared as described above for [75Se]selenoethers, 
starting with alkylation of n.c.a. 1,3-dicyclohexyl [75Se]selenourea (and N-cyclohexyl [75Se]se-
lenourea-N’-methyl polystyrene, alternatively) with trifluoromethanesulfonic acid methyl ester 
(11 µL, 0.1 mmol) in benzene (0.5 mL). The resulting [75Se]selenouronium salt was purified 
according to the method described above and hydrolyzed with tetrabutylammonium hydroxide 
(0.06 mmol) in 0.6 mL tetrahydrofuran in the presence of 5’-bromo-2’,3’-isopropylidenedioxy-N6-
cyclopentyladenosine (23) (44 mg, 0.1 mmol) resulting in 5’-(methyl[75Se]seleno)-2’,3’-isopropy-
lidenedioxy-N6-cyclopentyladenosine ([75Se]24). After hydrolysis using hydrochloric acid 
(0.3 mL, 1 N) at 80°C, 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine ([75Se]19) was obtained 
and analyzed by radio-HPLC and radio-TLC as detailed below. 
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4.4 Radioanalytical methods 
 
4.4.1 Radio high performance liquid chromatography 
 
Analytical radio high performance liquid chromatography (radio-HPLC) was performed on a 
system consisting of a Knauer pump 6400 and a Knauer UV/vis photometer 3060 with a 
detector wavelength of 220 nm. Sample injection was accomplished by a Rheodyne-Injector 
block 7125. For measurement of radioactivity the outlet of the UV detector was connected to a 
NaI(Tl) well-type scintillation detector and the recorded data were processed by the software 
system Raytest Ramona MCS (Nuclear Interface, Germany). 
 
Tab. 4.1: K’-values of seleno compounds on a Lichrosorb RP Select B column, used as 
reference substances for co-chromatographic identification 
 
Compound            k’ 
 
 Selenium (ionic)         0.231) 
 Cyclohexyl isoselenocyanate (1a)       6.441) 
 1,3-Dicyclohexyl selenourea (2a)       4.361) 
 Benzylmethylselenide (5a)        3.732) 
 1-Phenyl-1-(methylseleno)ethane (5d)      4.352) 
 3-(Methylseleno)-1-propanyl p-toluenesulfonate (5g)     3.012) 
 Benzylethylselenide (5b)        2.612) 
 1-Phenyl-1-(ethylseleno)ethane (5e)       3.462) 
 Benzylpropylselenide (5c)        3.802) 
 1-Phenyl-1-(propylseleno)ethane (5f)       5.002) 
 Benzyl selenocyanate (10a)        3.231) 
 1-Phenylethyl-1-selenocyanate (10b)       5.151) 
 1-Phenyl-1-(butylseleno)ethane (5h)      11.142) 
 Benzylphenylselenide (5k)        6.132) 
 1-Phenyl-1-(phenylseleno)ethane (5i)       7.322) 
 1-Phenyl-1-(4-fluorophenylseleno)ethane (5j)     5.972) 
 Phenylmethylselenide (5l)        1.712) 
 5’-(Methylseleno)-2’,3’-isopropylidenedioxy-N6-cyclopentyladenosine (24)  4.223) 
 5’-(Methylseleno)-N6-cyclopentyladenosine (19)     2.074) 
 
1)
 CH3CN/H2O 50:50.  2) CH3CN/H2O 60:40.  3) MeOH/H2O 70:30.  4) MeOH/H2O 60:40. 
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HPLC of aliquots of labelled products and standards was performed using a Lichrosorb RP 
Select B (250 x 4 mm) column (CS-Chromatographie Service GmbH, Germany) and a mobile 
phase consisting of acetonitrile/H2O and MeOH/H2O mixtures, respectively, in various concen-
tration ratios (given as V:V ratios) at a flow rate of 1.0 mL/min. The typical amount of 75Se 
radioactivity was 37 kBq (1 µCi). All analyses were performed at ambient temperature. 
Individual k’-values of standards and elution solvents are given in Table 4.1. 
 
 
 
4.4.2 Radio thin layer chromatography 
 
Analytical radio thin layer chromatography (radio-TLC) was carried out in order to verify that no 
radioactive species other than those eluted and detected in the HPLC scans were present. This 
would include colloidal material or species strongly retained and not eluted from the HPLC 
column under the conditions employed. Radio-TLC was performed on Merck silica gel plates 
(Type F254S) with the solvent system hexane/diethyl ether and CH2Cl2/MeOH, respectively, in 
various concentrations (given as V:V ratios). The developed TL-chromatograms were measured 
for radioactivity on an Instant ImagerTM (Packard, USA). Individual Rf-values of standards and 
solvent systems are given in Table 4.2. 
 
Tab. 4.2: Rf-values of seleno compounds on Merck silica gel plates, used as reference 
substances for co-chromatographic identification 
 
Compound            Rf 
 
 Selenium (elemental, n.c.a.)        0.951) 
 Selenium (ionic)         0.001) 
 Cyclohexyl isoselenocyanate (1a)       0.352) 
 1,3-Dicyclohexyl selenourea (2a)       0.521) 
 Selenouronium salts (3)        0.1 – 0.21) 
 Benzylmethylselenide (5a)        0.412) 
 1-Phenyl-1-(methylseleno)ethane (5d)      0.402) 
 3-(Methylseleno)-1-propanyl p-toluenesulfonate (5g)     0.603) 
 Benzylethylselenide (5b)        0.392) 
 1-Phenyl-1-(ethylseleno)ethane (5e)       0.372) 
 Benzylpropylselenide (5c)        0.452) 
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Table 4.2 continued 
 1-Phenyl-1-(propylseleno)ethane (5f)       0.392) 
 Homocysteine selenolactone (6)       0.684) 
 Potassium selenocyanate (9a)        0.001) 
 Benzyl selenocyanate (10a)        0.661) 
 1-Phenylethyl-1-selenocyanate (10b)       0.771) 
 Methyl selenocyanate (10c)        0.911) 
 1-Phenyl-1-(butylseleno)ethane (5h)       0.472) 
 Benzylphenylselenide (5k)        0.422) 
 1-Phenyl-1-(phenylseleno)ethane (5i)       0.502) 
 1-Phenyl-1-(4-fluorophenylseleno)ethane (5j)     0.422) 
 Phenylmethylselenide (5l)        0.465) 
 5’-(Methylseleno)-2’,3’-isopropylidenedioxy-N6-cyclopentyladenosine (24)  0.356) 
 5’-(Methylseleno)-N6-cyclopentyladenosine (19)     0.226) 
 
1)
 Hexane/diethyl ether 2:3.  2) Hexane/diethyl ether 100:3.  3) Hexane/diethyl ether 1:1. 
4) n-Butanol/ethanol/formic acid 5:1:1.  5) Hexane/diethyl ether 100:2.  6) CH2Cl2/MeOH 25:1. 
 
 
 
4.4.3 Determination of the specific activity of n.c.a. 5’-(methyl[75Se]seleno)-N6-
cyclopentyladenosine 
 
The analysis of the specific activity of n.c.a. 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine 
([75Se]19) was carried out via HPLC. The applied amount of non-radioactive standard 
compound is proportional to the integral of the UV-signal obtained by HPLC. The measured 
peak-area was fitted as a function of amount of 19, resulting a straight line that was used for 
calibration (Figure 4.3). 
For the determination of the specific activity the solvent of a complete reaction batch contai-
ning [75Se]19 was evaporated, the residue was solved in 100 µL HPLC eluent and injected on 
HPLC. [75Se]19 was collected and its activity was ascertained (300 kBq (8 µCi)). Since no 
corresponding UV signal was detected, only a lower limit of the specific activity As of 
> 300 GBq/mmol (> 8 Ci/mmol) could be determined in consideration of the limit of detection of 
1 nmol. 
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Fig. 4.3: Dependence of the integral as a function of amount of 5’-(methylseleno)-N6-cyclo-
pentyladenosine ([75Se]19) 
 
 
 
4.5 Radioligand binding assays 
 
Radioligand binding assays were carried out by the Pharmacology Group of the Institute of 
Nuclear Chemistry. Corpora striata (for A2AAR assays) and frontal cortices (for A1AR assays) 
were dissected from pig brain and the tissue was homogenized for one minute in 20 volumes of 
ice-cold 50 mM TRIS-HCl buffer, pH 7.4 containing 10 mM MgCl2, Soybean Trypsin Inhibitor 
(20 µg/mL), Bacitracin (200 µg/mL), and Benzamidine HCl (160 µg/mL) by means of an Ultra 
Turrax at 20,000 rpm. The homogenate was centrifuged at 48,000 × g for 10 min at 4°C 
(Beckmann Optima L, SW41Ti rotor). The pellet was suspended in 20 volumes of TRIS-HCl, 
pH 7.4, containing adenosine deaminase (2 U/mL) and Trypsin Inhibitor (20 µg/mL), then was 
incubated for 30 min at 37°C. After centrifugation at 48,000 × g for 10 min at 4°C the resulting 
pellet was diluted in 20 volumes of 50 mM TRIS-HCl, pH 7.4, containing 10 mM MgCl2. Aliquots 
of the homogenate (1 mL) were stored at – 80°C. The assays were performed in triplicate by 
incubating aliquots of the membrane fractions (87 µg protein/assay for A1-assays, 68 µg 
protein/assay for A2A-assys) in TRIS-HCl, pH 7.4, containing adenosine deaminase (2 U/mL). 
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Cortical homogenates were used for A1AR- and striatal homogenates for A2AAR-assays. 
Incubation was carried out at 20°C for 60 min in a total assay volume of 200 µL. In A2AAR 
competition experiments [3H]CGS21680 (A2A receptor radioligand, KD = 26 nM) was used in a 
concentration of 5 nM. In A1AR competition experiments [3H]CPFPX (A1 receptor radioligand, 
KD = 0.62 nM) was used in a concentration of 2 nM. Centrifugation at 48,000 × g for 6 min at 
8°C separated bound from free ligand. Supernatants were discarded, the pellets washed with 
1 mL ice cold buffer and dissolved by incubating in SolvableTM (500 µL, Canberra-Packard) for 
120 min at 50°C. Aliquots of 450 µL were placed in scintillation vials with scintillation cocktail 
(10 mL, Ultima Gold XR, Canberra-Packard). Radioactivity was measured in a Liquid 
Scintillation Analyzer. Protein estimation was performed with a commercial assay (Bio-Rad DC 
Protein Assay) after solubilization in 15 % NH4OH containing 2 % SDS (v,w); human serum 
albumin served as a standard. Ki was calculated by a computer-assisted curve-fitting program 
(GraphPad Prism, version 3.0) as exemplified in Figure 4.4 for the adenosine A1 receptor. 
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Fig. 4.4: Determination of the Ki value of 5’-(methylseleno)-N6-cyclopentyladenosine (19) for 
the adenosine A1 receptor 
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Chapter 5 
 
Summary 
 
With the increasing use of positron emission tomography as a method of in vivo molecular 
imaging, there has been great interest in the development of methods suitable for the synthesis 
of compounds labelled with positron-emitting radionuclides, as these can be used as tracers for 
physiological and pharmacological phenomena. In addition to the commonly used labels 
carbon-11 and fluorine-18, selenium-73 is an alternative positron emitter with suitable charac-
teristics for tomographic imaging, and its half-life of 7.1 h permits imaging over an extended 
period of many hours. 
For the preparation of 73Se-labelled radiopharmaceuticals, it must be taken into account that 
selenium compounds may be toxic or may disturb the physiological system to be studied. Both 
of these drawbacks could be circumvented if no-carrier-added compounds are available, so that 
pharmacodynamic effects or even toxic events are excluded. This implicit necessity for prepa-
ration methods that can avoid the addition of substantial amounts of natSe-carrier, however, 
places constraints on chemical approaches used to prepare selenium-73 labelled compounds. 
In fact, most of the techniques developed during the last 40 years to introduce radioselenium 
into an appropriate organic compound work only with the addition of natSe-carrier. Very few 
methods for the preparation of n.c.a. radioselenium-labelled compounds have been investigated 
thus far and their limitation to quite a small class of selenium-containing compounds is a major 
disadvantage. 
 
In this thesis work, the scope of available asymmetric n.c.a. radioselenoethers was exten-
sively enlarged by development of two new n.c.a. radioselenation methods. For convenience 
and costs, these labelling routes were elaborated and optimized using the longer-lived isotope 
selenium-75 (T1/2 = 120.4 d). 
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The first radiosynthetic concept examined was based on the intermediate formation of a di-
substituted [75Se]selenourea derivative. The initial key step, i.e. the introduction of n.c.a. sele-
nium-75 into an organic compound, was performed via nucleophilic attack of cyclohexyl 
isocyanide on n.c.a. 75Se0 yielding cyclohexyl iso[75Se]selenocyanate as model compound. 
Subsequent addition of cyclohexylamine resulted in the formation of 1,3-dicyclohexyl [75Se]sele-
nourea. Optimization studies showed that this intermediate was conveniently produced in a 
direct one-pot procedure starting from n.c.a. 75Se0, cyclohexyl isocyanide and cyclohexylamine 
within 90 min with a radiochemical yield of 95 ± 5 %. 
The outstanding chemical property of selenourea derivatives with respect to the reactivity of 
the selenium atom enables these compounds to act as versatile intermediates for the pre-
paration of asymmetric selenoethers. Due to a reduced C=Se double-bond character the sele-
nium atom is polarized with a negative charge, and alkylation of 1,3-dicyclohexyl [75Se]seleno-
urea via alkyl triflates gave rise to the formation of corresponding (biscyclohexylamino-
methylene)alkyl[75Se]selenouronium trifluoromethanesulfonates (alkyl [75Se]selenouronium 
salts) in nearly quantitative yield. In order to separate the alkyl [75Se]selenouronium salts from 
surplus alkyl triflates and byproducts, a small scale silica gel column chromatography was 
developed. 
Hydrolysis of a purified alkyl [75Se]selenouronium salt by treatment with hydroxide yielded the 
corresponding alkyl [75Se]selenolate, which could be alkylated in situ with various alkyl halides 
and tosylates yielding asymmetric n.c.a. [75Se]selenoethers analogous to the Williamson ether 
synthesis. Studies showed that this reaction sequence was most effective using a one-pot 
procedure with simultaneous addition of base and alkylating agent to the alkyl [75Se]seleno-
uronium salt. Thus, starting from elemental selenium-75 a wide variety of asymmetric n.c.a. 
dialkyl [75Se]selenoethers were synthesized as model compounds in radiochemical yields of 15 
to 48 %, depending on the substituents, within a total reaction time of 130 min. 
 
This labelling technique is extremely time-consuming due to the tedious purification step 
required. An improved approach was therefore developed using a polymer-supported pathway. 
A big advantage of this strategy is that, after each step of the procedure, the polymer-supported 
radioselenium-labelled intermediates can be purified by washing the resin with an appropriate 
solvent whereby the impurities are eluted out of the resin. Since the labelled intermediate 
compounds were covalently attached to the resin, none of them was lost in the purification step, 
leading to high radiochemical yields of purified selenourea and selenouronium salts, respec-
tively, within a very short time. 
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Starting from n.c.a. elemental selenium-75, cyclohexyl isocyanide and aminomethylated poly-
styrene, the corresponding polymer-bound [75Se]selenourea was synthesized within 10 min with 
a radiochemical yield of 80 ± 5 % (related to n.c.a. 75Se0). Subsequent alkylation via alkyl 
triflates yielded the corresponding alkyl [75Se]selenouronium salts. After their purification and 
basic hydrolysis, the in situ alkylation of alkyl [75Se]selenolate yielded the same model com-
pounds as produced via the non-polymer-supported strategy in radiochemical yields of 13 to 
56 % (related to 75Se0) within a total reaction time of 35 min. Besides similar radiochemical 
yields, these were attained in only a quarter of the reaction time necessary for the free 
selenourea method. Furthermore, the polymer-supported labelling route lends itself much more 
to automation, which is desirable in particular for future routine application. 
 
Comparative n.c.a. labelling experiments with the positron emitter selenium-73 showed no dif-
ferences in radiochemical yields of the same model compounds. Thus, 73Se-labelled com-
pounds at the n.c.a. level can be obtained using both, the free and polymer-supported seleno-
urea method without modifying the reaction conditions. 
However, as a major drawback, attempts made to synthesize aryl radioselenoethers via this 
labelling technique failed. 
 
Therefore, another reaction concept was explored in order to extend the range of available 
n.c.a. radioselenium-labelled compounds to aryl selenoethers. This radiosynthetic pathway was 
based on the formation of alkyl [75Se]selenocyanates as intermediates. The reaction of n.c.a. 
75Se0 and sodium cyanide to sodium [75Se]selenocyanate and subsequent alkylation with an 
alkyl bromide to form the corresponding alkyl [75Se]selenocyanate were tested and optimized by 
use of (1-bromoethyl)benzene as model alkylating agent yielding 1-phenylethyl-1-[75Se]seleno-
cyanate. These studies showed inter alia that this alkyl [75Se]selenocyanate was conveniently 
produced in a one-pot procedure using an ethanol/water mixture as solvent with a ratio of about 
5/1. Obviously, both the cyanide and the [75Se]selenocyanate anions need a certain degree of 
water to reach their highest possible reactivity. Under these optimized reaction conditions, 
several alkyl [75Se]selenocyanates were produced in radiochemical yields of up to 73 % (related 
to 75Se0) within 5 min. The disappointingly low yield of  benzyl [75Se]selenocyanate (15 ± 4 %) 
can probably be explained by an isomerization of this compound to its corresponding 
iso[75Se]selenocyanate. 
After separation of the n.c.a. alkyl [75Se]selenocyanates from the ethanolic/aqueous solvent 
mixture via a reversed phase cartridge, these intermediates were converted to the desired 
n.c.a. [75Se]selenoethers by reacting them with organometallic compounds. Since both, aliphatic 
and aromatic lithium or Grignard compounds can be used in this last reaction step, the n.c.a. 
preparation of a wide variety of asymmetric dialkyl and alkylaryl [75Se]selenoethers was 
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possible as demonstrated for various model compounds, which were synthesized in radio-
chemical yields of 9 to 55 % (related to 75Se0), depending on the substituents within a total 
reaction time of only 20 min. 
This is the first method described to obtain n.c.a. aryl radioselenoethers and offers the 
advantage of a very rapid and efficient labelling technique. 
 
Both the radiosyntheses developed in this work have proven to be valuable methods for the 
preparation of a broad range of symmetric and asymmetric radioselenoethers at the no-carrier-
added level. These new approaches to n.c.a. radioselenium labelling enlarge the availability of 
73,75Se-labelled compounds, whereas previous radioselenation methods at the n.c.a. level were 
limited to methyl radioselenoethers. 
For proof of identity via radioanalysis appropriate radio high performance liquid chromato-
graphy and radio thin layer chromatography methods were developed. Several non-radioactive 
seleno compounds, which served as reference substances, were prepared for the first time. 
 
In order to demonstrate the versatility of the selenourea method in particular, two more 
complex, physiologically relevant molecules were labelled with selenium-75. Firstly, L-homo-
cysteine [75Se]selenolactone, an artificial amino acid derivative for potential measurement of 
adenosine production in ischemic myocardial tissue, was synthesized with a total radiochemical 
yield of about 20 – 30 % (related to 75Se0). Since the appropriate triflate compound to alkylate 
the [75Se]selenourea derivative could not be obtained, however, this alkylation step had to be 
performed with c.a. 1,3-dicyclohexyl [75Se]selenourea in order to allow the use of the corres-
ponding bromine derivative of the precursor. Thus, the indispensable addition of natSe-carrier 
limits the maximum possible specific activity of L-homocysteine [75Se]selenolactone. However, 
this is not a problem in case of this metabolic tracer. 
Secondly, the receptor ligand 5’-(methyl[75Se]seleno)-N6-cyclopentyladenosine was synthe-
sized at the n.c.a. level. This adenosine derivative is a high-affinity partial agonist for the 
adenosine A1 receptor and could be applied as radioligand in PET studies if labelled with 
selenium-73. Using both, the free and the polymer-supported selenourea methods, the final 
n.c.a. product was obtained with a radiochemical yield of about 30 % (related to 75Se0), within a 
total reaction time of 135 and 40 min, respectively and with a specific activity of more than 
300 GBq/mmol (8 Ci/mmol). Provided no further isotopic dilution would occur in large scale 
syntheses, a much higher specific activity will be obtained. If selenium-73 is used as radiolabel, 
the achievable specific activity would be even higher in case of a large scale synthesis, and one 
can suggest that the obtainable specific activity would be sufficient to perform in vivo receptor 
studies with 73Se-labelled ligands using PET. 
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Chapter 6 
 
Zusammenfassung 
 
Aufgrund der wachsenden Bedeutung der Positronen-Emissions-Tomographie auf dem Gebiet 
der molekularen in vivo Bildgebung besteht großes Interesse an der Entwicklung von Markie-
rungstechniken. Hierbei sollen neue, mit Positronenstrahlern markierte Verbindungen zugäng-
lich gemacht werden, die als Tracer für physiologische und pharmakologische Untersuchungen 
genutzt werden können. Neben den gebräuchlichsten Nukliden Kohlenstoff-11 und Fluor-18 
bietet sich dabei das Selen-73 als alternativer Positronenemitter an, da es geeignete Charak-
teristika für die tomographische Bildgebung aufweist und seine Halbwertzeit von 7.1 h die 
Durchführung ausgedehnter nuklearmedizinischer Untersuchungen zulässt. 
Für die Herstellung 73Se-makierter Radiopharmaka muss die mögliche Toxizität von Se-Ver-
bindungen und eventuelle Störungen der zu untersuchenden physiologischen Systeme in Be-
tracht gezogen werden. Um diese Nachteile umgehen zu können, sind trägerarme (n.c.a.) 
Verbindungen erforderlich, die pharmakodynamische oder sogar toxische Effekte ausschließen 
würden. Dies erfordert Markierungstechniken, die keinen natSe-Trägerzusatz benötigen, wo-
durch jedoch die Anzahl der möglichen Methoden zur Synthese von 73Se-markierten Verbin-
dungen stark eingeschränkt wird. So benötigen die meisten der in den letzten 40 Jahren ent-
wickelten Techniken zur Radioselenierung organischer Verbindungen den Zusatz von natSe-
Träger. Nur sehr wenige Strategien zur Darstellung von trägerarmen Radioselenverbindungen 
sind entwickelt worden, die zudem auf die sehr kleine Klasse der Methylselenoether beschränkt 
sind. 
 
Im Rahmen dieser Arbeit konnte die Bandbreite der verfügbaren asymmetrischen n.c.a. 
Radioselenoether stark erweitert werden, indem zwei neue n.c.a. Radioselenierungsmethoden 
entwickelt wurden. Aufgrund von praktischen Erwägungen und aus Kostengründen wurden 
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diese Syntheseverfahren mit dem langlebigeren Isotop Selen-75 (T1/2 = 120.4 d) ausgearbeitet 
und optimiert. 
 
Das erste umgesetzte Radiosynthesekonzept basierte auf der Bildung von disubstituierten 
[75Se]Selenoharnstoffderivaten als Zwischenprodukte. Der entscheidende initiale Schritt war die 
Einführung des trägerarmen Selen-75 in eine organische Verbindung und wurde durch einen 
nukleophilen Angriff von Cyclohexylisonitril auf n.c.a 75Se0 realisiert. Das resultierende Cyclo-
hexyliso[75Se]selenocyanat fungierte als Modellverbindung und wurde durch anschließende Re-
aktion mit Cyclohexylamin zu 1,3-Dicyclohexyl[75Se]selenoharnstoff umgesetzt. Dieses Zwi-
schenprodukt konnte nach Optimierungsstudien ausgehend von n.c.a. 75Se0, Cyclohexylisonitril 
und Cyclohexylamin in einer Eintopf-Reaktion mit einer radiochemischen Ausbeute von 
95 ± 5 % innerhalb 90 min hergestellt werden. 
Die außerordentliche chemische Eigenschaft von Selenoharnstoffderivaten bezüglich der Re-
aktivität des Selens ermöglicht den Einsatz dieser Verbindungen als vielseitige Zwischenstufen 
für die Darstellung asymmetrischer Selenoether. Durch den verminderten C=Se-Doppelbin-
dungscharakter wird das Selen negativ polarisiert, und die Alkylierung von 1,3-Dicyclohexyl-
[75Se]selenoharnstoff durch Alkyltriflate führt zu der Bildung von entsprechenden (Biscyclo-
hexylaminomethylen)alkyl[75Se]selenonium Trifluoromethansulfonaten (Alkyl[75Se]selenonium-
salzen) in nahezu quantitativer Ausbeute. Zur Abtrennung der Alkyl[75Se]selenoniumsalze von 
überschüssigem Alkyltriflat und Nebenprodukten wurde eine miniaturisierte Säulenchromato-
graphie entwickelt. 
Die Hydrolyse der aufgereinigten Alkyl[75Se]selenoniumsalze durch Hydroxid-Anionen setzte 
entsprechende Alkyl[75Se]selenolate frei, die in situ mit verschiedenen Alkylbromiden und 
-tosylaten alkyliert und so in Analogie zur Williamson-Ethersynthese zu asymmetrischen n.c.a. 
[75Se]Selenoethern umgesetzt werden konnten. Diese Sequenz verlief am effektivsten in einer 
Eintopf-Reaktion mit gleichzeitiger Zugabe der Base und des Alkylierungsmittels zum 
Alkyl[75Se]selenoniumsalz. Auf diese Weise konnten verschiedene asymmetrische n.c.a. 
Dialkyl[75Se]selenoether dargestellt werden. Diese Modellverbindungen erhielt man ausgehend 
von 75Se0 in radiochemischen Ausbeuten zwischen 15 und 48 % abhängig von den 
Alkylsubstituenten innerhalb von 130 min. 
 
Da diese Markierungstechnik aufgrund des benötigten Reinigungsschrittes sehr zeitaufwendig 
ist, wurde eine verbesserte Methode entwickelt, welche auf eine festphasengebundene Strate-
gie zurückgreift. Ein großer Vorteil dieses Konzeptes ist, dass nach jedem Reaktionsschritt die 
polymergebundenen, radioselenmarkierten Zwischenprodukte von Verunreinigungen befreit 
werden konnten, indem das Harz mit einem geeigneten Lösungsmittel gewaschen wurde. Da 
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diese Zwischenprodukte kovalent an den polymeren Träger gebunden waren und deshalb nicht 
vom Harz eluiert wurden, konnten entsprechend der oben beschriebenen Reaktionssequenzen 
innerhalb kürzester Zeit hohe Ausbeuten an aufgereinigtem Selenoharnstoff und daraus Sele-
noniumsalzen erzielt werden. 
Ausgehend von n.c.a. 75Se0, Cyclohexylisonitril und aminomethyliertem Polystyrol gelang die 
Darstellung des entsprechenden polymergebundenen [75Se]Selenoharnstoffs innerhalb von 
10 min mit einer radiochemischen Ausbeute von 80 ± 5 % (bezogen auf 75Se0). Anschließende 
Umsetzung mit Alkyltriflaten ergab die entsprechenden Alkyl[75Se]selenoniumsalze. Nach ihrer 
Aufreinigung und basischer Hydrolyse wurden durch in situ Alkylierungen der Alkyl[75Se]seleno-
late die gleichen Modellverbindungen dargestellt wie mit Hilfe der nicht-polymergebundenen 
Reaktionsführung. Diese erhielt man in radiochemischen Ausbeuten zwischen 13 und 56 % 
(bezogen auf 75Se0) innerhalb einer Gesamtsynthesedauer von 35 min. Neben vergleichbaren 
Ausbeuten konnte die Reaktionszeit gegenüber der Methode über Selenoharnstoffe in homo-
gener Phase auf ein Viertel reduziert werden. Außerdem begünstigt die festphasenfixierte Mar-
kierungstechnik eine Automatisierung, was insbesondere für zukünftige Routineanwendungen 
wünschenswert ist. 
 
Vergleichende Experimente mit dem Positronenstrahler Selen-73 ergaben keine Unterschiede 
in den radiochemischen Ausbeuten der gleichen Modellverbindungen. Damit wurde gezeigt, 
dass trägerarme 73Se-markierte Verbindungen sowohl mit Hilfe der freien als auch der fest-
phasengebundenen Selenoharnstoff-Methode synthetisiert werden können, ohne dass die 
bereits optimierten Reaktionsbedingungen modifiziert werden müssten. 
Jedoch schlugen alle Versuche fehl, mit dieser Markierungsmethode Arylradioselenoether 
herzustellen. 
 
Deshalb wurde ein weiteres Reaktionskonzept entwickelt, um den Bereich der verfügbaren 
n.c.a. radioselenmarkierten Verbindungen um die Klasse der Arylselenoether zu erweitern. 
Diese Radiosynthese basierte auf der Bildung von Alkyl[75Se]selenocyanaten als Zwischen-
produkte. Die Reaktion von n.c.a. 75Se0 und Natriumcyanid zu Natrium[75Se]selenocyanat und 
die anschließende Alkylierung mit einem Alkylbromid zum entsprechenden Alkyl[75Se]seleno-
cyanat wurden anhand von 1-Phenylethylbromid als Modellalkylierungsmittel für die Darstellung 
von 1-Phenylethyl-1-[75Se]selenocyanat getestet und optimiert. Diese Untersuchungen zeigten 
unter anderem, dass dieses Alkyl[75Se]selenocyanat am effektivsten in einer Eintopf-Reaktion 
mit einem Ethanol/Wasser-Gemisch im Verhältnis von 5/1 zugänglich war. Offensichtlich 
erreichten sowohl das Cyanid- als auch das [75Se]Selenocyanat-Anion ihre höchste Reaktivität 
bei einem bestimmten Wasseranteil. Verschiedene Alkyl[75Se]selenocyanate wurden unter den 
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optimierten Reaktionsbedingungen in radiochemischen Ausbeuten von bis zu 73 % (bezogen 
auf 75Se0) innerhalb von 5 min dargestellt. Die dabei enttäuschend geringe Ausbeute von 
Benzyl[75Se]selenocyanat (15 ± 4 %) kann möglicherweise mit der Isomerisierung dieser 
Verbindung zum entsprechenden Iso[75Se]selenocyanat erklärt werden. 
Nach der Abtrennung der n.c.a. Alkyl[75Se]selenocyanate vom Ethanol/Wasser-Lösungsmittel-
gemisch mittels Festphasenfixierung wurden diese Intermediate durch Reaktion mit organo-
metallischen Verbindungen zu den gewünschten n.c.a. [75Se]Selenoethern umgesetzt. Da 
sowohl aliphatische als auch aromatische Lithium- oder Grignard-Verbindungen in diesem 
letzten Reaktionsschritt verwendet werden können, ist die Darstellung vieler unterschiedlicher 
asymmetrischer Dialkyl- und Alkylaryl[75Se]selenoether möglich. Dies wurde anhand verschie-
dener Modellverbindungen demonstriert, die in radiochemischen Ausbeuten von 9 bis 55 % 
(bezogen auf 75Se0) abhängig von den Substituenten innerhalb einer Gesamtsynthesedauer 
von nur 20 min dargestellt wurden. 
Diese Markierungstechnik ist die erste beschriebene Methode, die trägerarme Arylseleno-
ether zugänglich macht. Außerdem bietet sie den Vorteil einer schnellen und effizienten 
Radiosynthese. 
 
Beide in dieser Arbeit entwickelten Synthesekonzepte eignen sich sehr gut zur Darstellung 
einer großen Auswahl von trägerarmen symmetrischen wie auch unsymmetrischen Radio-
selenoethern. Diese neuen n.c.a. Radioselenierungstechniken vergrößern den Bereich der 
zugänglichen 73,75Se-markierten Verbindungen erheblich; wohingegen mit bereits etablierten 
Methoden die Synthesemöglichkeiten auf die Stoffklasse der n.c.a. Methylradioselenoether 
begrenzt waren. 
Zur Identifizierung der Reaktionsprodukte mittels Radioanalytik wurden im Rahmen dieser 
Arbeit entsprechende Radio Hochleistungschromatographie- und Radio Dünnschicht-
chromatographie-Methoden entwickelt. Mehrere nicht-radioaktive Selenverbindungen wurden 
erstmalig synthetisiert. 
 
Um die Vielseitigkeit insbesondere der Selenoharnstoff-Methode zu überprüfen, wurden zwei 
komplexere, physiologisch relevante Moleküle mit Selen-75 markiert. Das artifizielle Amino-
säurederivat L-Homocystein[75Se]selenolacton, das für die Messung der Adenosinfreisetzung in 
ischämischen Herzgewebe dienen soll, wurde mit einer radiochemischen Ausbeute von 20 –
 30 % (bezogen auf 75Se0) synthetisiert. Da die entsprechende Triflatverbindung zur Alkylierung 
des n.c.a. [75Se]Selenoharnstoffderivates nicht zugänglich war, musste dieser Reaktionsschritt 
mit geträgertem 1,3-Dicyclohexyl[75Se]selenoharnstoff und der entsprechenden Bromverbin-
dung des Vorläufers durchgeführt werden. Der unentbehrliche natSe-Trägerzusatz führt zu einer 
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Verminderung der maximal erreichbaren spezifischen Aktivität des L-Homocystein[75Se]seleno-
lactons, was sich aber für diesen metabolischen Tracer als nicht störend auswirken sollte. 
Außerdem wurde der Rezeptorligand 5’-(Methyl[75Se]seleno)-N6-cyclopentyladenosin in 
trägerarmen Mengen synthetisiert. Dieses Adenosinderivat ist ein hoch-affiner partieller Agonist 
für den Adenosin A1-Rezeptor und könnte mit Selen-73 markiert als Radioligand für PET-
Studien dienen. Sowohl mittels der freien als auch der festphasengebundenen Selenoharnstoff-
Methode konnte dieser n.c.a. Radioligand mit einer radiochemischen Ausbeute von rund 30 % 
(bezogen auf 75Se0), innerhalb von 135 bzw. 40 min und mit einer spezifischen Aktivität von 
mindestens 300 GBq/mmol (8 Ci/mmol) hergestellt werden. Keine weitere Isotopen-Verdün-
nung bei Synthesen mit großen Aktivitätsmengen vorausgesetzt, kann eine viel höhere spezi-
fische Aktivität erzielt werden. Bei der Verwendung von Selen-73 als Radionuklid würde die 
erreichbare spezifische Aktivität im Falle einer Synthese mit entsprechenden Aktivitätsmengen 
noch höher sein und höchstwahrscheinlich ausreichen, um PET-Untersuchungen an Rezeptor-
systemen mit 73Se-markierten Liganden in vivo durchführen zu können. 
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As   specific / molar activity 
ATP   adenosine 5’-triphosphate 
b   broad 
b.p.   boiling point 
Bq   Becquerel (decays per second) 
c.a.   carrier-added 
cAMP   adenosine 3’,5’-cyclic monophosphate 
cf.   confer 
c.f.   carrier-free 
Ci   Curie (1 Ci = 3.7x1010 Bq) 
CNS   central nervous system 
CPA   N6-cyclopentyladenosine 
CT   computed tomography 
d   dublet 
EC   electron capture 
e.g.   for example 
EI   electron ionization 
Eq.   Equation 
eq.   equivalent 
ESI   electron spray ionization 
EtOH   ethanol 
FDG   2-[18F]-2-deoxy-D-glucose 
Fig.   Figure 
GC   gas chromatography 
HPLC   high performance liquid chromatography 
HR-MS  high-resolution mass spectrum 
i.e.   id est 
IR   infrared 
lit.   literature 
m   muliplet 
M   molecule ion 
MeOH   methanol 
MeOTf   methyl trifluoromethanesulfonate 
  
 
m.p.   melting point 
MRT   magnetic resonance tomography 
MS   mass spectrum 
n.c.a.   no-carrier-added 
NMR   nuclear magnetic resonance 
q   quartet 
PET   positron emission tomography 
ppm   parts per million 
RCY   radiochemical yield 
r.t.   room temperature 
s   singulet 
SN   nucleophilic substitution 
Sch.   Scheme 
SPECT  single photon emission computed tomography 
t   triplet 
T1/2   half-life 
Tab.   Table 
TBAH   tetrabutylammonium hydroxide 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
US   ultrasound 
UV   ultraviolet 
vol.   volume 
vs.   versus 
  
Acknowledgements 
 
I would like to thank all the people at the Institute of Nuclear Chemistry of the Forschungs-
zentrum Jülich GmbH, whose vital support made this work a stimulating experience. 
In particular: 
 
Prof. Dr. H.H. Coenen for suggesting the subject of this thesis and for his genuine interest in 
my progress. He provided constant guidance and excellent working conditions. 
 
Dr. J. Ermert for being more than just a scientific advisor. I was fortunate enough to learn a 
lot from him. His steady and extensive support was very important for the success of my 
doctoral thesis. 
 
Dr. D. Bier, Dr. K. Hamacher, Dr. M. Holschbach and Dr. W. Sihver for their manifold advice 
and for helpful discussions. 
 
Prof. Dr. Dr. h.c. S.M. Qaim, Dipl.-Ing. G. Blessing, Mr. S. Spellerberg and Mr. H. Rosezin for 
their reliable and comprehensive assistance regarding the production of selenium-75 and 
selenium-73. 
 
Mr. W. Wutz for recording the NMR spectra and for performing the radioligand binding 
assays. 
 
Mr. S. Mahbubfar for recording the mass spectra. 
 
Mr. H. Printz for everything required in a lab. 
 
Mrs. G. Faulbrück for being the “dogsbody” of the Institute. 
 
Dipl.-Chem. T. Bastian, Dipl.-Chem. M. Breidenbach, Dr. C. Dittmar, Dr. E. Heß, Dipl.-Chem. 
K. Hilgers, Dr. C. Hocke, Dr. M. Jelinski, Dipl.-Chem. K. Kettern, Dr. B. Krebs, Dr. T. Ludwig, 
Dr. E. Mennicke, Dipl.-Chem. T. Ross, Dipl.-Chem. I. Spahn, Dipl.-Chem. T. Stoll and Dr. T. 
Tierling for many scientific and relaxing talks and for the very pleasant atmosphere. 
 
 
Last but not least, the success of this thesis would not have been possible without the 
support of my mother, my brother and especially Tanja, whose endless understanding and 
encouragement made many things easier. 
 
  
 
Erklärung 
 
Ich versichere, dass ich die von mir vorgelegte Dissertation selbständig angefertigt, die be-
nutzten Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit einschließ-
lich Tabellen, Karten und Abbildungen, die anderen Werken im Wortlaut oder dem Sinn nach 
entnommen sind, in jedem Einzelfall als Entlehnung kenntlich gemacht habe; dass diese 
Dissertation noch keiner anderen Fakultät oder Universität zur Prüfung vorgelegen hat; dass 
sie abgesehen von unten angegebenen Teilpublikationen noch nicht veröffentlicht worden ist 
sowie, dass ich eine solche Veröffentlichung vor Abschluss des Promotionsverfahrens nicht 
vornehmen werde. 
Die Bestimmungen der geltenden Promotionsordnung sind mir bekannt. Die von mir vorge-
legte Dissertation ist von Herrn Prof. Dr. H.H. Coenen betreut worden. 
 
Köln, im Februar 2003 
 
 
Teilpublikationen 
 
in rezensierten Fachzeitschriften: 
 
Blum T., Ermert J., Coenen H.H.: No-carrier-added synthesis of aliphatic and aromatic radio-
selenoethers via selenocyanates. Nucl. Med. Biol., in Druck (2003). 
 
Blum T., Ermert J., Coenen H.H.: No-carrier-added (n.c.a.) synthesis of asymmetric 
[73,75Se]selenoethers with isonitriles. Appl. Radiat. Isot. 57, 51 – 56 (2002). 
 
Ermert J., Blum T., Hamacher K., Coenen H.H.: Alternative syntheses of 
[73,75Se]selenoethers exemplified for homocysteine[73,75Se]selenolactone. Radiochim. Acta 
89, 863 – 866 (2001). 
 
Konferenzbeiträge: 
 
Blum T., Ermert J., Coenen H.H.: No-carrier-added synthesis of aliphatic and aromatic 
radioselenoethers via selenocyanates. Annual Congress of the European Association of 
Nuclear Medicine, 31.8.-4.9.2002, Wien, Österreich. Eur. J. Nucl. Med. 29, S59 (2002). 
 
Blum T., Ermert J., Coenen H.H.: N.c.a. syntheses of asymmetric [73Se]selenoethers. 49th 
Annual Meeting of the Society of Nuclear Medicine, 15.-19.6.2002, Los Angeles, USA. J. 
Nucl. Med. 43, 135P (2002). 
 
Blum T., Ermert J., Coenen H.H.: N.c.a. synthesis of asymmetric [73,75Se]selenoethers. 14th 
International Symposium on Radiopharmaceutical Chemistry, 10.-15.6.2001, Interlaken, 
Schweiz. J. Labelled Cpd. Radiopharm. 44, S140 – S142 (2001). 
  
Lebenslauf 
 
Till Blum 
Luxemburgerstr. 441-443 
50939 Köln 
Tel.: 0221 / 4680602 
Email: t.blum@fz-juelich.de 
 
geboren am 08.08.1974 in Remscheid 
Staatsangehörigkeit: deutsch 
 
 
Schulausbildung 
08/1980 - 06/1993 Grundschule und Gymnasium in Remscheid 
 Abschluss: allgemeine Hochschulreife 
 
Grundwehrdienst 
07/1993 - 06/1994  Flugabwehrregiment Wuppertal 
 
Studium 
10/1994 - 02/1999  Studium der Chemie an der Universität zu Köln 
12/1996   Diplom-Chemiker-Vorprüfung 
02/1999   Mündliche Diplomprüfungen 
 
Diplomarbeit 
03/1999 - 12/1999  „N.c.a. Synthese von [73,75Se]Selenoethern mit Hilfe 
    polymergebundener Carbodiimide“ 
durchgeführt am Institut für Nuklearchemie der 
Forschungszentrum Jülich GmbH unter Anleitung von 
Prof. Dr. H.H. Coenen 
12/1999  Diplom-Chemiker-Hauptprüfung 
 
Promotion 
02/2000 - 02/2003  „Development of no-carrier-added radioselenation 
methods for the preparation of radiopharmaceuticals“ 
durchgeführt am Institut für Nuklearchemie der 
Forschungszentrum Jülich GmbH unter Anleitung von 
Prof. Dr. H.H. Coenen 
mit dem Vorhaben einer Promotion an der Mathematisch-
Naturwissenschaftlichen Fakultät der Universität zu Köln 
 
 
 
Köln, im Februar 2003 
